**Biografija i bibliografija**

**Goran Brajušković**

## *Datum: 30. 05. 2023. godine*

## Lični podaci:

## Datum rođenja: *30. 11. 1968. godine*

Mesto rođenja: *Kragujevac (SFRJ)*

Državljanstvo: *Republika Srbija*

Vojni rok: *JNA, (12 meseci)*

Strani jezik: *Engleski*

ResearcherID:  *A-6281-2017*

Orcid ID: 0000-0002-3935 6755

Scopus Author ID: 55508235500

*h* index 11

Kvantitativno: **697+577,6**=**1274,6**



*Dr Goran Brajušković za redovnog profesora Biološkog fakulteta Univerziteta u Beogradu izabran je 2018.godine. Bibilografiju čini ukupno 273 bibliografske jedinice. Autor je 46 rada u časopisima kategorije M20 i 45 radova u časopisima kategorije M50. Pored toga, autor je 168 saopštenja, i to 83 na međunarodnim naučnim skupovima od kojih je jedno predavanje bilo po pozivu i 85 na domačim naučnim skupovima od kojih su 18 bila predavanja po pozivu. Radovi su mu citirani 514 puta od čega 56 rada 372 puta u časopsima sa SCI liste (h index 11). Bio je učesnik dva međunarodna i tri domaća naučna projketa. Učestvovao je u organizaciji osam naučnih skupova a član je 12 naučnih organizacija. Do sada je recenzirao dva univezitetska udžbenika, jedan praktikum, 82 publikacije iz časopisa kategorije M20, 6 publikacija iz časopisa kategorije M50 i jednog rada kategorije M60. Istovreno, bio je član uređivačkog odbora dva časopisa kategorije M20. Bio je urednik i jedne knjige sažetaka sa nacionalnog naučnog skupa (CoMBoS 2017). Autor je jednog univerzitetskog udžbenika, jedne recenzirane skripte, dva poglavlja u monografijama međunarodnog značaja, jedne monografije nacionalnog značaja i četiri poglavlja u monografijama nacionalnog značaja. Bio je mentor 22 doktorskih disertacija, 88 master i/ili diplomskih radova i jednog specijalističkog rada. Učestvovao je u komisijama za odbranu doktorskih (32), magistarskih (3), specijalističkih (1) i master i/ili diplomskih (24) radova. Drži ili je držao nastavu na ukupno 10 kurseva na svim nivoima studija Biološkog fakulteta, dva kursa na osovnim studijama Hemijskog fakulteta Univerziteta u Beogradu i jednog kursa na osnovnim studijama PMF-Odsek Biologija u Novom Sadu.*

**Trenutna pozicija: Redovni profesor** **za užu naučnu oblast Biohemija i molekularna biologija** Katedra za biohemiju i molekularnu biologiju, Univerzitet u Beogradu-Biološki fakultet

**Poslovna adresa:** Centar za humanu molekularnu genetiku, Univerzitet u Beogradu -Biološki fakultet, Studentski trg 16, p.fah 43, 11158 Beograd, Republika Srbija

**E.mail:**  brajuskovic@bio.bg.ac.rs

**Edukacija:**

2001. Doktorska disertacija, Univerzitet u Beogradu-Biološki fakultet

1997. Magistarski rad, Univerzitet u Beogradu-Biološki fakultet

1988–1994 Univerzitet u Beogradu-Biološki fakultet, smer: Molekularna biologija i fiziologija, odsek: Eksperimentalna biomedicina, Beograd, SFRJ/SRJ, započeo studije na Prirodno-matematičkom fakultetu, Odsek Biologija.

1984–1987 OC „Kragujevačka gimnazija”, Kragujevac, SFRJ

1983–1944 OC „Toza Dragović“, Kragujevac, SFRJ

1975–1983 Osnovna škola „Svetozar Marković”, Kragujevac, SFRJ

**Stručno iskustvo:**

* Molekularno–biološke metode za analizu molekula DNK (PCR, *real-time* PCR, HRM, MLPA, RFLP, automatsko sekvenciranje)
* Molekularno–biološke metode za analizu proteina (imunohistohemija, Western blot, ko-imunoprecipitacija, *Imuno*–*gold* TEM)
* Rad sa ćelijskim kulturama *in vitro* (detekcija CFU-GM i klastera, BFU-E, CFU-GEMM i CFU-Mk u kratkoživećim kulturama hematopoetskih progenitora u semi-solidnim medijumima)
* Rad sa ekstrćelijskim vezikulama (izolacija i karakterizacija) metodama imunoafinitativne hromatografije, protočne citometrije i elektronske mikroskopije
* *Humana identifikacija bazirana na analizi molekula DNK*
* *Molekularno–biološka dijagnostika bolesti čoveka*
* *Transmisiona elektronska mikroskopija–TEM (ultrastrukturna patologija kože, bubrega, malignih tumora, mišića, nerava, jetre i detekcija mikroorganizama metodom negativnog bojenja)*

**Stručno usavršavanje:**

2002– Studijski boravak u Institutu za patologiju, Medicinski fakultet Univerziteta u Ljubljani, Republika Slovenija;

Oblast usavšavanja: Elektronska mikroskopija za TNM dijagnostiku u oblasti nefropatologije (TEM analiza glomeruloneuropatija).

1995 – Šest meseci u Laboratoriji za kulturu tkiva, Odeljenja za eksperimentalnu onkologiju Nacionalnog centra za istraživanje raka u Beogradu, Institut za onkologiju i radiologiju Srbije, Republika Srbija;

Oblast usavšavanja: Obuka za rad sa ćelijskim kulturama.

**Profesionalno i akademsko iskustvo:**

2018 – **Redovni profesor**, Univerzitet u Beogradu-Biološki fakultet

2013 – 2018 **Vanredni profesor**, Univerzitet u Beogradu-Biološki fakultet

2007 – 2013 **Docent**, Univerzitet u Beogradu-Biološki fakultet

2003 – 2007 **Docent**, predmet Patološka anatomija, Vojnomedicinska akademija, Beograd, Republika Srbija

2022 – **Šef Katedre za biohemiju i molekularnu biologiju**, Univerzitet u Beogradu-Biološki fakultet

2012 – 2018 **Upravnik**, Institut za fiziologiju i biohemiju, Univerzitet u Beogradu-Biološki fakultet

2005 – 2007 **Načelnik**, Odeljenje za elektronsku mikroskopiju i kulturu tkiva, Institut za patologiju, Centar za patologiju i sudsku medicinu, Vojnomedicinska akademija, Beograd, Republika Srbija

2008 – 2009 **Sekretar**, Katedra za biohemiju i molekularnu biologiju, Univerzitet u Beogradu-Biološki fakultet

2003 – 2007 **Sekretar**, Katedra za patologiju, Vojnomedicinska akademija

2007 – Saradnik Centra za humanu molekularnu genetiku, Univerzitet u Beogradu-Biološki fakultet

1995 – 2005 Molekularni biolog, Odeljenje za elektronsku mikroskopiju i kulturu tkiva, Institut za patologiju, Zavod za patologiju i sudsku medicinu, Vojnomedicinska akademija

1994–1995 Volonter, Odeljenje za elektronsku mikroskopiju i kulturu tkiva, Institut za patologiju, Zavod za patologiju i sudsku medicinu, Vojnomedicinska akademija

**Članstvo u naučnim i stručnim organizacijama:**

* 2023 – Član, Upravni odbor Srpskog društva za molekularnu biologiju
* 2015–2023 Zamenik predsednika Upravnog odbora Srpskog društva za

molekularnu biologiju (http://molbios.bio.bg.ac.rs/organi-drustva)

* 2006 – 2010 Član, Predsedništvo Srpskog društva za mikroskopiju

(http://www.vin.bg.ac.rs/SDM/index\_s.html)

* 2002 – 2006 Član, Komitet za kongresnu delatnost Upravnog odbora

Udruženja patologa Srbije i Crne Gore

* 2017 – Član, *European Society of Human Genetics*
* 1995 – Član, *European Microscopy Society*
* 2022 – Član, Srpsko društvo za ekstracelularne vezikule
* 2015 – Član, Srpsko društvo za molekularnu biologiju
* 2015 – Član, Biohemijsko društvo Srbije
* 2013 – Član, Društvo genetičara Srbije
* 2010 – 2020 Član, Društvo za neuronauke Srbije
* 200 7– Član, Srpsko biološko društvo
* 1999 – Član, Sekcija za transplantaciju, Srpsko lekarsko društvo
* 1995 – Član, Sekcija za patologiju, Srpsko lekarsko društvo
* 1995 – Član, Udruženje patologa i citologa Srbije
* 1994 – Član, Srpsko društvo za mikroskopiju

**Nagrade i priznanja**

* Najbolja prezentacija, Filipović L, Spasojević M, Prodanović R, Korać A, Matijašević S, **Brajušković G**, Ariode M, Popović M. Developing reversible immuno-affinity capture for extracellular vesicles purification Book of abstracts:66-7. Serbian Biochemical Society Eleventh Conference Scientific meeting of an international character September 22nd and 23rd, 2022, Novi Sad, Serbia “Amazing Biochemistry”.
* Najbolja prezentacija na skupu *Genomics of rare diseases symphosium. GoldenHelix Symposium31.10.-1.11. 2014, Beograd* (*Pešović J, Perić S, Brkušanin N, Mandić M,* ***Brajušković G****, Romac S, Rakočević Stojanović V, Savić-Pavićević D. PCR-based Southern blot for detection of DMD 2 expansions*).
* Apsolutno prvo mesto i prvo mesto iz oblasti medicine i genetike petočlanog tima (Romac S, Savić-Pavićević D, **Brajušković G**, Janković-Pavlović N. i Todorović S.) na takmičenju za najbolju tehnološku inovaciju u Srbiji 2008. godine u kategoriji „Potencijali“ u organizaciji Ministarstva za nauku i tehnološki razvoj Republike Srbije
* Najbolji poster XII Kongresa patologa Srbije i Crne Gore sa međunarodnim učešćem 2006. godina (***Brajušković G****. et al. The ultrastructural investigation of mitochondria in B-CLL cells during process of apoptosis. Materia Medica 2006; 22 (2, suppl 1):80*)
* Autor godine *Vojnosanitskog pregleda* za 2006. godinu *(VSP 2007; 64(3):179-81)*
* Autor godine *Vojnosanitskog pregleda* za 2004. godinu (*VSP 2005; 63(3):239-46)*

http://www.vma.mod.gov.rs/sr-lat/o-vma/nagrade-i-priznanja/autor-godine-vsp

* Zlatna povelja Srpskog biološkog društva (2013. godine)
* Diploma Srpskog lekarskog društva (2006. godine)
* Zahvalnica Srpskog lekarskog društva (1999. godine)
* Nagrada za mlade naučnike Vlade Republike Srbije za 2001. godinu

**Ostale aktivnosti:**

* 2022– Član, Veća prirodnih nauka Univerziteta u Beogradu
* 2016– Predsednik Upravnog odbora fondacije „Fondacija Stanka Romac“
* 2015 – Član Komisije za dodelu nagrade fondacije „Stanka Romac“ za najbolju

doktorsku disertaciju iz oblasti humane molekularne genetike I biomedicine

* 2023 Član Komisije za dodelu godišnje nagrade fondacije „Ivan Đaja“

za najbolje doktorske disertacije i master radove iz oblasti fiziologije

* 2015 – 2017 Član Komisije za dodelu godišnje nagrade fondacije „Ivan Đaja“ za

najbolje doktorske disertacije i master radove iz oblasti fiziologije

* 2015-2016 Član komisije za reakreditaciju Biološkog fakulteta UB
* 2010-2011 Član komisije za reakreditaciju Biološkog fakulteta UB
* 2008. Član komisije za akreditaciju Biološkog fakulteta UB
* 2010 – Sudski veštak za užu specijalnost: Forenzička genetika, DNK analize.

Rešenje Ministarstva pravde RS broj: 740-05-04748/2010-03 (http://www.mpravde.gov.rs/court-experts.php)

* Član Komisija za izbor u nastavna zvanja Univerziteta u Beogradu-Biološki fakultet

1. Jovčić Branko – zvanje redovni profesor,
2. Pešović Jovan – zvanje docent,
3. Kecmanovič Miljana – zvanje docent,
4. Keckarević-Marković Milica – zvanje docent,
5. Keckarević Dušan – zvanje docent,
6. Pešovič Jovan – zvanje asistent sa doktoratom,
7. Keckarević Dušan – zvanje asistent,
8. Kecmanovič Miljana – zvanje asistent,
9. Keckarević-Marković Milica – zvanja asistent, i
10. Suzana Matijašević Joković – zvanje asistent.

* Član Komisija za izbor u nastavna zvanja Univerzitet u Beogradu-Hemijski fakultet

1. Polović Natalija – zvanje redovni profesor,
2. Milica Popović – zvanje vanredni profesor, i
3. Stojadinović Milica – zvanje asistent.

* Član Komisija za izbor u nastavna zvanja Kriminalističko-policijski univerzitet

1. Ana Branković – zvanje vanredni profesor,
2. Ana Branković – zvanje docent (re-izbor), i
3. Ana Branković – zvanje docent

* Član Komisija za izbor u naučno-istraživačka zvanja na
* *Univerzitetu u Beogradu-Biološkom fakultetu*

1. Matijašević Suzana – zvanje istaživač saradnik,
2. Radenković Lana – zvanje istraživač saradnika,
3. Nikolić Zorana – zvanje naučni saradnik,
4. Nikolić Zorana – zvanje istraživač saradnik,
5. Karanović Jelena – zvanje naučni saradnik (reizbor),
6. Karanović Jelena – zvanje naučni saradnik,
7. Karanović Jelena – zvanje istraživač saradnik,
8. Brkušanin Miloš – zvanje naučni saradnik,
9. Brkušanin Miloš – zvanje istraživač saradnik,
10. Pešović Jovan – zvanje naučni saradnik,
11. Pešović Jovan –istraživač saradnik,
12. Kotarac Neveva – zvanje naučni saradnik,
13. Kotarac Neveva – zvanje istraživač saradnik, i
14. Vučić Nemanja – zvanje istraživač saradnik.

* *Univerzitetu u Beogradu-Institutu za molekularnu genetiku i genetičko inženjerstvo*

1. Lazić Adrijana – zvanje viši naučni saradnik,
2. Klajn Aleksandra – zvanje viši naučni saradnik,
3. Mojsin Marija – zvanje viši naučni saradnik (reizbor), i
4. Mojsin Marija – zvanje viši naučni saradnik.

* *Univerzitetu u Beogradu - Institutu za nuklearne nauke Vinča*

1. Mandušić Vesna – zvanje viši naučni saradnik,
2. Kožuk Bojana – zvanje naučni saradnik,
3. Krajnović Milena – zvanje naučni saradnik (reizbor),
4. Krajnović Milena – zvanje naučni saradnik,
5. Jovanovič-Čupić Snežana – zvanje naučni saradnik (reizbor),
6. Radošević Draginja – zvanje naučni saradnik
7. Jovanovič-Čupić Snežana – zvanje naučni saradnik,
8. Petrović Nina – zvanje naučni saradnik,
9. Davidović Radoslav – zvanje naučni saradnik,
10. Popović Milan – zvanje naučni saradnik
11. Kolaković Ana – zvanja naučni saradnik
12. Kolaković Ana – zvanje istraživač saradnik,
13. Životić Ivan – zvanje istraživač saradnik (reizbor),
14. Životić Ivan – zvanje istraživač saradnik,
15. Stefanović Milana – zvanje istraživač saradnik,
16. Aleksić Milan – zvanje istraživač pripravnik, i
17. Kožuk Bojana – zvanje istraživač pripravnik

* Univerzitetu odbrane u Beogradu - Fakultetu medicinskih nauka (VMA)

1. Todorić Živanović Biljana – zvanje naučni saradnik, i
2. Strnad Milica – zvanje naučni saradnik

* *Univezitetu u Beogradu – Hemijskom fakultetu*

1. Popović Milica – zvanje viši naučni saradnik i
2. Lidija Filipović – istraživač saradnik

* Član komisija za ocenu i odbranu doktorskih disertacija na ne-matičnom fakultetu:
* Univerzitet u Beogradu-Medicinski fakultet

1. Zolotarevska Lidija

* Univerzitet u Novom Sadu-Medicinski fakultet

1. Fenjveši Atila, i
2. Krnolejac Dijana

* Univerzitet odbrane u Beogradu-Fakultet medicinskih nauka (Vojno-medicinska akademija)

1. Jeremić Nebojša, i
2. Jović Milena

**NASTAVNA DELATNOST**

**Kvantitativan prikaz postignutih rezultata nastavnog rada prema kritrijumima Pravilnika za izbor u nastavna zvanja Univerziteta u Beogradu – Biološkog fakulteta**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vrsta rezultata** | **Vrednost** | | | |  | | | |  | | | | **Broj** | | | **Poeni** |
| **Osnovne nastavne aktivnosti** | | | | | |  | | | | | |  | | | | |
| **Objavljen udžbenik** | **20** | |  | | | |  | | | **1** | | | | **20** | | |
| **Objavljena recenzirana skripta** | **10** | |  | | | |  | | | **1** | | | | **10** | | |
| **Mentorstvo – odbranjena doktorska disertacija** | **12** | |  | | | |  | | | **4** | | | | **48** | | |
| **Mentor sa fakulteta – odbranjena doktorska disertacija** | **6** | |  | | | |  | | | **18** | | | | **108** | | |
| **Mentor sa fakulteta – odbranjen specijalistički rad** | **3** | |  | | | |  | | | **1** | | | | **3** | | |
| **Mentorstvo – odbranjen diplomski ili master rad** | **4** | |  | | | |  | | | **36** | | | | **144** | | |
| **Mentor sa fakulteta – odbranjen diplomski ili master rad** | **2** | |  | | | |  | | | **52** | | | | **104** | | |
| **Učešće u komisiji za odbranu doktorske disertacije** | **4** | |  | | | |  | | | **32** | | | | **128** | | |
| **Učešće u komisiji za odbranu magistarskog rada** | **3** | |  | | | |  | | | **3** | | | | **9** | | |
| **Učešće u komisiji za odbranu specijalističkog rada** | **2** | |  | | | |  | | | **1** | | | | **2** | | |
| **Učešće u komisiji za odbranu diplomskog ili master rada** | **1** | |  | | | |  | | | **24** | | | | **24** | | |
| **Držanje nastave na kursu**   * **u potpunosti pripremljen nastavni program** * **pripremljena dopuna nastavnog programa** * **preuzet program** | **6**  **5**  **2** | |  | | | |  | | | **10**  **1**  **3** | | | | **71** | | |
| **Ukupno** |  | |  | | | |  | | |  | | | | **671** | | |
| **Ostale nastavne aktivnosti** | | | | | |  | | | | | |  | | | | |
| **Držanje nastave za stručno usavršavanje nastavnika** | | **1** | |  | | | |  | | | **2** | | | | **2** | |
| **Učešće u pedagoškom radu sa učenicima osnovnih i srednjih škola** | | **1** | |  | | | |  | | | **5** | | | | **5** | |
| **Recenzija udžbenika kategorije M90** | | **3** | |  | | | |  | | | **3** | | | | **9** | |
| **Članstvo u organizacionim odborima međunarodnih/nacionalnih/ stručnih skupova** | | **2/1/0.5** | |  | | | |  | | | **0/8/5** | | | | **10,5** | |
| **Ukupno** | |  | |  | | | |  | | |  | | | | **26,5** | |
| **Ukupno osnovne i ostale nastavne aktivnosti** | |  | |  | | | |  | | |  | | | | **697,5** | |

**Udžbenici, skripta i praktikumi**

**Objavljen udžbenik**

1. **Brajušković G**. Molekularna biologija 2. Beograd: Savremena administracija. 2012. ISBN 978-86-387-0803-1.

Recezenti: dr Romac Stanka, dr Matić Gordana, dr Radović Svetlana, dr Savić-Pavićević Dušanka

**Objavljena recenzirana skripta**

1. **Brajušković G**. Molekularna genetika. Beograd: Biološki fakultet, Univerzitet u Beogradu. 2010. ISBN 978-86-7078-063-7.

Recezenti: dr Romac Stanka, dr Radović Svetlana, dr Knežević-Vukčević Jelena

**Mentorstva i komisije za odbranu doktorskih disertacija, master, magistarskih, specijalističkih i diplomskih radova**

**Mentorstva odbranjenih doktorskih disertacija**

1. **Vučić Nemanja**. Povezanost strukturnih varijanti u hromozomu *Y* i genu *NOS3* i tačkastih varijanti u hromozomima 1 i 12 sa rizikom za pojavu idiopatskog steriliteta kod muškaraca u Srbiji. Biološki fakultet, Univerzitet u Beogradu, 2022.

**Mentor: dr Brajušković Goran**

Komisija: dr Savić-Pavićević Dušanka (član), dr Dobrijević Zorana (član), dr Vuković Ivan (član).

1. **Kotarac Nevena**. Studija asocijacije gena za mikro RNK (*MIR34*, *MIR143*, *MIR145* i *MIR378*) i gena za održavanje tkivne homeostaze sa karcinomom prostate. Biološki fakultet, Univerzitet u Beogradu, 2020.

**Mentor: dr Brajušković Goran**

Komisija: dr Savić-Pavićević Dušanka (član), dr Dobrijević Zorana (član), dr Vuković Ivan (član).

1. **Nikolić Zorana**. Studija asocijacije varijanti u genima za mikroRNK i za proteine utišavajućeg kompleksa sa rizikom za razvoj i progresiju karcinoma prostate kod bolesnika iz Srbije. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: **dr Brajušković Goran (mentor),** dr Savić-Pavićević Dušanka (član), dr Krajnović Milena (član), dr Tanić Nikola (član).

1. **Branković Ana**. Studija asocijacije genetičkih varijanti u regionima 7q36, 8q24 i 17q12 sa rizikom za razvoj i progresiju karcinoma prostate. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: **dr Brajušković Goran (mentor),** dr Savić-Pavićević Dušanka (član), dr Vukotić Vinka (član)

* Mentor doktorske disertacije sa odobrenom temom kandidata Suzane Matijašević
* Mentor doktorske disertacije kandidata Srećka Rajovskog

**Mentorstva sa fakulteta odbranjenih dokorskih disertacija**

1. **Valenta Šobota Ana.** Uticaj referentnih monoterpenskih komponenti i ekstrakta korena *Genitiana lutea* na apoptozu i nekroptozu mononuklearnih ćelija periferne krvi čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Lozo Jelena, dr Lakić Iva i dr Filipović-Tričković Jelena.

Mentori: dr Drakulić Dunja (mentor) i dr Brajušković Goran (mentor),

1. **Radošević Draginja**. *In silico* odabir lekova iz baze Drug Bank kao potencijalnih inhibitora M2 proteina virusa gripa i provera njihove aktivnosti *in vitro*. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Glišić Sanja (mentor), dr Brajušković Goran (mentor), dr Senćanski Milan (član).

1. **Kozik Bojana**. Metilacioni status p16INK4a i p14ARE tumor-supresor gena i prisustvo mutacija K-RAS onkogena u korelaciji sa odgovorom na preoperativnu hemioradioterapiju u lokalno uznapredovalom karcinomu rektuma čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Krajnović Milena (mentor), dr Brajušković Goran (mentor), dr Knežević-Ušaj Slavica (član).

1. **Životić Ivan**. Asocijacija genskih varijanti na hromozomu 9p21 i transkripcije gena za CDKN2B i HACD4 sa nastankom ateroskleroze i njenim kliničkim komplikacijama kod čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor), dr Tamara Đurić (član).

1. **Todorović Lidija**. Ekspresija i varijante gena za tumorski supresor *VHL*u papilarnim karcinomima štitaste žlezde. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Stanojević Boban (mentor), dr Brajušković Goran (mentor), dr Mandušić Vesna (član).

1. **Dragoj Miodrag**. Efekti inhibicije CXCR4 receptora i fokalne adhezione kinaze u supresiji invazije i prevazilaženju rezistencije kod nesitnoćelijskog karcinoma pluća. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Stanković Tijana (mentor), dr Brajušković Goran (mentor), dr Dinić Jelena (član).

1. **Petrović Nina**. Mikro RNK-21 kao indikator invazivnosti karcinoma dojke kod pacijenata sa različitim statusom estrogenskog i progesteronskog receptora. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Mandušić Vesna (mentor), dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), dr Stanojević Boban (član).

1. **Davidović Radoslav**. Analiza mutacionog statusa gena *p53* i metilacionog statusa promotora gena *p14* i *p16* u liposarkomima. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Mandušić Vesna (mentor), dr Brajušković Goran (mentor), dr Sopta Jelena (član).

1. **Žakula Jelena**. Inaktivacija ćelija melanoma čoveka zračenjem jonima ugljenika: određivanje radiobioloških parametara i analiza signalnih puteva ćelijske smrti. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Korićanac Lela (mentor), dr Brajušković Goran (mentor), dr Petrović Ivan (član), dr Savić-PavićevićDušanka (član).

1. **Kolaković Ana**. Genetičko-epidemiološka analiza i analiza ekspresije gena renin-angiotenzin sistema (RAS) u karotidnoj aterosklerozi kod čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Stanković Aleksandra (mentor), dr Brajušković Goran (mentor), dr Đurić Delić Tamara (član).

1. **Krajnović Milena**. Prognostički značaj aberantne metilacije CpG ostrvaca u folikularnim i difuznim B-krupnoćelijskim limfomima čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Krtolica Žikić Koviljka (mentor), dr Brajušković Goran (mentor), dr Radojković Milica (član).

1. **Petrović Isidora**. Transkripciona regulacija ekspresije humanog Sox18 gena. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Stevanović Milena (mentor), dr Brajušković Goran (mentor), dr Radović Svetlana (član).

1. **Tomić Branko**. Struktura topološki zatvorene *ori* sekvence dihidrofolatreduktaznog lokusa u interakciji sa inicijacionim proteinom ORC. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Kušić Tišma Jelena (mentor), dr Brajušković Goran (mentor), dr Stefanović Dragana (član), dr Radojković Dragica (član)

1. **Jovanović Ćupić Snežana**. Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Glišić Sanja (mentor), dr Brajušković Goran (mentor), dr Stanojević Maja (član), dr Nožić Darko (član).

1. **Todorić Živanović Biljana**. Detekcija i praćenje ekspresije bcr-abl gena i hromozomskih aberacija u bolesnika sa hroničnom mijeloidnom leukemijom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Magić Zvonko (mentor), dr Brajušković Goran (mentor), dr Guć Šćekić Marija (član), dr Krtolica Žikić Koviljka (član)

1. **Drakulić Danijela**. Analiza efekta povećane ekspresije SOX2 gena na održavanje pluripotentnosti, proliferaciju i neuralnu diferencijaciju embrionalnih karcinomskih NT2/D1 ćelija. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Stevanović Milena (mentor), dr Brajušković Goran (mentor), dr Radović Svetlana (član).

1. **Stanković Marija**. Analiza genskih varijanti u hroničnoj opstruktivnoj bolesti pluća kod čoveka. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Radojković Dragica (mentor), dr Brajušković Goran (mentor), dr Kojić Snežana (član).

1. **Đorđević Valentina**. Analiza uticaja 3’ kraja humanog protrombinskog gena na njegovu ekspresiju i patogenezu trombofilije. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Radojković Dragica (mentor), dr Brajušković Goran (mentor), dr Kojić Snežana (član).

**Učešća u komisijama za odbranu doktorskih disertacija**

1. **Ristivojević** Boja. Farmakogenetički markeri odgovora na terapiju tiopurinskim lekovima, metotreksatom i vinkristinom kod dece sa akutnom limfoblasnom leukemijom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2023.

Komisija: dr Kotur Nikola, dr Brajušković Goran, dr Čolović Natašt.

1. **Gligorovska Ljupka**. Metabolizam lipida i signalni put glukokortikoida u visceralnom masnom tkivu i jetri Mif -/- miševa na režimu ishrane obogaćene fruktozom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (predsednik), dr Đorđe Miljković (član), dr Biljana Bursać (član).

1. **Prvovanović Mirjana**. Analiza ekspresije ključnih molekula PTEN/PI3K/mTOR signalnog puta i ABC transportera kod trostruko negativnih karcinoma dojke i njihova povezanost sa histopatološkim i kliničkim parametrima. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (predsednik), dr Dušanka Savić-Pavićević (član), Svetislav Tatić (član), dr Tatjana Ivkov-Kapicl (član), dr Zorka Milovanović (član).

1. **Bošković Srđan**. Karakterizacija gena ankrd1a, ankrd1b i anked2 zebrice (*Danio rerio*) u razviću i odgovoru na stres.Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Kojić Snežana (mentor), dr Savić-Pavićević Dušanka (mentor), dr Gordana Matić (član), dr Brajušković Goran (član).

1. **Vuković M. Vladanka.** Epigenetički mehanizmi regulacije ekspresije humanog gena SOX3 i gena faktora pliripotentnosti (SOX2, OCT4 i NANOG) tokom ranih faza neuralne diferencijacije NTera2/D1 ćelija. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Mojsin Marija (mentor), dr Stevanović Milena (mentor), dr Brajušković Goran (član).

1. **Marjanović Jelena**. Analiza uloge gena SОX1 i SОX3 u promovisanju malignog fenotipa ćelija glioblastoma. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Drakulić Danijela (mentor), dr Stevanović Milena (mentor), dr Brajušković Goran (član).

1. **Skakić Anita**. Genomsi profil pacijenata dečijeg uzrasta sa hepatičnim glikogenozama: korelacija genotipa i fenotipa i funkcionalna karakterizacija novih varijanti. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Stoiljković Maja (mentor), dr Pavlović Sonja (mentor), dr Brajušković Goran (član), dr Radović Svetlana (član), dr Đorđević Milošević Maja (član).

1. **Anđelković Marina**. Genomski profil pacijenata dečijeg uzrasta sa primarnim cilijarnom diskinezijom: korelacija genotipa i fenotipa i funkcionalna karakterizacija novih genetičkih varijanti. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Spasovski Vesna (mentor), dr Pavlović Sonja (mentor), dr Brajušković Goran (član), dr Radović Svetlana (član), dr Minić Predrag (član).

1. **Pešović Jovan**. Mitotička i mejotička nestabilnost *DMPK* ekspanzija sa varijantnim ponovcima kao genetički modifikator fenotipa miotonične distrofije tipa 1. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Vidosava Rakočević Stojanović (mentor), dr Pavle Anđus (član), dr Brajušković Goran (član, predsednik Komisije).

1. **Vreća Miša**. Ekspresija gena markera inflamacije i fibroze i gena kandidata za optimizovanu ćelijsku terapiju kod pacijenata sa sistemskom sklerozom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Spasovski Vesna (mentor), dr Pavlović Sonja (mentor), dr Brajušković Goran (član), dr Damnjanov Nemanja (član), dr Radović Svetlana (član).

1. **Brkušanin Miloš**. Struktura segmentalne duplikacije 5q13,2 kao modifikator fenotipa spinalne mišićne atrofije i amiotrofične lateralne skleroze. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Stević Zorica (član), dr Milić Rašić Vedrana (član), dr Mojsin Marija (član), dr Brajušković Goran (član, predsednik Komisije).

1. **Novaković Milica**. Analiza promotorskih varijanti gena *CYP2C19* i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijanata sa infatktom miokarda i stenozom karotida. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Rakočević Ljiljana (mentor), dr Savić-Pavićević Dušanka (mentor), dr Radojković Dragica (član), dr Antonijević Nebojša (član), dr Brajušković Goran (član).

1. **Nedeljković Milica**. Molekularno profilisanje i karakterizacija trostruko negativnih i hormnoski zavisnih tumora dojke. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Tanić Nikola (mentor), dr Konjević Gordana (mentor), dr Tanić Nasta (član), dr Brajušković Goran (član), dr Matić Gordana (član).

1. **Ilić Bojana**. Efekat mutacije gena VHL na nivo ekspresije proteina mTOR signalnog puta u svetloćelijskom karcinomu bubrega. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2017.

Mentori: dr Matić Gordana i dr Damjanović Svetozar

Komisija: dr Brajušković Goran (predsednik Komisije), dr Đorđević Ana (član), dr Marković Lipkovski Jasmina (član).

1. **Karanović Jelena**. Varijante u genima za editovanje RNK, serotoninski receptor 2C i triptofan-hidroksilazu 2 kao faktori rizika za pokušaj samoubistva kod psihijatrijskih bolesnika. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), dr Ivković Maja (član), dr Jovanović Vladimir (član).

1. **Đorđević Crnogorac Marija**. Značaj razlika nivoa imunoglobulina specifičnih za melanin i tirozinazu u antitumorskoj imunosti bolesnika sa melanomom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Božić Nedeljković Biljana (mentor), dr Matić Ivana (mentor), dr Brajušković Goran (član).

1. **Jović Milena**. Procena bioloških svojstava tumora na osnovu patohistološkog tipa, *in situ* ekspresije i serumskih koncentracija survivina u bolesnika sa melanomom. Doktorska disertacija. Medicinski fakultet, Univerzitet odbrane Beograd, 2015.

Komisija: dr Cerović Snežana (mentor), dr Vojvodić Danilo (predsednik Komisije), dr Kostov Miloš (ćlan), dr Jauković Ljiljana (član), dr Brajušković Goran (član).

1. **Zolotarevski Lidija**. Morfološke i funkcionalne promene u koži pacova nakon epikutane aplikacije varfarina. Doktorska disertacija. Medicinski fakultet, Univerzitet u Beogradu, 2015.

Mentori: dr Tatić Svetislav, dr Kataranovska Milena.

Komisija: dr Brašanac Dimitrije (član), dr Dobrosavljević Danijela (član), dr Brajušković Goran (član).

1. **Stanković Biljana**. Molekularni markeri hronične inflamacije i apoptoze kod inflamatornih bolesti creva. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Pavlović Sonja (mentor), dr Nikčević Gordana (mentor), dr Brajušković Goran (član).

1. **Klaassen Kristel**. Uticaj varijanti u kodirajućim i nekodirajućim regionima gena uzorčnika i gena modifikatora na fenotip pacijenata sa hiperfenilalaninemijom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Pavlović Sonja (mentor), dr Stojiljković Maja (mentor), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član), dr Pérez Gonzáles Belen (član).

1. **Gemović Branislava.** Bioinformatička analiza proteina uključenih u patogenezu mijeloidnih maligniteta. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Veljković Nevena (mentor), dr Savić-Pavićević Dušanka (mentor), dr Marisavljević Dragomir (član), dr Brajušković Goran (član), dr Nikolić Katarina (član).

1. **Keckarević Dušan.** Molekularno genetička osnova amiotrofične lateralne skleroze kod pacijenata u populaciji Srbije. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Romac Stanka (mentor), dr Stević Zorica (mentor), dr Anđus Pavle (član), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član, predsednik Komisije), dr Todorović Slobodanka (član).

1. **Kecmanović Miljana**. Molekularno genetička analiza različitih tipova progresivnih miokloničnih epilepsija u populaciji Srbije. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Romac Stanka (mentor), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član, predsednik Komisije), dr Jović Nebojša (član).

1. **Keckarević Marković Milica**. Molekularno genetička osnova hereditarne motorne i senzorne neuropatije tip 1 (HMSN1) kod pacijenata u populaciji Srbije. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Romac Stanka (mentor), dr Todorović Slobodanka (član), dr Milić Rašić Vedrana (član), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član, predsednik Komisije).

1. **Šarić Marizela**. Molekularna genetika hereditarne hemohromatoze tip 1 i 2. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Romac Stanka (mentor), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član, predsednik Komisije), dr Jović Jasna (član).

1. **Mojsin Marija**. Uloga TALE transkripcionog faktora u regulaciji ekspresije SOX3 gena retioničnom kiselinom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Stevanović Milena (mentor), dr Radović Svetlana (mentor), dr Brajušković Goran (član).

1. **Jeremić Nebojša**. Značaj imunohistohemijske identifikacije ciklooksigenaze 2 u radikalnim prostatektomijama. Doktorska disertacija. Vojnomedicinska akademija, Beograd, Srbija, 2007.

Komsija: dr Cerović Snežana (mentor), dr Brajušković Goran (član), dr Vukotić Vinka (član), dr Milošević Aleksandar (član), dr Milović Novak (član).

1. **Fenjveši Atila**. Prognostički značaj mikrosatelitne nestabilnosti u kolorektalnim karcinomima. Doktorska disertacija. Medicinski fakultet, Univerzitet u Novom Sadu, 2006.

Komisija: dr Klem Ištvan (mentor), dr Eri Živka (član), dr Jovanović Dušan (član), dr Budakov Pavle (član), dr Brajušković Goran (član), dr Knežević-Ušaj Slavica (član).

1. **Krnolejac Dijana**. Morfološke odlike i mogućnost promene biološkog ponašanja eksperimentalnog fibrosarkoma u hrčka. Doktorska disertacija Medicinski fakultet, Univerzitet u Novom Sadu, 2005.

Komisija:  [dr Lalošević Dušan](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%9B%D0%B0%D0%BB%D0%BE%D1%88%D0%B5%D0%B2%D0%B8%D1%9B,%20%D0%94%D1%83%D1%88%D0%B0%D0%BD%22) (mentor), dr [Šljapić Nada](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%A8%D1%99%D0%B0%D0%BF%D0%B8%D1%9B,%20%D0%9D%D0%B0%D0%B4%D0%B0%22) (član), dr [Vučković Nada](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%92%D1%83%D1%87%D0%BA%D0%BE%D0%B2%D0%B8%D1%9B,%20%D0%9D%D0%B0%D0%B4%D0%B0%22) (član), dr [Somer Ljiljana](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%A1%D0%BE%D0%BC%D0%B5%D1%80,%20%D0%89%D0%B8%D1%99%D0%B0%D0%BD%D0%B0%22) (član), dr [Brajušković Goran](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%91%D1%80%D0%B0%D1%98%D1%83%D1%88%D0%BA%D0%BE%D0%B2%D0%B8%D1%9B,%20%D0%93%D0%BE%D1%80%D0%B0%D0%BD%22) (član), dr [Kovačević Zoran](http://www.vbs.rs/scripts/cobiss?ukaz=SEAL&mode=5&id=1320032794668403&PF=AU&term=%22%D0%9A%D0%BE%D0%B2%D0%B0%D1%87%D0%B5%D0%B2%D0%B8%D1%9B,%20%D0%97%D0%BE%D1%80%D0%B0%D0%BD%22) (član).

1. **Strnad Milica**. Ekspresija proteina programirane ćelijske smrti u bolesnika sa hroničnom granulocitnom leukemijom. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2005.

Komisija: dr Škaro-Milić Anđelija (mentor), dr Romac Stanka (mentor), dr Brajušković Goran (član), dr Stamatović Dragana (član), dr Magić Zvonko (član).

1. **Basta Tamara**. Uloga SOX3 gena u ranom embrionalnom razviću *Xenopus laevis*-a. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2005.

Komisija: dr Romac Stanka (mentor), dr Brajušković Goran (član), dr Nataša Golić (član).

1. **Ćorić Tatjana**. Jonski kanali zavisni od pH kod ribe *Opsanus tau*: kloniranje gena i funkcionalna karakterizacija kanala. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2003.

Komisija: dr Vukosavić Slobodanka (mentor), dr Anđus Pavle (član), dr Brajušković Goran (član).

**Učešća u komisijama za odbranu magistarskih teza**

1. **Zamurović Ljubica**. Molekularno-genetička analiza gena kod pacijenata obolelih od shizofrenije: THO1, RAI1 i PCQAP lokusa. Magistarski rad. Biološki fakultet, Univerzitet u Beogradu, 2006.

Komisija: dr Romac Stanka (mentor), dr Savić-Pavićević Dušanka (član), dr Brajušković Goran (član).

1. **Stevanović Miljana**. Molekularna genetika spinalne mišićne atrofije: analiza haplotipova. Magistarski rad. Biološki fakultet, Univerzitet u Beogradu, 2004.

Komisija: dr Romac Stanka (mentor), dr Radak Stamenković Marina (član), dr Brajušković Goran (član, predsednik Komisije).

1. **Đarmati Ana**. Genetička osnova Retovog sindroma u populaciji Srbije i Crne Gore: identifikacija mutacija u kodirajućem regionu MECP2 gena kod obolelih devojčica. Magistarski rad. Biološki fakultet, Univerzitet u Beogradu, 2003.

Komisija: dr Romac Stanka (mentor), dr Vukosavić Slobodanka (član), dr Brajušković Goran (član).

**Mentorstva u odbranjenim master radovima**

1. **Brančić Anđela**. Primena tehnologija novih generacija sekvenciranja u detekciji genetičkih izmena u genomima PC3 i LNCaP ćelijskim linijama. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Radovanović Nemanja**. Studija asocijacije genetičke varijante rs10842262 sa idiopatskim sterilitetom kod muškaraca iz Severne Makedonije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Brajušković Goran (mentor), dr Brkušanin Miloš (član).

1. **Matijašević Suzana**. Studija asocijacije genetičkih varijanti rs1207821, rs2477686 i rs10842262 sa idiopatskim sterilitetom kod muškaraca iz Srbije.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Vučić Nemanja (član).

1. **Vuković Ana**. Epistatičke interakcije genetičkih varijanti povezane sa benignom hiperplazijom prostate u populaciji Srbije.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Brajušković Goran (mentor), dr Petrović Vladimir (mentor).

1. **Nonković Nikola**. Procena rizika za dobijanje karcinoma prostate u srpskoj populaciji na osnovu detekcije epistatičkih interakcija genetičkih varijanti. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Brajušković Goran (mentor), dr Veljković Nevena (mentor).

1. **Mišić Jelena**. Ispitivanje značaja mitohondrijskih nukleaza MGME1 i DNA2 u replikaciji mitohondrijske DNK kod *knock-out* mišjeg modela *Mgmc1-/- Dna2+/-.*Master rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Kotarac Nevena**. Primena metode amplifikacije višestruko ligiranih proba u identifikaciji mikrodelecija i varijacija u broju kopija regiona *AZF* hromozoma *Y* kod muškaraca sa idiopatskim sterilitetom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Vučić Nemanja (član).

1. **Ćurić Saša.** Citotoksični efekat specifičnog inhibitora fosfatidil inozitol-3 kinaze PIK-75 na ćelije osteosarkoma čoveka.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Šainović Nevena**. Značaj analize mutacionog statusa gena *HER2*u izboru terapijskog pristupa kod bolesnica sa invazivnim karcinomom dojke. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Brkušanin Miloš (član).

1. **Cidilko Stefan**. Studija asocijacije genetičkih varijanti rs374644 u genu *hsa-miR-499* i rs3742330 u genu *DICER1* sa rizikom za razvoj i progresiju karcinoma prostate u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Nikolić Zorana (član).

1. **Vučić Nemanja**. Studija asocijacije genetičkih varijanti rs1799983 i rs2070744 u genu za *NOS3* sa pojavom steriliteta kod muškaraca u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Nikolić Zorana (član).

1. **Preković Stefan**. Analiza asocijacije genetičkih varijanti rs3760511 i rs7501939 sa karcinomom prostate. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Nikolić Zorana (član).

1. **Nikolić Zorana**. Asocijacija genetičke varijante rs3787016 sa karcinomom prostate u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Kojić Aleksandar**. Asocijacija genetičke varijante rs378854 sa karcinomom prostate u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

**Mentorstva sa fakulteta u odbranjenim master radovima**

1. **Milanović Nikoleta**. Varinante u 3' kraju gena za protrombin kod bolesnika sa ponovljenim trombozama nepoznatog uzroka. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (mentor), dr Đorđević Valentina (mentor).

1. **Petrović Maja**. Povezanost polimorfizma gena za dugu nekodirajuću RNK CCAT1 sa kliničko-patološkim parametrima bolesnika sa oralnim karcinomom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (mentor), dr Šupić Gordana (mentor).

1. **Babić Mirjana**. Antioksidativni efekat toplotom ubijenih bakterija mlečne kiseline na nivou ekspresije gena Ahr i Nrf2 u bronhijalnim epitelijalnim ćelijama stimulisanih duvanskim dimom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (mentor), dr Marija Stanković (mentor).

1. **Stanković Sara**. Detekcija varijanti u kodirajućoj sekvenci gena ABCD1 kod bolesnika sa kliničkom dijagnozom X-vezane adrenoleukodistrofije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2022.

Komisija: dr Brajušković Goran (mentor), dr Janković Milena (mentror).

1. **Velimirović Milica.** Analiza efekata odabranih mikroRNK na ekspresiju gena *SOXB* u ćelijskim linijama poreklom od glioblastoma. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Stanisavljević Ninković Danijela (mentor), dr Brajuškovć Goran (mentor).

1. **Pašić Ivana**. Asocijacija varijante rs41423247 u genu za glukokortikoidni receptor *NR3C1* i samoubistva. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Stojković Oliver (mentor), dr Brajuškovć Goran (mentor), dr Brkušanin Miloš (član)

1. **Ćorović Miona**. Povezanost nutrigenetičkih markera cinka i selena sa težinom kliničke slike COVID-19. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Skakić Anita (mentor), dr Brajuškovć Goran (mentor).

1. **Mirecki Andrea**. Studija asocijacije varijante u broju trinukleotidnih ponovaka u genu za androgeni receptor i težine kliničke slike kod bolesnika sa COVID-19. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2021.

Komisija: dr Marjanović Irena (mentor), dr Brajuškovć Goran (mentor).

1. **Stevanović Nina**. Molekularna karakterizacija novootkrivenih genetičkih varijanti kod pacijenata sa primarnom cilijarnom diskenezijom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Anđelković Marina (mentor), dr Brajuškovć Goran (mentor).

1. **Pavlović Đorđe**. Analiza ekspresije duge nekodirajuće RNK GAS5 kod akutne mijeloidne leukemije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Gašić Vladimir (mentor). dr Brajuškovć Goran (mentor), dr Zukić Branka (član).

1. **Đokić Milena**. Studija asocijacije varijante *SOD2* rs4880 sa kliničkim parametrima i rizikom za nastanak multiple skleroze u populaciji pacijenata iz Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Živković Maja (mentor), dr Brajuškovć Goran (mentor).

1. **Čolić Aleksandra**. *In vitro* ispitivanje citotksične aktivnosti novih derivata dobijenih Biđinelijevom sintezom na humanim maignim ćelijskim linijama i neizemenjenim. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Stanojković Tatjana (mentor), dr Brajuškovć Goran (mentor), dr Matić Ivana (član).

1. **Miljuš Maša**. Citotoksični efekat diarilheptanoida izolovanih iz crne jove (*Alnus glutinosa (L.) Gaertn.*) na *HeLa*, *PC-3* i *MRC-5* humanim ćelijkim linijama. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Matić Ivana (mentor), dr Brajuškovć Goran (mentor), dr Stanojković Tatjana (član).

1. **Ristić Dušica**. Efekat *Salinomycin*-a na ćelijske linije meanoma različite invazivnosti u uslovima hipoksije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

**Komisija**: dr Marković Milan (mentor), dr Brajuškovć Goran (mentor), dr Mijatović Sanja (član).

1. **Džebrić Miloš**. Analiza uloge miR-219 u indukciji neuralne diferencijacije humanih pluripotentnih NT2/D1 ćelija. Mater rad.Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Švirtlih Marija (mentor), dr Brajušković Goran (mentor), dr Stanisavljević Danijela (član).

1. **Rajković Milica**. Analiza varijabilnosti funkcionalnih polimorfizama u genima *CYP3A4* i *CYP1A1* u romskoj populaciji Srbije. Mater rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Stojković Oliver (mentor), dr Brajušković Goran (mentor), Skadrić Ivan (član).

1. **Šenk Vladimir**. Uloga faktora inhibicije migracije makrofaga u inflamaciji, insulinskoj rezistenciji i sinaptičkoj plastičnosti prefrontalnog korteksa miša hranjenog fruktozom. Mater rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Đorđević Ana (mentor), dr Brajušković Goran (mentor), dr Bursać Biljana (član).

1. **Jelača Sanja**. Signalni put glukokortikoida u jetri pacova tretiranog 5alfa-dihidrotestosteronom kao animalnom modelu sindroma policističnih jajnika. Mater rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Vojnović-Milutinović Danijela (mentor), dr Brajušković Goran (mentor), dr Nestorov Jelena (član).

1. **Aleksić Milan**. Uticaj ponovljene primene propofola na ponašanje i ekspresiju biohemijskih pokazatelja sinaptičke, neuronske i dopaminske aktivnosti kod peripubertalnih pacova. Mater rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Pešić Vesna (mentor), dr Brajušković Goran (mentor).

1. **Stefanović Milan**. Studija asocijacije genetičkih varijanti *IL2RA* rs 2104286, *IFI30* rs 11554159 i *IKZF3* rs12946510 sa kliničkim parametrima multiple skleroze. Mater rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor).

1. **Dunjić Sofija**. Analiza ekspresije protrombina u permanentnim tumorskim ćelijskim linijama. Mater rad.Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Pruner Iva (mentor), dr Brajušković Goran (mentor), dr Tomić Branko (član).

1. **Jovanović Tamara**. Analiza protrombina u tumoru debelog creva čoveka. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Tomić Branko (mentor), dr Brajušković Goran (mentor), dr Pruner Iva (član).

1. **Mitrović Gordan**. Primena Raman mikroskopije za brzu detekciju malignih ćelija. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Brajušković Goran (mentor), dr Mitić-Ćulafić Dragana (mentor).

1. **Arsenijević Ana.** Uloga retonične kiseline u regulaciji profileracije, ćelijskog ciklusa i migracije MCF-7 ćelija poreklom od karcinoma dojke. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Petrović Isidora (mentor), dr Brajušković Goran (mentor), dr Stevanović Milena (član).

1. **Ercegović Jovana**. Varijante rs1042522 u genu *TP53* i rs25487 u genu *XRCC1* kao prognostički parametri karcinoma dojke. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Krivokuća Ana (mentor), dr Brajušković Goran (mentor), dr Čavić Milena (član).

1. **Kolakov Nikola**. Analiza metilacije gena *P14ARF* u lokalno uznapredovalim karcinomima rektuma čoveka. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Krajnović Milena (mentor), dr Brajušković Goran (mentor), dr Davidović Radoslav (član).

1. **Hranisavljević Jelena.** Ispitivanje metilacionog statusa netranslatirajućeg egzona OH gena za estrogenski receptor β kod rabdomiosarkoma. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Davidović Radoslav (mentor), dr Brajušković Goran (mentor), dr Mandušić Vesna (član).

1. **Vlatković Tijana**. Analiza nivoa genomske nestabilnosti kod invazivnih duktalnih i lobularnih tumora dojke DNK profilisanjem.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Dramićanin Tatjana (mentor), dr Brajušković Goran (mentor), dr Tanić Nasta (član).

1. **Šami Ahmad**. Ispitivanje povezanosti nivoa ekspresije gena *TIMP-3* sa invazivnošću karcinoma dojke. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Petrović Nina (mentor), dr Brajušković Goran (mentor), dr Zlatković Jelena (član).

1. **Ivančević Ilija**. Studija asocijacije polimorfizma rs36212560 u promotoru gena za tirozin fosfatazi sličan A domen sadržavajući protein 2 sa infarktom miokarda. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Đurić Delić Tamara (mentor), dr Brajušković Goran (mentor).

1. **Kuburović Mira.** Studija asocijacije varijanti rs25487 gena *XRCC1* i rs1801320 gena *RAD51* sa preživljavanjem bolesnika sa adenokarcinomom pluća tretiranih platinskom terapijom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Čavić Milena (mentor), dr Brajušković Goran (mentor), dr Krivokuća Ana (član).

1. **Ranković Branislava**.Uspostavljanje uslova za modulaciju *Hedgehog* signalnog puta u *HeLa* ćelijama. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Petrović Isidora (mentor), dr Brajušković Goran (mentor), dr Stevanović Milena (član).

1. **Kostić Milan.** Uticaj ishrane bogate fruktozom na ekspresiju i ćelijsku lokalizaciju lipina-1 u srcu pacova. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Korićanac Goran (mentor), dr Brajušković Goran (mentor).

1. **Savić Milica**. Antileukemijsko dejstvo cikloheksil analoga etilendiamin dipropanske kiseline *in vitro*. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Misirlić-Denčić Sonja (mentor), dr Brajušković Goran (mentor).

1. **Gotovac Jovana**. Studija asocijacije polimorfizma rs2282679 u genu za GC-globulin sa nastankom i kliničkim tokom multiple skleroze. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Stojković Ljiljana (mentor), dr Brajušković Goran (mentor).

1. **Jovičić Snežana**. Analiza mutacija u genima *B-Raf* i *K-Ras* u tkivu tumora štitne žlezde. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Nikolić Aleksandra (mentor), dr Brajušković Goran (mentor), dr Divac Rankov Aleksandra (član).

1. **Radović Ranko**. Ispitivanje uticaja polimorfizma c.457-397T>C u genu za estrogeni receptor alfa na pojavu tromboza kod žena sa kancerom dojke. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Rakočević Ljiljana (mentor), dr Brajušković Goran (mentor), dr Radojković Dragica (član).

1. **Pekmezović Marina**. Molekularna tipizacija i ispitivanje osetljivosti kliničkih sojeva *Cryptococcus neoformans* izolovanih kod pacijenata sa kompromitovanim imunskim sistemom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Arsić-Arsenijević Valentina (mentor), dr Brajušković Goran (mentor).

1. **Pokimica Biljana**. Analiza mutacije V600E u genu *BRAF* kod bolesnika sa oralnim planocelulanim karcinomom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Magić Zvonko (mentor), dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Marjanović Jelena**. Efekti modulacije kanonskog WNT signalnog puta na ekspresiju SOX gena u humanim Ntera2/D1 ćelijama. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Mojsin Marija (mentor), dr Brajušković Goran (mentor), dr Stevanović Milena (član).

**Učešća u komisijama za odbranu master radova**

1. **Garai Nemanja**.Učestalosti alela i stope mutacija 22 mikrosatelitska lokusa za humanu identifikaciju u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2020.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Rmandić Milica**. Analiza sekvence gena za angiogenin kod bolesnika sa Parkinsonovom bolešću sa teritorije Srbije. 2020.

Komisija: dr Novaković Ivana (mentor), dr Savić-Pavićević Dušanka (mentor), dr Brajuškovć Goran (član).

1. **Jeličić Milica**. Ispitivanje genetičke anticipacije u porodicama sa miotoničnom distrofijom tipa 2. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), Pešović Jovan (član).

1. **Radenković Lana**. Modelovanje kinetike neurotransmisije u serotoninskoj sinapsi. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), dr Karanović Jelena (član).

1. **Petrović Dunja.** Studija asocijacije varijante rs4263037 u genu *TNFRSF11A* sa miastenijom gravis u populaciji Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), Brkušanin Miloš (član).

1. **Dunjić Marko**. Evolucija sekundarnih struktura dugih nekodirajućih RNK povezanih sa razvojem psihijatrijskih poremečaja. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2018.

Komisija: dr Nowick Katja (mentor), dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Jovanović Olga**. Formiranje sferoida od matičnih embrionalnih ćelija miša i njihova diferencijacija u srčane mišićne ćelije.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2017.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Vunjak Milica**. Ispitivanje interakcije proteina uključenih u transkripciju prekursora piRNK kod *Drosophila melanogaster*.Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Maširević Srđan**. Procena starosti mutacije povezane sa miotoničnom distrofijom tip 2 u evropskim populacijama. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija:dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), dr Jovanović Vladimir (član), Brkušanin Miloš (član).

1. **Rajovski Srećko.** Citogenetička i biohemijska analiza amnionske tečnosti u drugom trimestru trudnoće kod žena sa rizikom pojave hromozomskih aberacija kod potomstva. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Jasnić Nebojša (mentor), dr Vasilevska Marinela (mentor), dr Brajušković Goran (član), dr Dimevska Gordana (član).

1. **Kovčić Vlado**. Analiza haplotipova kod bolesnika sa mitoničnom distrofijom tipa 2 iz Srbije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), Pešović Jovan (član).

1. **Mandić Miloš**. Uspostavljanje metode za analizu broja ponovaka CCTG u genu *CNBP*. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član), Pešović Jovan (član).

1. **Živković Jovana**. Primena laserske mikrodisekcije kuplovane sa fotoaktivirajućom lokalizacionom mikroskopijom (PALM-LCM) u analizi tragova seksualnih delikata. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Keckarević Dušan (mentor), dr Brajušković Goran (član), dr Kecmanović Miljana (član).

1. **Tomić Vanja**. Vrste i zastupljenosti numeričkih hromozomskih aberacija u nalazima kariotipa fetusa čovjeka na području Republike Srpske u periodu od januara 2009. godine do aprila 2013. godine. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Pešović Jovan**. Povezanost mutacija u genu za distrofin sa kognitivnim poremećajima kod Dišenove mišićne distrofije. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Milić-Rašić Vedrana (član), dr Brajušković Goran (član).

1. **Ivin Maša**. Studija asocijacije varijanti u genu *ADARB1*– rs1008983, rs2838817 i rs4818766 – sa šizofrenijom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Ivković Maja (član), dr Brajušković Goran (član).

1. **Đurica Svetlana**. Studija asocijacije varijanti u genu *ADARB1* – rs1008983, rs2838817 i rs4818766 – sa unipolarnom i bipolarnom depresijom. Master rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Ivković Maja (član), dr Brajušković Goran (član).

**Mentorstvo u odbranjenom specijalističkom radu**

1. **Latinović Nataša.** Primena molekularno-dijagnostičkog testa *Hybrid Capture 2 HPV DNA* i detekcija humanih papiloma virusa visokog onkogenog potencijala. Specijalistički rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Andrijević Ljiljana (mentor), dr Brajušković Goran (mentor), dr Božić Nedeljković Biljana (član).

**Učešća u komisiji za odbranu specijalističkog rada**

1. **Živković Tanja**. Značaj HLA-DQ tipizacije i serološkog skrininga u otkrivanju celijakije kod pedijatrijskih pacijenta. Specijalistički rad. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Božić Nedeljković Biljana (mentor), dr Brajušković Goran (član).

**Mentorstva u odbranjenim diplomskim radovima**

1. **Radovanović Aleksandra**. Uloga mikroRNK u patogenezi karcinoma prostate. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Brajušković Goran (mentor), dr Brkušanin Miloš (član).

1. **Marković Marko**. Molekularno-genetička istraživanja idiopatskog steriliteta kod muškaraca iz populacije Srbije. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2019.

Komisija: dr Brajušković Goran (mentor), dr Brkušanin Miloš (član).

1. **Janković Uroš**. CD104 kao marker stem ćelija karcinoma dojke. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2016.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Brkušanin Miloš (član).

1. **Filipović Ana.** Značaj tačkastih polimorfizama kao novih bioloških markera za dijagnostiku i praćenje karcinoma prostate. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Nikolić Zorana (član).

1. **Milošević Đorđe**. Meta-analiza genetičkih varijanti u genu za NOS3 sa rizikom za razvoj karicnoma prostate. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Nikolić Zorana (član).

1. **Radović Sanja**. Analiza indikacija za prenatalnu dijagnostiku kariotipa kod trudnica sa predisponirajućim faktorima za rizičnu trudnoću na teritoriji grada Novog Sada. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Vreća Miša**. Asocijacija genetičke varijante rs1799983 sa karcinomom prostate u populaciji Srbije. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Kalaba Predrag**. Analiza dva tačkasta polimorfizma lokusa 8q24 kod bolesnika sa karcinomom prostate u populaciji Srbije. Završni rad. Hemijski fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Brajušković Goran (mentor), dr Polović Natalija (mentor), dr Savić-Pavićević Dušanka (član).

1. **Mirković Mihailo**. Analiza tačkastog polimorfizma rs3760511 lokusa 17q12 kod bolesnika sa karcinomom prostate u srpskoj populaciji. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Karanović Jelena (član).

1. **Stanković Ivan**. Analiza tačkastog polimorfizma rs7501939 lokusa 17q12 kod bolesnika sa karcinomom prostate u srpskoj populaciji. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Divović Danka**. Molekularna osnova karcinoma prostate. Završni rad. Hemijski fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Brajušković Goran (mentor), dr Polović Natalija (mentor).

1. **Rašković Brankica**. Analiza tačkastog polimorfizma rs4242382 lokusa 8q24 kod bolesnika sa karcinomom prostate u srpskoj populaciji. Završni rad. Hemijski fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Brajušković Goran (mentor), dr Polović Natalija (mentor).

1. **Mirčetić Jovan**. Analiza tačkastih polimorfizama 8q hromozoma povezanih sa progresijom karcinoma prostate. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Petrićević Biljana**. Povezanost tačkastih polimorfizama u promotorskom regionu gena za NOS3 sa progresijom karcinoma prostate. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Karanović Jelena (član).

1. **Vukotić Goran**. Obnavljanje funkcije nokautiranih gena u mutantima *Vibrio salmonicida*. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član).

1. **Matić Miloš**. Uticaj tumorskih fibroblasta na pokretljivost ćelija karcinoma debelog creva. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Kecmanović Miljana (član), Karanović Jelena (član).

1. **Mijušković Ana**. Mikrobiološka biosinteza zlatnih nanopartikula. Završni rad. Hemijski fakultet. Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Mandić Ljuba (mentor).

1. **Despić Vladimir**. *Flower:* potencijalni marker procesa ćelijske kompeticije. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Brajušković Goran (mentor), dr Savić-Pavićević Dušanka (član), Karanović Jelena (član).

1. **Radivojević Miloš**. Molekularna analiza Gli3 gena kod bolesnika sa *Palister-Hall* sindromom. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2009.

Komisija: dr Brajušković Goran (mentor), Keckarević-Marković Milica (član).

1. **Diklić Miloš**. Molekularno genetička manipulacija hloroplastom DNK hrastova. Diplomski rad. Hemijski fakultet, Univerzitet u Beogradu, 2009.

Komisija: dr Brajušković Goran (mentor), dr Mandić Ljuba (mentor), dr Savić-Pavićević Dušanka (član).

1. **Branković Ivan**. Ultrastrukturna analiza procesa programirane ćelijske smrti po tipu apoptoze u ćelijama hronične limfocitne leukemije. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2007.

Komisija: dr Brajušković Goran (mentor), dr Korać Aleksandra (mentor).

1. **Tasić Jelena**. Uticaj tačkastog nukleotidnog polimorfizma na aktivnost promotora proteina kinaze C beta i moguća uloga u insulinskoj rezistenciji. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2007.

Komisija: dr Brajušković Goran (mentor), dr Romac Stanka (član).

**Mentorstva sa fakulteta u odbranjenim diplomskim radovima**

1. **Miletić Mirjana**. Detekcija izoformi estrogenskog receptora beta (ЕRβ) imunoprecipitacijom i Ramanovom spektrometrijom. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Mandušić Vesna (mentor), dr Brajušković Goran (mentor).

1. **Krnjajić Mina**. Ispitivanje unutarćelijske lokalizacije proteina hAnkrd1 i ZO-1 u kulturi epitelijalnih ćelija HeLa. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2014.

Komisija: dr Nestorović Aleksandra (mentor), dr Brajušković Goran (mentor).

1. **Skakić Anita**. Analiza varijanti u FTO, FABP2, PPARG, ADARB2 i ADARB3 genima kod ispitanika iz srpske populacije – kao preduslov za razvoj nutrigenetičkog algoritma za gojaznost. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Stojiljković Maja (mentor), dr Brajušković Goran (mentor).

1. **Brkljač Marko**. Analiza insercionog polimorfizma u genu *TP53* u akutnoj limfoblasnoj leukemiji kod dece. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2013.

Komisija: dr Milašin Jelena (mentor), dr Brajušković Goran (mentor).

1. **Marković Bojana**. Detekcija B-raf gena i mutacije V600E kod humanih kolorektalnih kancera. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Krtolica-Žikić Koviljka (mentor), dr Brajušković Goran (mentor).

1. **Životić Ivan**. Delecioni polimorfizmi u genima za GST M1 i T1 kao faktor rizika za nastanak multiple skleroze. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor).

1. **Lukić Nikola**. Uticaj polimorfizma Pro12Ala gena *PPARγ* u nastanku multiple skleroze. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor).

1. **Karanović Jelena**. Polimorfizam DNK u genu za apolipoprotein E kao faktor rizika za aterosklerozu karotida. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor).

1. **Filipović Lana**. Molekularna dijagnostika Hepatitis C virusa. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Ristanović Elizabeta (mentor), dr Brajušković Goran (mentor).

1. **Gemović Branislava**. Analiza primarne strukture proteina hemaglutinina 1 influence virusa H5N1 izolovanih u 2008. godini. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Veljković Nevena (mentor), dr Brajušković Goran (mentor).

1. **Stojković Ljiljana**. Polimorfizam -174 G/C u genu za interleukin-6 kao faktor rizika za inflamaciju i nastanak ožiljnih promena na bubrezima u akutnom pijelonefritisu. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2007.

Komisija: dr Živković Maja (mentor), dr Brajušković Goran (mentor).

**Učešća u komisijama za odbranu diplomskih radova**

1. **Marjanović Nemanja**. Značaj bivalentnog hromatina na promotoru Zeb1 gena za fenotipsku plastičnost i tumorogeni potencijal ćelija raka dojke. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2015.

Komisija: dr Božić Biljana (mentor), dr Brajušković Goran (član).

1. **Jovanović Marija**. Uticaj zračenja na ekspresiju miRNK u ćelijskim linijama kancera dojke. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Novković Mirjana**. Genetička studija asocijacije varijanti u promotoru gena za triptofan hidroksilazu sa izvršenjem samoubistva. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2012.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Brkušanin Miloš**. Studija genetičke asocijacije polimorfizama G-703T i T-437A u promotoru gena za triptofan hidroksilazu 2 sa depresijom. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Savić-Pavićević Dušanka (mentor), dr Brajušković Goran (član).

1. **Vučićević Dubravka**. Dejstvo arilpiperazina na citotoksičan efekat azot monoksida u kulturi neuroblastomske ćelijske linije SH-SYY. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2011.

Komisija: dr Zogović Nevena (mentor), dr Korać Aleksandra (mentor), dr Brajušković Goran (član), Veličković Ksenija (član).

1. **Bursać Biljana**. Analiza sekvence citohrom B gena u cilju forenzičke diskriminacije viših kičmenjaka. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2010.

Komisija: mr Keckarević Dušan (mentor), dr Brajušković Goran (član).

1. **Šerbanović Jovana**. Indukcija transkripcionog faktora Hey 1 od strane BMP-2. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 2008.

Komisija: dr Božić Biljana (mentor), dr Brajušković Goran (član)

**Držanje nastave na kursevima**

**Držanje nastave na kursevima za koje je kandidat uradio program**

osnovne studije

2017 – **Istorija biologije** – izborni predmet za sve studijske grupe

2005 – **Molekularna genetika**, Biološki fakultet, Univerzitet u Beogradu - obavezni predmet

2012 – **Molekularna biologija ćelije**, Biološki fakultet, Univerzitet u Beogradu - obavezni predmet

2017 – 2024 **Molekularna biologija**, studijska grupa Biologija, u saradnji sa prof. dr Dušankom Savić-Pavićević (nastavnici na kursu doc. dr Miljana Kecmanović i doc. dr Milica Keckarević-Marković) - obavezni predmet

2006 – 2017 **Molekulska genetika**, Hemijski fakultet, Univerzitet u Beogradu - obavezni predmet

2015 – 2018 **Molekularna biologija eukariota**, Biološki fakultet, Univerzitet u Beogradu - obavezni predmet

2010 – 2012 **Viši kurs molekularne biologije**, Biološki fakultet, Univerzitet u Beogradu - obavezni predmet

2008 – 2009 **Biologija na internetu** – izborni predmet

master studije

2011 – **Molekularna biologija maligne ćelije**, Biološki fakultet, Univerzitet u Beogradu- obavezni predmet

doktorske studije

2021 – **Molekularna patogeneza bolesti čoveka**. Biološki fakultet, Univerzitet u Beogradu – izborni predmet

2013 – 2020 **Molekularna dijagnostika malignih bolesti**, Biološki fakultet, Univerzitet u Beogradu – izborni predmet

Predavanja u okviru doktorskih studija Biološkog fakulteta (moduli Molekularna biologija i Biologija) u okviru predmeta:

*2021* – *Molekularna biologija ćelije*

2010 – 2021 *Metodološki pristupi u molekularnoj biologiji*

1. – 2021 *Molekularna biologija gena*

*2010* – *2012 Molekularna osnova neuroloških i psihijatrijskih bolesti*

*2007 – 2008 Ultrastrukturna patologija (modul Biologija ćelije i tkiva)*

**Držanje nastave na kursu za koji je kandidat pripremio dopunu nastavnog programa**

2019/2020 **Molekularna genetika**, Prirodno-matematički fakultet u Novom Sadu

**Držanje nastave na kursevima sa preuzetim programom**

2006 – 2007 **Osnovi molekularne biologije**, Biološki fakultet, Univerzitet u Beogradu

2006 – 2008 **Osnovi molekularne biologije**, Hemijski fakultet, Univerzitet u Beogradu

2010 – 2011 **Molekularna biologija eukariota**, Biološki fakultet, Univerzitet u Beogradu

----------------- bez bodovanja

2001 – 2005 Učešće u nastavi na magistarskim studijama Biološkog fakulteta, Univerziteta u Beogradu na predmetima **Molekulski regulacioni mehanizmi** i **Molekularna biologija eukariota – viši kurs**.

2001 – 2007 **Molekularna osnova tumora**, poslediplomske specijalističke studije za lekare, stomatologe i farmaceute, Vojnomedicinska akademija u Beogradu

2001 – 2007 **Ultrastrukturna patologija**, poslediplomske specijalističke studije patološke anatomije, Vojnomedicinska akademija u Beogradu

2006 – 2007 **Mikrobiologija**, Viša sanitarno-zdravstvena škola „Visan”, Beograd, Republika Srbija

2006 – 2007 **Sanitarna mikrobiologija**, Viša sanitarno-zdravstvena škola „Visan”, Beograd, Republika Srbija

**Ostale nastavne aktivnosti**

**Recenzija udžbenika**

1. **Branković A**. Biologija: Praktikum sa radnim listovima. Kriminalističko-policijski univerzitet. 2022. Rešenje Kriminalističko-policijskog univerziteta 01/br. 15/27-2 od 17.11.2022.
2. **Polović N**. Osnovi biohemije. Beograd: Univerzitet u Beogradu-Hemijski fakultet. 2021.
3. **Savić-Pavićević D**, **Matić G**. Molekularna biologija 1. Beograd: NNK internacional. 2011. ISBN 978-86-6157-001-8.

**Držanje nastave za stručno usavršavanje nastavnika osnovnih i srednjih škola**

Na osnovu obaveštenja Zavoda za unapređenje obrazovanja i vaspitanja broj:570-620/2016 od 18. aprila 2016. godine o odbrenom programu za školske 2016/2017 i 2017/2018. godine

26.11.2017.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Beograd

25. 02. 2017.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Beograd

Na osnovu obaveštenja Zavoda za unapređenje obrazovanja i vaspitanja broj:16621/2015 od 2. februara 2015. godine o odbrenom programu za školske 2014/2015 i 2015/2016. godine

04. 06. 2016.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Beograd

12.03. 2016.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Beograd

6. 06. 2015.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Užice

25. 04. 2015.- Seminar „MOLEKULARNA BIOLOGIJA – lakšim putem do funkcionalnog znanja“ (akreditovani seminar od strane Zavoda za unapređivanje obrazovanja i vaspitanja, kataloški broj:K890791-1), Beograd

**Učešće u pedagoškom radu sa učenicima osnovnih i srednjih škola**

2020- seminar Biologija, 21. februar 2020. godine – „Regulacija ekspresije gena kod eukariota i Epigenetika“

2016- seminar Biologija, 12. april 2016. godine – „Uvod u molekularnu biologiju – koncepti gen, genom, fenomeni odgovorni za održavanje i ekspresiju genoma“

2016- seminar Biomedicina, 19. februar 2016. godine – „Signali u apoptozi“

2014 - seminar Biologija, 28. mart 2014. godine – „Nevidljivi” svet bioloških makromolekula“

2014 - seminar Biomedicina, februar2014. godine – „Osnovni principi naučno-istraživačkog rada“

**Predavanja po pozivu**

* Simpozijum: Medicinsko obrazovanje je osnovno u zaštiti naroda tokom pandemije izazvane virusom SARS-COV-2

Predavanje: „*Savremena dostignuća genomske medicine kao kontraverza i skepsa među doktorima medicine – razloci i moguća rešenja”*

Organizator: Akademija medicinskih nauka SLD i Srpsko lekarsko društvo

Datum i mesto održavanja: 8. april 2022. godine, prostorije SLD – Beograd

* Kongres: Drugi kongres studenata biologije „Simplast“

Predavanje: „*Aleli niske penetrabilnosti kao biološki markeri karicnoma prostate“*

Organizator: Savez studenata Biološkog fakulteta, Univerzitet u Beogradu - Biološki fakultet

Datum i mesto održavanja: 27. – 31. oktobar 2016, Zlatibor

* Simpozijum „Dijagnostika i lečenje karcinoma prostate“

Predavanje: *„Tačkaste genetičke varijante kao parametri karcinoma prostate“*

Organizator: Srpsko lekarsko društvo (SLD) u saradnji sa Institutom za patologiju i sudsku medicinu VMA

Datum i mesto održavanja: 7. oktobar 2016. godine, prostorije SLD – Beograd

* Simpozijum „Značaj genetskog istraživanja u dijagnostici i lečenju“

Predavanje: *„Studije asocijacije genetickih varijanti u nekodirajućim regionima genoma, u genima za proteine i u genima za mikro RNK sa rizikom za razvoj i progresiju karcinoma prostate”* (http://kme-srbija.com/tag/goran-brajuskovic)

Organizator: Akademija medicinskih nauka SLD i Društvo lekara Vojvodine

Datum i mesto održavanja: 13. maj 2016. godine, Sremski Karlovci

Internet adresa: http://www.sldkcs.org/simpozijum-znacaj-genetskog-istrazivanja-u-dijagnostici-i-lecenju/

* Kurs prve kategorije „Novine u modernoj patologiji – sećanje na dr Jeremić Nenada“

Predavanje: *„Genomika“*

Organizator: Savez udruženja zdravstvenih radnika Srbije, Društvo laboratorijskih tehničara Srbije

Datum i mesto održavanja: 05.03.2012. godine, VMA – Beograd

Internet adresa: http://www.kmszts.org.rs/edukacija/Plan2012.pdf

* Simpozijum „Tumori testisa“

Predavanje: *„Molekularna osnova malignih tumora testisa“*

Organizator: Akademija medicinskih nauka SLD i Vojnomedicinska akademija

Datum i mesto održavanja: 2004. godina, VMA – Beograd

**Članstvo u organizaciji naučnih skupova:**

* 2019. Član, Naučni odbor IX konferenciju Biohemijskog društva Srbije
* 2017. Predsednik, Organizacioni odbor Prvog kongresa molekularnih biologa Srbije
* 2017. Član, Naučni odbor Prvog kongresa molekularnih biologa Srbije
* 2010. Član, Naučni odbor IV Kongresa mikroskopije Srbije
* 2007. Član, Organizacioni i naučni odbor III Kongresa mikroskopije Srbije
* 2006. Član, Naučni odbor XII Kongresa patologa Srbije i Crne Gore
* 2002. Sekretar, Organizacionog odbora X Kongresa patologa Jugoslavije
* 2002. Član, Naučnog odbora X Kongresa patologa Jugoslavije

**Članstvo u organizaciji stručnih skupova:**

* 2019. Prva napredna petnička škola molekularne biologije „Kvantitativni PCR“ namenjena studentima doktorskih studija
* 2019. Četvrta Petnička škola molekularne biologije – PCR u biološkim i medicinskim istraživanjima, namenjena studentima svih nivo studija (od osnovnih do doktorskih)
* 2017. Druga Petnička škola molekularne biologije – PCR u biološkim i medicinskim istraživanjima, namenjena studentima svih nivo studija (od osnovnih do doktorskih)
* 2016. Prva Petnička škola molekularne biologije – PCR u biološkim i medicinskim istraživanjima, namenjena studentima svih nivo studija (od osnovnih do doktorskih)

**Organizacija:**

* Stručni skup – obeležavanje jubileja „50 godina molekularne biologije u Srbiji“ , 3. jun 2022. godine, Botanička bašta „Jevremovac“ Univezitet u Beogradu-Biološki fakultet.

**NAUČNA DELATNOST**

**Kvantitativan prikaz postignutih rezultata naučnog rada prema kriterijumima Pravilnika za sticanje nastavnih znanja Univerziteta u Beogradu – Biočpškog fakulteta**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Vrsta rezultata** | **Vrednost** |  | |  | **Broj** | | **Poeni** |
| **Osnovne naučne aktivnosti** | | | |  | | |  | |
| **М14** | **Monografska studija/poglavlje u knjizi М12** | **4** |  | |  | **2** | | **8** |
| **М21** | **Rad u vrhunskom međunarodnom časopisu** | **8** |  | |  | **11** | | **88** |
| **М22** | **Rad u istaknutom međunarodnom časopisu** | **5** |  | |  | **13** | | **65** |
| **М23** | **Rad u međunarodnom časopisu** | **3** |  | |  | **18** | | **54** |
| **М24** | **Rad u časopisu verifikovan posebnom odlukom** | **2** |  | |  | **4** | | **8** |
| **M32** | **Predavanje po pozivu sa skupa međunarodnog značaja štampano u izvodu** | **1,5** |  | |  | **1** | | **1,5** |
| **M33** | **Saopštenje sa međunarodnog skupa štampano u celini** | **1** |  | |  | **3** | | **3** |
| **М34** | **Saopštenje sa međunarodnog skupa štampano u izvodu** | **0.5** |  | |  | **79** | | **39,5** |
| **M42** | **Monografija nacionalnog značaja** | **5** |  | |  | **1** | | **5** |
| **M44** | **Poglavlje u knjizi kategorije M41** | **2** |  | |  | **1** | | **2** |
| **М45** | **Poglavlje u knjizi kategorije M42** | **1.5** |  | |  | **3** | | **4,5** |
| **М52** | **Rad u časopisu nacionalnog značaja** | **1.5** |  | |  | **40** | | **60** |
| **M53** | **Rad u naučnom časopisu** | **1** |  | |  | **3** | | **3** |
| **M57** | **Naučna kritika u časopisu ranga M52** | **0,2** |  | |  | **2** | | **0,4** |
| **М61** | **Predavanje po pozivu sa skupa nacionalnog značaja štampano u celini** | **1.5** |  | |  | **14** | | **21** |
| **М62** | **Predavanje po pozivu sa skupa nacionalnog značaja štampano u izvodu** | **1** |  | |  | **4** | | **4** |
| **M63** | **Saopštenje sa skupa nacionalnog značaja štampano u celini** | **1** |  | |  | **9** | | **9** |
| **М64** | **Saopštenje sa skupa nacionalnog značaja štampano u izvodu** | **0.2** |  | |  | **58** | | **11,6** |
| **M66** | **Uređivanje zbornika saopštenja** | **1** |  | |  | **1** | | **1** |
| **M66a** | **Stručni rad, naučno-popularni i popularni radovi** | **0.2** |  | |  | **2** | | **0,4** |
| **М71** | **Odbranjena doktorska teza** | **6** |  | |  | **1** | | **6** |
| **М72** | **Odbranjen magistarski rad** | **3** |  | |  | **1** | | **3** |
| **Ukupno** | |  |  | |  |  | | **397,9** |
| **Ostale naučne aktivnosti** | | | |  | | |  | |
|  | **Učešće na međunarodnom projektu** | **2** |  | |  | **2** | | **4** |
|  | **Učešće u nacionalnom projektu** | **1** |  | |  | **3** | | **3** |
|  | **Recenzija publikacija kategorije M20** | **1,5** |  | |  | **82** | | **123** |
|  | **Recenzija publikacije kategorije M50/60** | **1/0,5** |  | |  | **6/1** | | **6,5** |
|  | **Članstvo u uredništu međunarodnog časopisa** | **3** |  | |  | **2** | | **6** |
|  | **Citiranost na SCI listi** | **0.1** |  | |  | **372** | | **37,2** |
| **Ukupno** | |  |  | |  |  | | **179,7** |
| **Ukupno osnovne i ostale naučne aktivnosti** | |  |  | |  |  | | **577,6** |

**Monografska studija/poglavlje u knjizi M12 ili rad u tematskom zborniku međunarodnog značaja**

1. Nikolić Z, Savić-Pavićević D, **Brajušković G**. Genetic Association Studies on Prostate Cancer. In: Mohan R, ed. Prostate Cancer - Leading-edge Diagnostic Procedures and Treatments. InTECH 2016. ISBN 978-953-51-2645-4. p.145-177.
2. Savić-Pavićević D, Ivković M, Karanović J, **Brajušković G**, Romac S. Retinoic acid inducible-1 gene (*RAI1*) and clinical subtypes of schizophrenia. In:Li-Hong C, Yuto I, eds. Retinoic acid: Structure, Metabolism and Roles in Disease. New York: NOVA Publisher. 2012. ISBN: 978-1-62100-597-1.

**Radovi u međunarodnim časopisima – 44 rada od kojih 40 sa IF** *(ukupni IF=84.136)*

**Radovi u vodećim međunarodnim časopisima (M21)**

1. Filipović L, Spasojević M, Prodanović R, Korać A, Matijaševic S, **Brajušković G**, de Marco A, Popović M. Affinity-based isolation of extracellular vesicles by means of single-domain antibodies bound to macroporous methacrylate-based copolymer. N Biotechnol. 2022;69:36-48. (M21, IF2021=6.490).
2. Vučić N, Dobrijević Z, Kotarac N, Matijašević S, Vuković I, Budimirović B, Djordjević M, Savić-Pavićević D, **Brajušković G.** Association study between single-nucleotide variants rs12097821, rs2477686, and rs10842262 and idiopathic male infertility risk in Serbian population with meta-analysis. Journal of Assisted Reproduction and Genetics 2020. 37(11):2839-52. (M21, IF2019=2.829).
3. Kotarac N, Dobrijević Z, Matijašević S, Savić-Pavićević D, **Brajušković G**. Analysis of association of potentially functional genetic variants within genes encoding miR-34/b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population. EXCLI Journal 2019; 18:515-29. (M21, IF2019=2.837).
4. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. Front. Genet. 2018; 9:601. (M21, IF2017=4.151)
5. Nikolić Z, Savić-Pavićević D, Vučić N, Cerović S, Vukotić V, **Brajušković G**. Genetic variants in RNA-induced silencing complex genes and prostate cancer. World J Urol. 2017; 35(4):613-24. (M21, IF2017=2.981)
6. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Neurogenetics 2017; 18(4):207-18. (M21, IF2015=3.426)
7. Karanović J, Ivković M, Jovanović VM, Pantović M, Pavlović-Janković N, Damjanović A, **Brajušković G**, Romac S, Savić-Pavićević D. Tryptophan Hydroxylase 1 Variant rs1800532 is Associated with Suicide Attempt in Serbian Psychiatric Patients but does not Moderate the Effect of Recent Stressful Life Events.Suicide Life Threat Behav. 2016. 46 (6): 664-8. (M21, IF2016=3.252)
8. Nikolić Z, Savić-Pavićević D, Vučić N, Romac S, **Brajušković G**. Association between genetic variant in hsa-miR-146a gene and cancer risk: an updated meta-analysis. Public Health Genomics 2015; 18(5):283-98. (M21, IF2013=2.462)
9. Nikolić Z, Savić-Pavićević D, Vučić N, Cidilko S, Filipović N, Cerović S, Vukotić V, Romac S, **Brajušković G**. Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Experimental and Molecular Pathology 2015; 99:145-50. (M21, IF2013=2.881).
10. Karanović J, Šviković S, Pantović M, Đurica S, **Brajušković G**, Damjanović A, Jovanović V, Ivković M, Romac S, Savić-Pavićević D. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. World Journal of Biological Psychiatry 2015; 1-11. (M21=8, IF2013= 4.225).
11. Nikolić Z, Savić-Pavićević D, Vukotić V, Tomović S, Cerović S, Filipović N, Romac S,ancer progression: evidence from Serbian population. Cancer Causes Control. 2014; 25(11):1571-5. (M21=8, IF2012= 3.200)

**Radovi u istaknutim međunarodnim časopisima (M22)**

1. Joković SM, Dobrijević Z, Kotarac N, Filipović L, Popović M, Korać A, Vuković I, Savić-Pavićević D, **Brajušković G**. MiR-375 and miR-21 as Potential Biomarkers of Prostate Cancer: Comparison of Matching Samples of Plasma and Exosomes. Genes (Basel). 2022; 13(12):2320. (M22=5, IF2022= 4.141)
2. Dobrijević Z, Matijašević S, Išić Denčić T, Savić-Pavićević D, Nedić O, **Brajušković G**. Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis. Gene. 2021;766:145132. (M22, IF2021=3.913)
3. Dobrijević Z, Matijašević S, Savić-Pavićević D, **Brajušković G**. Association between genetic variants in genes encoding Argonaute proteins and cancer risk: a meta-analysis. Pathology - Research and Practice 2020; 216(5):152906. (M22, IF2020=3.250)
4. Kotarac N, Dobrijević Z, Matijašević S, Savić-Pavićević D, **Brajušković G**. Association of KLK3, VAMP8 and MDM4 genetic variants within microRNA binding sites with prostate cancer: evidence from Serbian population. Pathology and Oncology Research 2020; 26(4):2409-23. (M22=5, IF2020=3.201)
5. Vučić N, Nikolić Z, Vukotić V, Tomović S, Vuković I, Kanazir S, Savić-Pavićević D,**Brajušković G**. *NOS3* gene variants and male infertility: association of 4a/4b with oligoasthenozoospermia. Andrologia 2018; 50(1). (M22=5, IF2016=1.458)
6. Karanović J, Ivković M, Jovanović V, Šviković S, Pantović-Stefanović M, Brkušanin M, Damjanović A, **Brajušković G**, Savić-Pavićević D.Effect of childhood general traumas on suicide attempt depends on TPH2 and ADARB1 variants in psychiatric patients. J Neural Transm 2017; 124(5):621-9. (M22=5, IF2015=2.776)
7. Brkušanin M, Kosać A, Jovanović V, Pešović J, **Brajušković G**, Dimitrijević N, Todorović S, Romac S, Milić Rašić V, Savić-Pavićević D. Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients. J Hum Genet.2015; 60(11):723-8. (M22=5, IF2013=2.526)
8. Nikolić Z, Savić-Pavićević D, Romac S, **Brajušković G**. Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta-Analysis. Clinical and Translational Science 2015; 8(1):23-31. (M22=5, IF2013=2.110)
9. Nikolić Z, Branković A, Savić-Pavićević D, Preković S, Vukotić V, Cerović S, Filipović N, Tomović S, Romac S, **Brajušković G**. Assessment of association between common variants at 17q12 and prostate cancer risk – evidence from Serbian population and meta-analysis. Clinical and Translational Science 2014; 7(4):307-13. (M22=5, IF2012=2.330)
10. **Brajušković G,** Branković A,Nikolić Z. Vukotić V, Cerović S, Savić-Pavićević D, Romac S. Endothelial nitric oxide synthase gene polymorphism and prostate cancer risk in Serbian population. Int. J. Exp. Path. 2013;94(6):355-61. (M22=5, IF2011=2.556)
11. **Brajušković G**, Branković A, Mirčetić J, Nikolić Z, Kalaba P, Vukotić V, Tomović S, Cerović S, Radojičić Z, Savić-Pavićević D, Romac S. Common variants at 8q24 are associated with prostate cancer risk in Serbian population. Pathology and Oncology Research 2013; 19:559-69. (M22=5, IF2013=1.806).
12. Savić-Pavićević D, Miladinović J, Brkušanin S, Šviković S, Djurica S, **Brajušković G**, Romac S. Molecular genetics and genetic testing in myotonic dystrophy type 1 (DM1). BioMed Research International (Journal of Biomedicine and Biotechnology) 2013; 2013:391821. (M22=5, IF2013=2.706)
13. Bulajić N, Velimirović S, Vukojević J, Nonković Z, Jovanović D, Kučera I, Ilić S, **Brajušković G**, Bokun R, Pavlićević G, Trnjak Z. Fungus – like hyphochytrids associated with human disease. APMIS 1999;107: 833-6. (M22=5, IF1999=1.097)

**Radovi u međunarodnim časopisima (M23)**

1. Rajovski S, Vučić N, Karanović J, Matijašević S, Savić-Pavićević D, Dobrijević Z, **Brajušković G**. Association of PRMT6, PEX10 and SOX5 genetic variants with idiopathic male infertility: Evidence from North Macedonian population and an updated meta-analysis. Genetika 2023;55(1):355-72. (IF2021=0.753)
2. Dobrijević Z, Karanović J, Savić-Pavićević D, **Brajušković G**. The effect of epistatic interactions between genetic variants located in MicroRNA and silencing complex genes on prostate cancer progression risk. Genetika 2023;55(1):263-75. (IF2021=0.753)
3. Kalezić T, Vuković I, Stojković M, Stanojlović S, Karanović J, **Brajušković G**, Savić-Pavićević D. Keratitis-Ichthyosis-Deafness Syndrome with heterozygous P.D50N in the GJB2 gene in two Serbian adult patients. Balkan Journal of Medical Genetics 2022; 25(1): 1-6. (M23=3, IF2021=0.810)
4. Vučić N, Kotarac N, Matijašević S, Radenković L, Vuković I, Budimirović B, Djordjevic M, Savić-Pavićević D, **Brajušković G**. Copy number variants within AZF region of Y chromosome and their association with idiopathic male infertility in Serbian population. Andrologia 2022; 54(1):e14297. (M23, IF2020=2.775)
5. Brkušanin M, Jeftović Velkova I, Jovanović VM, Perić S, Pešović J, **Brajušković G**, Stević Z, Savić-Pavićević D. SMN1 copy number as a modifying factor of survival in Serbian patients with sporadic amyotrophic lateral sclerosis. Serbian Archives of Medicine 2018; 146 (11-12):646-52.(M23=3, IF2017=0.300)
6. Zolotarevski L, Jović M, Popov Aleksandrov A, Milosavljević P, **Brajušković G**, Demensku J, Mirkov I, Ninkov M, Kataranovski D, Kataranovski M. Skin response to epicutaneous application of anticoagulant rodenticide warfarin is characterized by differential time- and dose-dependent changes in cell activity. Cutaneous and Ocular Toxicology 2016;35(1):41-8. (M23=3, IF2016=1.213)
7. Petrović N, Jovanović-Ćupić S, **Brajušković G**, Lukić S, Roganović J, Krajnović M, Mandušić V. Micro RNA-21 expression levels in invasive breast carcinoma with a non-invasive component. Arch Biol. Sci. Belgrade 2015; 67(4):1285-95. (M23=3, IF2014=0.718)
8. Nikolić Z, **Brajušković G**, Savić-Pavićević D, Kojić A, Vukotić V, Tomović S, Cerović S, Filipović F, Mišljenović Đ, Romac S. Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population. Int J Clin Exp Med. 2013; 6(1):57-66. (M23=3, IF2013=1.422)
9. **Brajušković G**, Nikolić Z, Kojić A, Savić-Pavićević D, Cerović S, Tomović S, Filipović N, Vukotić V, Romac S. Assessment of possible association between rs378854 and prostate cancer risk in Serbian population. Arch Biol. Sci. Belgrade 2013; 65(2):475-86. (M23=3, IF2012=0.791)
10. **Brajušković G**, Savić-Pavićević D, Romac S. 60th Anniversary of the DNA Secondary Structure Discovery. Vojnosanitetski pregled 2013; 70(12):1165-70. (M23=3, IF2013=0.269).
11. Mirčić A, Vilimanović U, **Brajušković G**, Bumbaširević V. Apoptosis and appearance of multinuclear C6 glioma cells after treatment by microtubulepoisons. Acta Veterinaria (Beograd) 2012; 62(1):17-26. (M23=3, IF2012=0.258)
12. **Brajušković G,** Strnad M, Cerović S, Romac S. The programmed cell death proteins and chronic leukemias. Arch Biol. Sci. Belgrade 2011; 63(3):527-35. (M23=3, IF2011=0.356)
13. Dimitrijević R, Čadež I, Keckarević-Marković M, Keckarević D, Kecmanović M, Dobričić V, Savić-Pavićević D, **Brajušković G**, Romac S. Polymorphisms of the Prion Protein Gene (PRNP) in a Serbian Population.International Journal of Neuroscience 2010; 120(7):496-501. (M23=3, IF2008=0.884)
14. Šijačić Nikolić M, Milovanović J, Bobinac M, Savić-Pavićević D, **Brajušković G**, Diklić M. Variability of the Choloroplast DNA of Seddile Oak (*Quercus Petraea Agg, Enrendorfer, 1967*) in Serbia. Arch Biol. Sci. Belgrade 2009; 61(3):459-65. (M23=3, IF2009=0.238)
15. Strnad M, **Brajušković G**, Strelić N, Todorić-Živanović B, Stamatović D, Tatomirović Ž, Magić Z. Expression of programmed cell death proteins in patients with chronic myeloid leukemia. Journal of BUON 2008, 13(3):403-8.(M23=3, IF2009=0.600)
16. Trbojević J, Nešić D, Laušević Ž,Obradović M, **Brajušković G**, Stojimirović B. Histological characteristics of healthy animal peritoneum. Acta Veterinaria(Beograd) 2006; 56(5-6):405-412. (M23=3, IF2005=0.149)
17. Pavlica Lj, Nikolić D, Magić Z, **Brajušković G**, Strelić N, Miličić B, Jovelić A. Successful Treatment of Postveneral Reactive Arthritis With Synovectomy and 3' Months' Azitthromycin. J Clin Rheumatol 2005; 11(5):257-63.(M23=3, IF2005=0.344)
18. [Balint B, Vučetić D, Trajković-Lakić Z, Petakov M, Bugarski D, **Brajušković G**, Taseski J.](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12803111&dopt=Abstract)Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap). 2002;32(4):363-75. (M23=3, IF2000=0.405)

**Rad u časopisu međunarodnog značaja verifikovan posebnom odlukom (M24)**

1. Karanović J, Ivković M, Pantović M, **BrajuškovićG**, Romac S, Savić-Pavićević D. TPH2 Variant rs7305115 and its Interaction with Acute Stressful Life Events in Etiology of Suicide Attempt in Serbian Psychiatric Patients. 2015; 2(2):34-9. DOI: 10.5530/ami.2015.2.8. (M24=2)
2. Dimitrijević J, Todorović V, Aleksić A, Jovanović D, Pilčević D, Vignjević S, Mićić S, Jovanović P, Pilčević D, Kovačević Z, Hrvačević R, Maksić D, **Brajušković G**, Savić V, Bogdanović R. [Alport's syndrome and benign familial haematuria: light and electron microscopic studies of the kidney][*Article in Serbian*].Srpski arhiv za celokupno lekarstvo 2008; 136(Suppl 4):275-81. (M24=2)
3. Balint B, Vučetić D, Vojvodić D, Petakov M, **Brajušković G**, Ivanović Z, Trkuljić M, Stojanović N. Cell recovery, cryothermal micro – damages and surface antigen expression as predictors for cold – induced GPIb/CD42b – cluster mediated platelet clearance after controlled – rate *vs.* Uncontrolled – rate cryopreservation. Blood Blank Transfus Med. 2004; 2(1):22-6.
4. Vučetić D, Balint B, Trajković Lakić Z, Mandić Radić S, **Brajušković G**, Miković D, Trkuljić M. Cryopreserved *vs.* Liquid – state stored platelets – quantitative and qualitative comparative study. Blood Blank Transfus Med. 2003; 1(2):81-88.

**Predavanje po pozivu sa međunarodnog skupa štampano u izvodu (M32)**

1. Savić-Pavićević D, Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V. Identifying modifiers of somatic instability and age at onset in myotinic dystrphy type 1 by modeling genetic data. Biologia Serbica 2018; 40(1):49. Belgrade BioInformatics Conference, Belgrade, Serbia, 18-22 June 2018.

**Radovi saopšteni na skupovima međunarodnog značaja štampani u celini (M33)**

1. **Brajušković G**, Škaro Milić A, Cerović S, Ušaj Knežević S. Apoptosis in acute myelogenous leukemia. Proceedings:437-8. 7th Multinacional Congress on Mycroscopy-European Extension. Portorož, Slovenia, June 26-30, 2005.
2. **Brajušković G**, Marjanović S, Škaro Milić A. Apoptosis in chronic lymphocytic leukemia. Proceedings:273-4. 6th Multinacional Congress on Mycroscopy-European Extension. Pula, Croatia, June 1-5, 2003.
3. Djuričić B, Arsić D, **Brajušković G,** Bumbaširević V. Apoptotic thymocytes change appearance if ionic pump is inhibited. Electrone Microscopy 1998; IV:815-6. ICEM 14, Cancun, Mexico, 31 August to 4 September 1998.

**Radovi saopšteni na skupovima međunarodnog značaja štampani u izvodu (M34)**

1. Garai N, Pešović J, Dobrijević Z, Brkušanin M, Matijašević Joković S, Radenkovic L, Radovanović N, Karanovic J, **Brajuškovic G**, Savić-Pavićević D. Mutation Rates of 22 Autosomal STR Loci In a European population from Central Balkan, Republic of Serbia. Genetics and Aplicatons (Book of Abstracts):78. ABMBBIH CONFERENCE 2023 - International Conference of Biochemists and Molecular Biologists in Bosnia and Herzegovina. BiH, Sarajevo, May 2023.
2. Brkušanin M, Milić-Rašič V, Branković V, Stević Z, Nikolić D, Kosać A, Kristina J, Pešović J, **Brajušković G**, Savić-Pavićević D. Phosphorylated neurofilament heavy chain in cerebrospinal fluid of nusinersen treated SMA patients from Serbia. 3rd International Scientific Congress on Spinal Muscular Atrphy. 21-23 October 2022, Barselona, Spain.
3. Pešović J, Perić S, Radovanovic N, Radenković L, Brkušanin M, **Brajušković G**, Rakočević Stojanović V, Savić-Pavićević D. CpG sites surrounding DMPK expansions are heterogeneously methylated in myotonic dystrophy type 1 patients with variant repeats. Book of Abstrasts:40. IDMC-13 - The 13th International Myotonic Dystrophy Consortium, June 22nd-25th, 2022 Osaka. Japan.
4. Radovanovic N, Pešović J, Perić S, Radenković L, Vuković J, **Brajušković G**, Rakočević Stojanović V, Savić-Pavićević D. Analysis of circulating myomiRs as potential biomarkers of progression of muscular impairment in myotonic dystrophy type 1 patients. Book of Abstrasts:64. IDMC-13 - The 13th International Myotonic Dystrophy Consortium, June 22nd-25th, 2022 Osaka. Japan.
5. Radenković L, Perić S, Pešović J, Radovanovic N, **Brajušković G**, Rakočević Stojanović V, Savić-Pavićević D.Cluster Analysis of Phenotypic Characteristics in patients with Myotonic dystrophy type 2. Book of Abstrasts:108. IDMC-13 - The 13th International Myotonic Dystrophy Consortium, June 22nd-25th, 2022 Osaka. Japan.
6. Brkušanin M, Kosać A, Poešović J, **Brajušković G**, Milić-Rašić V, Savić-Pavićević D. First steps towards implementation of a newborn screening program for Spinal Muscular Atrophy in Serbia. Abstract book:71. 2nd International scientific and Clinical Congress on Spinal Muscular Atrophy. Paris, France, 5th – 7th February 2020.
7. Brkušanin M, Kosać A, Jovanović V, Pešović J, **Brajušković G**, Vesna Branković, Todorović S, Milić Rašić V, Savić-Pavićević D. Joint effect of the SMN2 and SERF1A genes on early onset Spinal Muscular Atrophy patients. Abstract book:46. European Paediatric Neurology Society (EPNS) Congress. Athens, Greece, 17-21 September 2019.
8. Milić Rašić V, Branković V, Kosac A, Todorović S, Stević Z, Bkušanin M, Pešović J, **Brajušković G**, Savić-Pavićević D. Phenotypic variability in siblings with Spinal Muscular Atrophy. Abstract book:306. 13th European Paediatric Neurology Society (EPNS) Congress. Athens, Greece, 17-21 September 2019.
9. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Variant repeats stabilize expansion and modify age at onset in Myotonic Dystrophy Type 1. Journal of Neuromuscular Diseases 2018: S164 (#673). 15th International Congress on Neuromuscular Diseases- ICNMD XV, Vienna, Austria, 6 – 10 July, 2018.
10. Šumonja N, Vuković A, Nonković N, Gemović B, Nikolić Z, Savić-Pavićević D, Veljković N, **Brajušković G**, Perović V. Higher-order genetic interactions in prostate cancer and bening prostatic hyperplasia. Biologia Serbica 2018; 40(1):96. Belgrade BioInformatics Conference, Belgrade, Serbia, 18-22 June 2018.
11. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Dynamics of somatic instability in myotonic dystrophy type 1 patients carrying variant repeats within *DMPK* expansions. Abstract Book: 49. IUBMB SEOUL 2018 – Young Scientist Program. Seoul, Korea, June 2-4, 2018.
12. Brkušanin M, Kosać A, Jovanović V, Jeftović Velkova I, Pešović J, Perić S, **Brajušković G**, Milić Rašić V, Stević Z, Savić-Pavićević D. Structure of the 5q13.2 segmental duplication as a modifier of the phenotype of spinal muscular atrophy and amyotrophic lateral sclerosis. Book of Abstracts: 73-74. Clinical Genomics and NGS. Bertinoro – Italy, April 29 – May 4, 2018.
13. Pešović J, Brkušanin M, Perić S, Radvanszky J, Maširević S, Kovčić V, Musova Z, Stehlikova K, Leonardis L, Kekou K, Jovanović V, Mazanec R, **Brajušković G**, Ranum LP, Rakočević-Stojanović V, Savić-Pavićević D. The Origin and Historical Route of Myotonic Dystrophy Type 2 Mutation Across Europe. Book of Apstracts of Internation Myotonic Dystrophy Consortium Meeting (IDMC-11):38; San Francisco, California, USA, September 05-09 2017.
14. Brkušanin M, Kosać A, Jovanović A, Pešović J, **Brajušković G**, Milić-Rašić V, Savić-Pavićević D. SMN2 gene copy number and promoter methylation as disease modifers of childhood-onset spinal muscular atrophy. Book of abstracts: 186. European Network to Cure ALS (ENCALS) Meeting. Ljubljana, Slovenija, May 18-20, 2017.
15. Karanović J, Ivković M, Jovanović V, Pantović Stefanović M, Brkušanin M, Damjanović A, **Brajušković G**, Savić Pavićević D. Effect of childhood general traumas on suicde attempt depends on TPH2 and ADARB1 variants in psychiatric patients. In: Psihijat dan, 2016, suppl./48/1/5-145. XV Congress of Serbian Psychiatric Association and Regional Congress of Psychiatric Association for Eastern Europe and the Balkans: Pathways and Crossroads of Psychiatry; 2016 October 12-15; Belgrade, Serbia. p. 80, P30.
16. Savić-Pavićević D, **Brajušković G**. Coevolution of the repeated glutamine and proline codons in the mammalian Huntington disease gene. Abstract Book of the 2nd NGP-NET Symposium: 25; Belgrade, Serbia,September 15-17 2016.
17. Nikolić Z, Savić-Pavićević D, Vučić N, Cidilko S, Vukotić V, Filipović N, Romac S, **Brajušković G**. Assessment of association between rs496128 located in *AGO2* gene and prostate cancer risk in Serbian population. Book of abstracts: 38. 11th Balkan Congress of Human Genetics. Belgrade, Serbia. 17th-20th September 2015.
18. Brkušanin M, Kosać A, Jovanović V, Pešović J, **Brajušković G**, Dimitrijević N, Todorović S, Romac S, Milic Rašić V, Savić-Pavićević D. Joint effect of the *SMN2* and *SERF1A* genes on early-onset Serbian spinal muscular atrophy patients. Book of abstracts: 38-9. 11th Balkan Congress of Human Genetics. Belgrade, Serbia. 17th-20th September 2015.
19. Karanović J, Šviković S, Pantović M, Djurica S, **Brajušković G**, Damjanović A, Jovanović V, Ivković M, Romac S, Savić-Pavićević D. Association of *HTR2C* gene with suicide attempt risk in Serbian patients with major psychiatric disorders. Book of abstracts: 58-9. 11th Balkan Congress of Human Genetics. Belgrade, Serbia. 17th-20th September 2015.
20. Pešović J, Rakočević Stojanović V, Perić S, Brkušanin M, **Brajušković G**, Romac S, Savić-Pavićević D. Variant repeats in DM1 patients might be associated with milder clinical presentation. Programme & Abstracts: 102. IDMC-10. International Myotonic Dystrophy Consortium Meeting. Paris, France. 8-12 June 2015.
21. Kovčić V, Perić S, Pešović J, Brkušanin M, **Brajušković G**, Romac S, Ranum L, Rakočevič Stojanović V, Savić-Pavićević D. European founder haplotypes in Serbian patients with myotonic dystrophy type 2. Programme & Abstracts: 105. IDMC-10. International Myotonic Dystrophy Consortium Meeting. Paris, France. 8-12 June 2015.
22. Nikolić Z, Savić-Pavićević D, Vučić N, Cidilko S, Vukotic V, Filipović N, Romac S, **Brajušković G**. Analysis of potential association between genetic variants in microRNA genes hsa-miR-499 and hsa-miR-196a2 and prostate cancer risk in Serbian population. European Journal of Human Genetics 2015; 23(Suppl 1): 471. European Human Genetics Conference 2015. Glasgow, Scotland, UK. June 6-9, 2015.
23. Karanović J, Šviković S, Pantović M, Durica S, **Brajušković G**, Damjanović A, Jovanović V, Ivković M, Romac S, Savić-Pavićević D. Association of ADARB1 gene with suicide attempt risk in patients with major psychiatric disorders. European Journal of Human Genetics 2015; European Human Genetics Conference 2015. Glasgow, Scotland, UK. June 6-9, 2015.
24. Brkušanin M, Kosać A, Jovanović V, Pesovic J, **Brajušković G**, Dimitrijević N, Romac S, Milić Rašić V, Savić-Pavićević D. Correlation of copy number of the SMN2, SERF1A and NAIP genes with severity of spinal muscular atrophy in Serbian patients. European Journal of Human Genetics 2015; European Human Genetics Conference 2015. Glasgow, Scotland, UK. June 6-9, 2015.
25. Pešović J, Rakočević-Stojanović V, Perić S, **Brajušković G**, Romac S, Savić-Pavićević D. Variant repeats as genetic modifiers of DM1 – a case report. Book of Abstracts:67. Sinapsa Neurosicience Conference'15. Ljubljana, Slovenija. 15-17 May 2015.
26. Pešović J, Perić S, Brkušanin M, Mandić M, **Brajušković G**, Romac S, Rakočević-Stojanović V, Savić Pavićević D. PCR based Southern blot method for detection of expansions associated with myotonic dystrophy type 2. Symposium Genomics of Rare Diseases Serbordisinn & 2014 Golden Helix Symposium; 2014 October 31-November 1; Belgrade, Serbia.
27. Nikolić Z, Savić-Pavićević D,Vučić N, Vukotić V, Tomović S, Cerović S, Filipović N, Romac S, **Brajušković G**. Assessment of association between genetic variant in hsa-miR-146a gene and prostate cancer risk in Serbian population. European Urology Supplements 2014; 13(5):127. 6th European Multidisciplinary Meeting on Urological Cancers (EMUC) — 3rd Meeting of the EAU Section of Urological Imaging (ESUI). Lisbon, Portugal, 13–16 November 2014.
28. Nikolić Z, Savić-Pavićević D, Vučić N, Vukotić N, Tomović S, Cerović S, Filipović N, Romac S, **Brajušković G.** Assessment of association between genetic variant rs7813 in GEMIN4 and prostate cancer risk in Serbian population. European Urology Supplements 2014; 13(7): e1505. EAU 10th South Eastern European Meeting (SEEM). Belgrade, Serbia, 24-26 October 2014.
29. Vučić N, Nikolić Z, Savić-Pavićević D, Kanazir S, Vukotić V, Romac S, **Brajušković G.** Assessment of possible association between genetic variant rs895819 in miR-27a gene and infertility in males diagnosed with non-obstructive azoospermia (NOA) from Serbian population. European Urology Supplements 2014; 13(7): e1475. EAU 10th South Eastern European Meeting (SEEM). Belgrade, Serbia, 24-26 October 2014.
30. Nikolić Z, Brajušković G, Vukotić V, Filipović N, Cerović S, Savić-Pavićević D, Romac S. Epistatic interactions between prostate cancer susceptibility loci: evidence from Serbian population. European Journal of Human Genetics 2013; 21(Supplement 2):316. European Human Genetics Conference 2013, Paris, France, 8-11 June 2013.
31. Đurica S, Miladinović J, Pantović M, Ivin M, Šviković S, **Brajušković G**, Ivković M, Savić-Pavićević D. Association of ADARB1 gene with major psychiatric disorders. European Journal of Human Genetics 2013; 21(Supplement 2):198. European Human Genetics Conference 2013, Paris, France,8-11 June 2013.
32. Kojić A, **Brajušković G**, Savić-Pavićević D, Nikolić Z, Vukotić V, Tomović S, Vuković I, Cerović S, Romac S. Analysis of association between single nucleotide genetic variant rs378854 and prostate cancer risk in Serbian population. European Urology Supplements 2012; 11(5):224-25. 4th European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain,16-18 November 2012.
33. Nikolić Z, **Brajušković G**, Savić-Pavićević D, Kojić A, Vukotić V, Tomović S, Cerović S, Romac S. Analysis of association between single nucleotide genetic variant rs3787016 and prostate cancer risk in Serbian population. European Urology Supplements 2012; 11(4):143.EAU 8th South Eastern European Meeting (SEEM), Sofia, Bulgaria,26-27 October 2012.
34. **Brajusković G**, Mirković M, Stanković I, Savić-Pavićević D, Branković A, Cerović S, Tomović S, Vukotić V, Romac S. Analysis of two single nucleotide polymorphisms at locus 17q12 associated with prostate cancer in Serbian population. European Urology Supplements 2011; 10(9):614. EAU 11th Central European Meeting (CEM), Timisoara, Romania, 28-29 October, 2011.
35. **Brajušković G,** Branković A, Savić-Pavićević D, Mirčetić J, Cerović S, Tomović S, Vuković I, Vukotić V, Romac S. Correlation between polymorphisms at promoter region of the NOS3 gene and prostate cancer in Serbian population. Virchows Arch 2011; 459 (Suppl 1):S319. 23rd European Congress of Pathology. Helsinki, Finland. 27 August– 1 September, 2011.
36. **Brajušković G,** Mirčetić J, Savić-Pavićević D, Cerović S, Tomović S, Jeremić N, Vuković I, Vukotić V, Romac S. Analysis of five single nucleotide polymor­phisms at locus 8q24 associated with pros­tate cancer in Serbian population. Virchows Arch 2011; 459 (Suppl 1):S319. 23rd European Congress of Pathology. Helsinki, Finland. 27 August– 1 September 2011.
37. Strnad M, Todorić-Živanović B, Strelić N, Tatomirović Ž, Stamatović D, **Brajušković G**, Magić Z. Expression of Bcl-2 protein, amplification of c-myc oncogene and presence of additional chromosomal alterations in patients with chronic myelogenous leukemia. Chromosome Research 2009; 17(Suppl 1):138-9. 7th European Cytogenetics Conference, Stockholm, Sweeden,4-7 July, 2009.
38. Savić-Pavićević D, Krndija D, **Brajušković G**, Romac S. Coevolution of the repeated glutamine and proline codons in the mammalian Huntington disease gene. European Journal of Human Genetics 2009; 17(2):271. European Human Genetics Conference, Vienna, Austria, May 23-26, 2009.
39. Cerović S, **Brajušković G**, Jeremić N, Vukotić Maletić V. The incidence of pelvic lymph nodes metastases in prostate cancer patients with intermediate values of prostate specific antigen. European Urology Meetings 2007; 2(5):74. EAU 3rd South Eastern European Meeting, Sarajevo, Bosnia and Herzegovina, 5-6 October, 2007.
40. Nikolajević S, Cerović S, **Brajušković G**, Vukotić Maletić V. Incidentally detected prostate cancer in cystoprostatectomy speciemens. European Urology Meetings 2007; 2(5):75. EAU 3rd South Eastern European Meeting, Sarajevo, Bosnia and Herzegovina, 5-6 October 2007.
41. **Brajušković G**, Cerović S, Strnad M, Marjanović S. The ultrastructural investigation of mitochondria in B – CLL cells during proces apoptosis. Virchows Archiv 2007; 451(2): 287-8. European Congress of Pathology, Instanbul, Turkey, September 8-13, 2007.
42. Cerović S, **Brajušković G**, Jeremić N, Milović N, Maletić Vukotić V. The inicidence of pelvic lymph node metastases in prostate cancer patients with intermediate values of prostata specific antigen. Virchows Archiv 2007; 451(2): 349. European Congress of Pathology, Instanbul, Turkey, September 8-13,2007.
43. Nikolajević S, Cerović S, **Brajušković G**, Milović N. Incidentally detected prostate cancer in cystoprostatectomy specimens. Virchows Archiv 2007; 451(2):349. European Congress of Pathology, Instanbul, Turkey, September 8-13,2007.
44. Strnad M, **Brajušković G**, Todorić Živanović B, Strelić N, Stamatović D, Magić Z. Expression of Bcl-2 protein and amplification of c-myc gene in patients with Chronic Myeloid Leukemia. Virchows Archiv 2007; 451(2):354. European Congress of Pathology, Instanbul, Turkey, September 8-13,2007.
45. **Brajušković G**, Orolicki Vukosavić S, Cerović S, Ušaj Knežević S, Marjanović S, Romac S. Bcl 2 and Bax interaction in peripheral blood B–lymphocytes in patients with chronic lymphocytic leukemia. Virchows Archiv 2005; 447(2):270-1. 20th European Congress of Pathology. Paris, France, September 3 – 8, 2005.
46. Ušaj S, Krtolica K, Bogdanović A, Cerović S, **Brajušković G**, Tarabar D. Thymidilate synthase quantitation, vascular endothelial growth factor and p53 protein overexpresion, and point K–ras mutation in colorectal carcinoma: relationships with tumor recurrence and survival. Virchows Archiv 2005; 447(2):142. 20th European Congress of Pathology. Paris, France, September 3 – 8, 2005.
47. Dimitrijević J, Djokić M, **Brajušković G**, Knežević Ušaj S, Aleksić A, Nožić D, Škaro Milić A. Significance of correlation between serological markers of Hepatitis B and pathohistology and ultrastructural findings. Virchows Archiv 2005; 447(2):295. 20th European Congress of Pathology. Paris, France, September 3 – 8, 2005.
48. Cerović S, Ignjatović M, **Brajušković G**, Knežević Ušaj S, Hrvačević R. Coincidence of hyperparathyroidism and thyroid cancer found at the time of parathyroidectomy. Virchows Archiv 2005; 447(2):417. 20th European Congress of Pathology. Paris, France, September 3 – 8, 2005.
49. Mirčić A, **Brajušković G**, Đuričić B, Bumbaširević V. Comparation of cell death morphology of C6 glioma cells treated with topoisomerase inhibitors and microtubular poisons. Abstrat book:142. XVIII International symposium on morphological sciences. Belgrade, Serbia and Montenegro June 5 – 8, 2005.
50. Dimitrijević J, Zaki S, Mićić S, Radosavljević R, **Brajušković G**, Cerović S, Bogdanović R, Kovačević Z, Škatarić V, Aleksić A, Gligić A. Renal pathohistological findings in HFRS patients in biopsy and autopsy speciements – experience from Balkan. Final program and book of Abstracts.The First Symposium of Zoonoses with international participation. Sarajevo, Bosnia and Hercegovina 22- 23 April, 2005.
51. Cerović S, Ignjatović M, **Brajušković G,** Knežević Ušaj S, Hrvačević R. Thyroid and renal malignancy in a patient under peritonel dialysis. Proceedings/education book 33. 5th Congress Balkan Union of Oncology. Beograd, Serbia & Montenegro, 14-17 October, 2004.
52. Marjanović S, Cerović S, **Brajušković G**, Stamatović D. High dose chemotherapy followed by hematopoietic stem cell autologous transplantation in patients with poor prognosis germ cell tumors (GCT). Proceedings/education book: 33. 5th Congress Balkan Union of Oncology. Beograd, Serbia & Montenegro, 14-17 October 2004.
53. Dimitrijević J, Zaki S, **Brajušković G,** Cerović S, Kovačević Z, Škuletić V, Aleksić A, Gligić A. Histology diagnostic of hemorrhagic fevers in biopsy and autopsy specimens: experience from Balcan. Book of Abstracts:118. The 6 th International Conference on Hemorrhagic Fever with Renal Syndrome (HFAS), Hantavirus Pulmonary Syndrome (HPS) and Hantaviruses, Republic of Korea, Seul, 23 – 25 June, 2004.
54. **Brajušković G**, Vukosavić S, Cerović S, Knežević-Ušaj S, Marijanović S, Dimitrijević J, Romac S, Škaro-Milić A. The expression of Bcl 2 family proteins in B-chronic lymphocytic leukemia. Virchows Archiv 2003; 443(3): 405. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
55. Dimitrijević J, Zaki S, **Brajušković G**, Knežević Ušaj S, Cerovic S, Tufegdžić I. Histopathological findings in autopsy tissues of Crimean Congo Hemorrhagic fever (a case report). Virchows Archiv 2003; 443(3): 286. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
56. Ušaj Knežević S, Bogdanović A, Peruničić M, **Brajušković G**, Cerović S, Klem I, Eri Ž, Panišić M, Tarabar D, Dimitrijević J. Vascular endothelial growth factor, microvessels count and overexpression of p53 protein in colorectal carcinomas.Virchows Archiv 2003; 443(3): 398. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
57. Cerović S, **Brajušković G**, Dimitrijević J, Knežević Ušaj S, Popović L, Vukotić Maletić V, Ajdinović B. Neuroendocrine differentiation in prostatic cancer: correlation with biochemical failure after radical prostectomy. Virchows Archiv 2003; 443(3): 441. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
58. Zolotarevski L, Jaćević J, Ilić S, Cerović S, **Brajušković G**. The types of tumor and peritumor stroma and biological behavior of fibrohystiocitis tumors. Virchows Archiv 2003; 443(3): 330. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
59. Medić N, Cerović S**, Brajušković G,** Knežević Ušaj S, Dimitrijević J, Popović L, Milović N, Aleksić P. Prostatic mucinous carcinoma with signet ring cells treated by radical prostatectomy. Virchows Archiv 2003; 443(3): 442. 19th European Congress of Pathology. Ljubljana, Slovenija, 6 – 11 September, 2003.
60. Marjanović S, **Brajušković G,** Vukosavić S, Romac S. The expression of Bax and Caspase 3 proteins in B-Chronic Lymphocytic Leukemia. The Hematology Journal 2003; 4(suppl 2):43-4. 8th Annual Congress of the European Hematology Association, Lyon, France, 12-15 June, 2003.
61. **Brajušković G**, Vukosavić S, Marjanović S, Ušaj Knežević S, Cerović S, Romac S, Dimitrijević J, Škaro Milić A. The expression and interaction of programmed cell death as prognostic paramethar in chronic lymphocytic leukemia. Histopathology 2002; 41(1):91. XXIV th International Congress of the International Academy of Pathology, Amsterdam, The Netherlands, October 5 -10, 2002.
62. Dimitrijević J, Škatarić V, Gligić A, Đukanović Lj, Kovačević Z, **Brajušković G**. Renal pathostilogical findings in patients with haemorrhagic fever (Hantaan virus infection). Histopathology 2002; 41(1):51. XXIV th International Congress of the International Academy of Pathology, Amsterdam, The Netherlands, October 5 -10, 2002.
63. Ušaj Knežević S, Krtolica K, Panišić M, **Brajušković G**, Ćuk V, Bogdanović A, Cerović S, Dimitrijević J, Klem I, Eri Z. Prognostic significance of K-ras mutation and adhesive molecules immunohistochemical expression in colorectal carcinomas. Histopathology 2002; 41(1):54. XXIV th International Congress of the International Academy of Pathology, Amsterdam, The Netherlands, October 5 -10, 2002.
64. Popović L, Cerović S, Knežević S, **Brajušković G**, Ilić S, Dimitrijević J. Mast cells and microscopic prognostic parameters for malignancy in fibrohistiocytomas. Histopathology 2002; 41(1):154. XXIV th International Congress of the International Academy of Pathology, Amsterdam, The Netherlands, October 5 -10, 2002.
65. Cerović S, Čizmić M, Milović N, Ajdinović B, Popović L, Ušaj Knežević S, **Brajušković G**. Adrenal composite pheochromocytoma. Histopathology 2002; 41(1):189. XXIV th International Congress of the International Academy of Pathology, Amsterdam, The Netherlands,October 5 -10, 2002.
66. Marjanović S, **Brajušković G**, Vukosavić S, Škaro Milić A, Malešević M. Immunochistochemical and Western blotting analysis for the expression of Caspasa 3 in mononuclear cells of the peripheral blood in CLL patients. Annals of Oncology 2002; 13(2):108. 8th Interantional Conference on Malignant Lymphoma Lugano, Switzerland,12 – 115 June, 2002.
67. Vučetić D, Balint B, Taseski J, **Brajušković G**, Trajković Lakić Z. Evaluation of sex different platelet cryopreservation procedures. Transfusion Clinique et biologique 2001; 8(1):211s. ISBT VII European Congress, Paris, France, July 15-18, 2001.
68. Dimitrijević J, Maksić Dj, Kovačević Z, Dujić A, Spasić P, Marić M, Štrbac M, **Brajušković G.** Renal graft histology with changes not considered to be due to rejection (case report). Patologia 38:M44. First International Congress of Pathology. Madeira, Portugal 2000.
69. Mihajlović Božić V, **Brajušković G**, Berger S, Spasić P. Malignant peritoneal mesotelioma. Patologia 38:M60. First International Congress of Pathology. Madeira, Portugal 2000.
70. Bumbaširević V, **Brajušković G,** Djuričić B. The change in apoptotic morphorology by inhibition of ionic pump. 10th European Interuniversity Symposium. Highlights in Female Cancers. Oral presentation No 03-6. Thessaloniki, Hellas, 2-5 November 2000.
71. Cerović S, Popović L, Milović N, Aleksić P, **Brajušković G.** Testicular Biopsy Findings in Infertility. 2nd Balkan Congress of Andrology. Belgrade, Yugoslavia September 15th and 16th 2000.
72. Dimitrijević J, Hrvačević R, Marić M, Kovačević Z, Spasić P, Štrbac M, **Brajušković G**, Škatarić V, Maksić Dj, Jovanović D, Savin M, Djukanović Lj. Renal Graft Histology: The Relationship Between Transplant rejection and Changes not Considered To Be Due to Rejection. Third BANTAO Congress, Belgrade, Yugoslavia, 18-20 September, 1998.
73. Marjanović S, **Brajušković G**, Škaro Milić A, Stamatović D, Malešević M. The Significance of Determination the Spontaneous and Therapy Induced Apoptosis in Patients with B-CLL. British Journal of Haematlogy 102(1):202. ISH-EHA Combined Haematology Congress, Amsterdam, The Netherlands, 4-8 July 1998.
74. Marjanović S, **Brajušković G**, Škaro Milić A, Stamatović D, Malešević M. The Significance of Determination the Spontaneous and Therapy Induced Apoptosis in Patients with B-CLL. Acta Haematologica 100(1):8. 11th Symposium on Molecular Biology of Hematopoiesis and Treatment of Myeloproliferative Diseases, Bormio, Italy, June 25-29, 1998.
75. **Brajušković G**, Bumbaširević V, Marjanović S, Spasić P, Škaro Milić A. The Spontaneous and Therapy Induced Apoptosis in Patients with B-CLL and ANLL-M4. Pathology Research and Practicle 193(5-6): 423. XVI European Congress of Pathology. Maastricht, August 31 – September 4, 1997.
76. Cerović S, Knežević Ušaj S, Bogdanović Z, Bokun R, Ignjatović M, Kostić Z, Aleksić P, Dragojević R, **Brajušković G,** Tatić V. Metastatic Thyroid Carcinoma Masquerading as Bilateral Renal Carcinoma. Pathology Research and Practicle 193(5-6):350. XVI European Congress of Pathology. Maastricht, August 31 – September 4, 1997.
77. Štrbac M, Berger S, Ćuk D, **Brajušković G,** Tatić V, Spasić P. Testicular Obstructive Arteriopathy – A Study of Four Case. Pathology Research and Practicle 193(5-6):364. XVI European Congress of Pathology. Maastricht, August 31 – September 4, 1997.
78. Škaro Milić A, Spasić P, **Brajušković G.** Protection of human myocardium by creatine phosphate during operation – ultrastructural investigation. Pathology International 46 (1): 153. XXI International Congress of the International Academy of Pathology and 12th World Congress of Academic and Environmental Pathology, Budapest, Hungary, 20 – 25 October 1996.
79. Knežević Ušaj S, Krtolica K, Urošević N, Cerović S, Bogdanović Z, Dimitrijević J, Todorović V, **Brajušković G.** Relationship of K-ras and p53 mutations with proliferative activity of colorectal tumors. Pathology International 46 (1): 334. XXI International Congress of the International Academy of Pathology and 12th World Congress of Academic and Environmental Pathology,Budapest, Hungary, 20 – 25 October 1996.

**Monografija nacionalnog značaj (M42)**

1. Cerovic S, **Brajušković G**, Vukotić V. Premaligne lezije i karcinom prostate. Beograd: IP Beograd. 2009. ISBN978-86-7519-107-0.

**Poglavlje u knjizi kategorije M41 (M44)**

1. Bogdanović Z, **Brajušković G**. Osnovne patološke reakcije kože. In: Karadaglić Đ,ed. Dermatologija. Beograd: Vojno-izdavački zavod i Verzal Press. 2000. p.46-55.

**Poglavlja u knjigama, pregledni radovi u tematskim zbornicima radova, u monografijama ili u edicijama posvećenoj određenoj naučnoj oblasti kategorije M42 (M45)**

1. Dobrijević Z, Matijašević-Joković S, Branković A, Djordjevič A, Popović M, **Brajušković G**. Savremeni pristupi u istrađivanju molekularne osnove karcinoma prostate. Trendovi u molekularnoj biologiji“ / „Trends in Molecular Biology“ 2022; No2:63-74. Izdavač: Institut za molekularno genetiku i genetičko inženjerstvo, Univerzitet u Beogradu ISSN 27872947.
2. Savić-Pavićević D, **Brajušković G**. Značaj DNK analiza u utvrđivanju biološkog srodstva. In: Šćepanović G, Stanković Z, Petrović Z, eds. Sudsko medicinsko veštaćenje nematerijalne štete. Beograd: Službeni glasnik. 2015. p.637-44. ISBN: 978-86-519-1890-5.
3. **Brajušković G**. Department for electron microscopy,Institute for Pathology and Forensic Medicine, Military Medical Academy, Belgrade, Serbia. Monography 50 years of electron microscopy in Serbia. Beograd: Serbian Society for Microscopy and Academy of Medical Science, SMS. 2006; p.87-9.

**Radovi u časopisima nacionalnog značaja (M50)**

**Radovi u časopisima nacionalnog značaja (M52)**

1. Cerović S, Jeremić N, **Brajušković G**, Milović N. Maletić Vukotić V. [Incidence of locally invasive prostate cancer in patients with intermediate values of prostata – specific antigen] [*Article in Serbian*]. Vojnosanitetski pregled 2007; 64(8):531-7.
2. Davidović G, **Brajušković G.** Apoptosis in cardiovascular diseases. Medicus 2006; 7(1):15-21.
3. **Brajušković G**, Cerovic S. [Regulation of eukaryotic gene expression and the Nobel prizes 2006] [*Article in Serbian*]. Vojnosanitetski pregled 2006; 63(12):993-4.
4. Jeremić N, Cerović S, **Brajušković G,** Tomović S, Maletić Vuković V. [Incidence of pelvic lymph node metastasis in radical prostatectomy] [*Article in Serbian*].Vojnosanitetski pregled 2006; 63(12):1011-4.
5. Cerović S, **Brajušković G**. [Forty years’ use of Gleason grading in the diagnostics and treatment of prostate cancer][*Article in Serbian*]. Vojnosanitetski pregled 2006; 63(12):1049-54.
6. **Brajušković G**.[Genomics] [*Article in Serbian*].Vojnosanitetski pregled 2006; 63(6):604-10.
7. **Brajušković G**, Cerović S. [Chernobyl: 20 years after] [*Article in Serbian*]. Vojnosanitetski pregled 2006; 63(5):89-93.
8. **Brajušković G.**[140 years of genetics] [*Article in Serbian*]. Vojnosaniteski pregled 2006; 63(5):509-12.
9. Strnad M, **Brajušković G,** Strelić N, Todorić Živanović B, Tukić Lj, Stanković D. [Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia] [*Article in Serbian*].Vojnosanitetski pregled 2006; 63(4):364-9.
10. [Balint B, Vučetić D, Drašković B, Vojvodić D, **Brajušković G**, Čolić M, Trkuljić M.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16605192&query_hl=1&itool=pubmed_docsum) Microprocessor-controlled *vs.* “dump-freezing”platelet and lymphocyte cryopreservation: a quantitative and qualitative comparative study. Vojnosanitetski pregled 2006; 63(3):261-8.
11. Joksimović B, Lačković V, Bajčetić M, **Brajušković G**, Rakočević Stojanović V. [Misdiagnosis of Myasthenia Gravis:Case Report] [*Article in Serbian*]. Medicinska istraživanja 2006; 40(1):10-2.
12. **Brajušković G**. [Half a century of electron microscopy in Serbia] [*Article in Serbian*].Vojnosanitetski Pregled 2005; 62(12):939-44.
13. **Brajušković G**, Vukosavić Orolicki S, Cerović S, Knežević Ušaj S, Marjanović S, Romac S. [Bcl-2 and Bax protein interaction in B-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia] [*Article in Serbian*]. Vojnosanitetski pregled 2005; 62(5):357-63.
14. Marjanović S, Cerović S, **Brajušković G**. [Use of high-dosage chemotherapy with autologous hematopoietic stem cell transplantation as a first-line therapy for the patients with poor-prognosis testicular tumors][*Article in Serbian*]. Vojnosanitetski pregled 2005; 62(3):213-8.
15. **Brajušković G**.Apoptosis in malignant diseases. Archive of Oncology 2005; 13(1):19-22.
16. **Brajušković G**, Škaro Milić A, Marjanović S, Cerović S, Knežević Ušaj S. The ultrastructural investigation of mitochondria in B–CLL cells during process apoptosis. Archive of Oncology 2004; 12(3):139-41.
17. Ušaj S, Tarabar D, Ćuk V, Cerović S, **Brajušković G**, Panišić M, Klem I, Eri Ž. The histological diagnosis of dysplastic and neoplastic lesions in inflammatory bowel disease: a pathological perspective. Acta Chrirurgica Iugoslavica 2004; LI(2):109-16.
18. Cerović S, **Brajušković G**, Vukotić Maletić V, Mićić S. Neuroendocrine differentiation in prostate cancer. Vojnosanitetski pregled 2004; 61(5):513-8.
19. **Brajušković G**, Škaro Milić A, Cerović S, Marjanović S, Knežević Ušaj S, Čizmić M, Dimitrijević J. [The Bcl-2 protein family in malignant diseases][*Article in Serbian*].Vojnosanitetski pregled 2004; 61(3):305-10.
20. Cerović S, Ignjatović M, **Brajušković G**, Knežević-Ušaj S, Ćuk V, Hrvačević R, Ajdinović B. [Papillary microcarcinoma of the thyroid and secondary hyperparathyroidism in a patient on hemodialysis] [*Article in Serbian*]. Acta Chir Iugosl. 2004; L:93-95.
21. **Brajušković G**, Vukosavić S, Dimitrijević J, Cerović S, Knežević Ušaj S, Marjanović S, Romac S, Škaro Milić A. [Expression of the Bcl-2 family of proteins in peripheral blood B-lymphocytes in patients with chronic lymphocytic leukemia] [*Article in Serbian*].Vojnosanitetski pregled 2004; 61(1):41-46.
22. Mikić D, Forcan S, Kostov M, Popović L, **Brajušković G**. [Primary localized cutaneous amyloidosis–lichen amyloidosis][*Article in Serbian*].Vojnosanitetski pregled 2004; 61(1):83-9.
23. **Brajušković G**.[DNA: 50 years’ of the double helix] [*Article in Serbian*].Vojnosanitetski pregled 2003; 60(6):763-6.
24. **Brajušković G**, Marjanović S, Škaro Milić A. [Effect of chlorambucil on B-lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia –study of cellular ultrastructure] [*Article in Serbian*].Vojnosanitetski pregled 2003; 60(2):175-180.
25. Dimitrijević J, Đukanović Lj, Kovačević Z, Bogdanović R, Maksić Đ, Hrvačević R, Aleksić A, Naumović R, Jovanović D, **Brajušković G**, Milosavljević I. Lupus nephritis: pathological features, classification and histologic scorning in renal biopsy. Vojnosanitetski pregled 2002; 59(6):21-33.
26. **Brajušković G**, Marjanović S, Škaro Milić A. *In vivo* monitoring of therapy – induced apoptotic process in patients with chronic lymphocytic leukemia and acute non-lymphoblastic leukemia. Archive of Oncology 2002; 10(2):55-60.
27. Cerović S, Tatić V, Dimitrijević J, Ilić S, Milović N, Aleksić P, **Brajušković G.** [Advanced prostatic carcinoma with low levels of serum prostate-specific antigen] [*Article in Serbian*].Vojnosanitetski pregled 2002; 59(2):137-140.
28. Dimitrijević J, **Brajušković G**, Aleksić A, Kovačević Z, Popović R, Stefanović D, Tatomirović Ž, Cerović S, Štrbac M, Petrović R, Bogdanović R, Đukanović Lj. [The importance of renal biopsy in lupus nephritis][*Article in Serbian*]. Srpski arhiv za celokupno lekarstvo 2002; 130(3):26-31.
29. Cerović S, Čizmić M, Milović N, Ajdinović B, **Brajušković G.** [Pheochromocytomas as adrenal gland incidentalomas][*Article in Serbian*].Srpski arhiv za celokupno lekarstvo 2002; 130(2):47-51.
30. **Brajušković G**, Vukosavić S, Romac S, Cerović S, Knežević Ušaj S, Popović L, Marjanović S, Dimitrijević J, Škaro Milić A.[Apoptosis in chronic lymphocytic leukemia] [*Article in Serbian*].Vojnosanitetski pregled 2002; 59(6):47-53.
31. Cerović S, Dimitrijević J, Milović N, Ajdinović B, Knežević Ušaj S, Popović L, **Brajušković G.** [Prostate-specific antigen in the diagnosis and treatment of carcinoma of the prostate][*Article in Serbian*].Vojnosanitetski pregled 2002; 59(6):53-59.
32. Popović L, Ilić S, Novaković M, Cerović S, **Brajušković G,** Štrbac M, Jaćević V. [Effect of mastocytes on the biological behavior of tumors] [*Article in Serbian*].Vojnosanitetski pregled 2002; 59(6):69-78.
33. Knežević Ušaj S, Krtolica K, **Brajušković G,** Cerović S, Panišić M, Ćuk V, Tarabar D, Klem I, Eri Ž. [New prognostic parameters in colorectal carcinoma] [*Article in Serbian*]. Vojnosanitetski pregled 2002; 59(6):59-67.
34. Tarabar D, Rabrenović Lj, Petrović Z, Jović J, Perišić N, Doder R, Roganović B, Bročić Pecelj T, Ćuk V, Kronja G, Panišić M, Ušaj S, **Brajušković G**, Lukačević S. [Importance of early detection of carcinoma of the large intestine] [*Article in Serbian*].Vojnosanitetski pregled 2000; 57(1): 59-65.
35. Knežević Ušaj S, Panišić M, Tarabar D, Ćuk V, **Brajušković G**, Petrović M. [Premalignant and malignant changes in idiopathic inflammatory bowel disease].[Article in Serbian]. Acta Chirurgica Iugoslavica 2000; XLVII (1/2):43-50.
36. Mihajlović Božić V, **Brajušković G**, Berger S, Spasić P. Malignant peritoneal mesothelioma. Archive of Oncology 2000; 8(1): 25-6.
37. Marjanović S, **Brajušković G**, Škaro Milić A, Malešević M. [In vivo study of spontaneous and therapy-induced apoptosis in patients with chronic lymphocytic leukemia treated with chlorambucil] [*Article in Serbian*].Vojnosanitetski pregled 1999; 56(4): 377-82.
38. Dimitrijević J, Hrvačević R, **Brajušković G**, Marić M, Kovačević Z, Spasić P, Štrbac M, Kronja G, Elaković D, Jovanović D, Savin M, Pavlović S, Blagojević R, Đukanović Lj. Renal Graft Histology: Relationship Between Transplant Rejection and Changes Not Considered to Be Due to rejection. Medicinska Istraživanja 1999; 33(1): 89-93.
39. Panišić M, Petrović M, **Brajušković G**, Knežević Ušaj S, Jovanović M. [Ulcerative colitis and familial adenomatous polyposis–risk factors in the development of colorectal carcinoma] [*Article in Serbian*]. Acta Chirurgica Iugoslavica 1998; XLV:29-33.
40. Škaro Milić A, **Brajušković G,** Hristić M. Apoptosis and Malignity. Jugoslav Physiol Pharmacol Acta 1997; 33 (1):1-31.

**Radovi u časopisima nacionalnog značaja (M53)**

1. Vučetić D, Balint B, Taseski J, Trajković Lakić Z, Mandić Radić S, Subota V, Lazić N, **Brajušković G**. Kvantifikacija, ispitivanje morfologije, ultrastrukture i funkcionalne očuvanosti trombocita zamrzavanih primenom šest protokola kriokonzervacije. Bilten za transfuziologiju 2001; 46(1-2):19-26.
2. Vučetić D, Balint B, Taseski J, Trajković Lakić Z, Mandić Radić S, Subota V, Miković D, **Brajušković G**. Ispitivanje broja, morfologije i ultrastrukture svežih i zamrzavanih trombocita. Anestezija, reanimacija, transfuzija 2001; 29(1-2):85-92.
3. Panišić M, Petrović M, Kostić Z, **Brajušković G**, Knežević-Ušaj S,Tarabar D, Jovanović M. [Possible strategies in diminish the risk for development of colorectal carcinoma in patients with ulcerative colitis and familial adenomatous polyposis] [*Article in Serbian*]. Zdravstvena zaštita 1999; XXVIII: 20-3.

**Naučna kritika u časopisu ranga M52 (M57)**

1. **Brajušković G**. Genetic polymorphism – a new biological marker in medical diagnostics. *Invited commentary*. Vojnosaniteski pregled 2006; 63(4):362-3.
2. **Brajušković G**. Expression of p53 protein in gastric adenocarcinoma. *Letters to the Editor.* Vojnosanitetski pregled 2006; 63(1):88-9.

**Predavanja po pozivu sa skupova nacionalnog značaja štampana u celini (M61)**

1. **Brajušković G**, Nikolić Z, Branković A, Kotarac N, Savić-Pavićević D. Genetic basis of prostate cancer: Association studies. Biologica Serbica 2017; 39(1):40-45. The First Congress of Molecular Biologists of Serbia with international participation. Belgrade, Serbia, 20-22 September 2017.
2. Savić-Pavićević D, **Brajušković G**, Romac S. Nestabilnost mikrosatelita kao molekularno-genetička osnova neuroloških i psihijatrijskih oboljenja. Zbornik radova: 219-44. Vek tehnologije molekularne genetike. Srpska akademija nauka i umetnosti, Ogranak SANU u Novom Sadu. Novi Sad, 10. oktobar 2014. godine.
3. Dimitrijević J, **Brajušković G**, Spasić P, Đuričić S, Bogdanović R, Radosavljević R. Pathologic characteristics of the kidney in hereditary nephropathy. Materia Medica 2006; 22 (2, suppl 1): 37-9. 12th Congress of the Association of Serbia and Montenegro pathologists with international participation. Palić, Serbia and Montenegro, May 31 – June 3, 2006.
4. Dimitrijević J, **Brajušković G**, Cerović S, Popović Z, Bogdanović R, Jovanović D, Hrvačević R, Aleksić A, Kovačević Z, Milosavljević I. Morphology of autoimmune diseases. Archive of Oncology 2004; 12(1):27-9. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, Serbia and Montenegro, 23-26 May 2004.
5. **Brajušković G**, Vukosavić Orolicki S, Cerović S, Knežević Ušaj S, Perić P, Marjanović S, Dimitrijević S, Romac S, Škaro Milić A. The expression of caspase 3 in chronic lymphocytic leukemia. Archive of Oncology 2004; 12(1):65. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, Serbia and Montenegro, 23-26 May 2004.
6. Cerović S, Ignjatović M, **Brajušković G**, Knežević Ušaj S, Dimitrijević J, Ćuk V. The value of intraoperative diagnosis in thyroid surgery. Archive of Oncology 2004; 12(1):47. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, Serbia and Montenegro, 23-26 May 2004.
7. Dimitrijević J, Škatarić V, Tatomirović Ž, Tufegđić I., Aleksić A, Kovačević Z, Đukanović Lj, **Brajušković G**, Gligić A. Hemorrhagic fever in hantavirus infection: Histopathologic presentation. Archive of Oncology 2002; 10(1):8. 10th Yugoslav Congress of Pathology with International Participation. Tara, Yugoslavia, September 24 – 28, 2002.
8. **Brajušković G**, Vukosavić S, Romac S, Marjanović S, Cerović S, Knežević Ušaj S, Popović L, Jovanović J, Dimitrijević J, Škaro Milić A. The expression and interaction bcl 2 and bax proteins as prognostic parameter in chronic lymphocytic leukemia. Archive of Oncology 2002; 10(1):28-9. 10th Yugoslav Congress of Pathology with International Participation. Tara, Yugoslavia, September 24 – 28, 2002.
9. Cerović S, Milović N, Dimitrijević J, Vukotić Maletić V, Popović L, Knežević Ušaj S, **Brajušković G.** Parameters for early prostate cancer biochemical failure –after radical prostatectomy. Archive of Oncology 2002; 10(1):17-8. 10th Yugoslav Congress of Pathology with International Participation. Tara, Yugoslavia, September 24 – 28, 2002.
10. Knežević Ušaj S, Krtolica K, Ćuk V, Panišić M, Tarabar D, **Brajušković G**, Cerović S, Magić Z. Prognostic significance of molecular and immunohistochemical markers in colorectal carcinomas. Archive of Oncology 2002; 10(1):27-8. 10th Yugoslav Congress of Pathology with International Participation. Tara, Yugoslavia, September 24 – 28, 2002.
11. Cerović S, Tatić V, Dimitrijević J, Popović L, Milović N, Aleksić P, Aleksić A, **Brajušković G.** Disseminated prostatic carcinoma with normal serum level of prostate specific antigen. Archive of Oncology 2001; 9(1):101-102. 9th Yugoslav Congress of Pathology with International Participation, Vrnjačka Banja, Yugoslavia, June 14-7, 2000.
12. Dimitrijević J, Dujić A. Đukanović Lj, Hrvačević R, Blagojević R, Milosavljević I, **Brajušković G**, Aleksić A. The place and role of a pathologist in the transplant team. 9th Yugoslav Congress on Pathology with International Participation. Vrnjačka Banja, Yugoslavia, June 14-17, 2000.
13. Popović L, Cerović S, Tatić V, **Brajušković G**, Škuletić V. Tumor margin and mast cell presence in fibrohistiocytic tumor. Archive of Oncology 2001; 9(1):136-7. 9th Yugoslav Congress of Pathology with International Participation, Vrnjačka Banja, Yugoslavia, June 14-7, 2000.
14. Škaro Milić A, Spasić P, Štrbac M, **Brajušković G.** Protection of the Human Myocardium by Creatine Phosphate during Operation. Ultrastructural Investigations. Bulletin T. CXV de l’ Académie serbe des sciences et des arts. Classe des sciences mathematiques et naturelles. Sciences naturelles 1998; 37:95-102. Second Congress on Electron Microscopy, Belgrade, Yugoslavia, 2-5 October 1996.

**Predavanja po pozivu sa skupova nacionalnog značaja štampana u izvodu (M62)**

1. Savić-Pavićević D, Pešović J, Brkušanin M, Perić S, Radvansky J, Maširević S, Kovčić V, Musova Z, Stehlikova K, Leonardis L, Kekou K, Jovanović V, Mayanec R, Ranum LP, **Brajušković G**, Rakočević Stojanović V. The Origin anf Historical Route of Myotonic Distrophy Type 2 Mutation Across Europe. Book of Apstracts [Elektronski izvor]: 11. 1st Congress of Molecular Biologists of Serbia with international participation - CoMBoS, Belgrade, Serbia, September 20 - 22, 2017. ISBN 978-86-7078-136-8.
2. Đurica S, Šviković S, Pantović M, Karanović J, **Brajušković G,** Romac S, Ivković M, Savić-Pavićević D. Asocijacija i epistaze mikroRNK 137 i enzima za editovanje adenozina u inozin u molekulima RNK kod šizofrenije i bipolarnog poremećaja. Knjiga sažetaka:8. VI Kongresa Društva za neuronauke Srbije, Beograd, Srbija, 14-16. novembar 2013.
3. Savić-Pavićević D, Milić Rašić V, Mladenović J, Rakočević Stojanović V, **Brajušković G**, Jordanova A, De Jonghe P, Todorović S, Romac S. 5. Molecular genetics of myotonic disorders in Serbian patients. Clinical Neurophysiology 2013; 124(7)e10. Symposium of Clinical Neurophysiology with international perticipation, Belgrade, Serbia, 2-3 November 2012.
4. Savić-Pavićević D, Mladenović J, Rakočević Stojanović V, Pekmezović T, Karanović J, **Brajušković G**, Apostolski S, Todorović S, Romac S. Molekularna genetika bolesti nestabilnih ekspanzija ponovaka. Zbornik radovaVIII/XIV Kongresa neurologa Srbije, V kongresa Društva za neuronauke Srbije, II simpozijuma medicinskih sestara – tehničara:42. Kopaonik, Srbija. 29. septembar-02. oktobar 2011.

**Radovi saopšteni na skupovima nacionalnog značaja štampani u celini (M63)**

1. Bajčetić M, Lačković V, Rakočević V**, Brajušković G**, Carević Z, Novaković A. The importance of transmission electron microscopy in differential diagnosis of mitochondrial myopathies – case report. Proceedings 3rd Serbian Congress for Microscopy:167-8. Belgrade, Serbia, 25-28 September 2007.
2. Kravić T, **Brajušković G**, Bumbaširević V. Involvement of Microtubules in the regulation of apoptosis induced by lovastatin and paclitaxel in HL-60 cells. Proceedings 3rd Serbian Congress for Microscopy:205-6. Belgrade, Serbia, 25-28 September 2007.
3. Cerović S, Milović N, **Brajušković G**, Maletić Vukotić V. *Ex tempore* dijagnostika u radikalnim prostatektomijama. Zbornik radova: 13-17. Simpozijum Bolesti prostate. Banja Vrućica Teslić, Bosna i Hercegovina, 21-23 oktobar 2005.
4. Milović N, Cerović S, Stijelja B, Čokić M, **Brajušković G**. Patološki stadijum kao prognostički faktor progresije karcinoma prostate nakon radikalne retropubične prostatektomije. Zbronik radova: 24-30. Simpozijum Bolesti prostate. Banja Vrućica Teslić, Bosna i Hercegovina, 21-23 oktobar 2005.
5. Dimitrijević J, Cerović S, Aleksić A, **Brajušković G**, Škatarić V, Đokić M, Salapura A, Tomić Lj, Balaban N, Gligić A. Hemorrhagic Fever with Renal and Pulmonary Syndrome: Pathohistology Findings. International congress »Health for all« Health perspective in 21st centry, Banja Luka, Bosnia and Hercegovina, 4th – 8th June 2003. p. 397-405.
6. Škaro Milić A, Bumbaširević V, Marjanović S, **Brajušković G.** Apoptosis and Ultrastructural Alteration of Leukemic Cells During Chemotherapy. Annals of the Academy of Studenica 1998; 1/1998:41-3.
7. Dimitrijević J, Štrbac M, **Brajušković G,** Spasić P. Značaj biopsije bubrega za kliničko–patološku ocenu stanja transplantiranog bubrega. Acta Mediana 1997; XXXVI (1): 120-2. Simpozijum “Dostignuća i stremljenja u patologiji” II sa međunarodnim učešćem.
8. **Brajušković G**, Bumbaširević V, Bokun R, Berger S, Marjanović S, Škaro Milić A. Hlorambucil-om indukovana apoptoza kod pacijenata sa hroničnom limfocitnom leukemijom. Elektronska mikroskopija u biomedicini i nauci o materijalima, 40 godina elektronske mikroskopije u Srbiji, ed. »EXCELSIOR« Novi Sad, 1997, p.31-2.
9. Škaro Milić A, **Brajušković G**, Čolić M, Trajković Z, Marjanović S, Bumbaširević V. Apoptoza CLL ćelija indukovana leukeranom i CD 19 pozitivnost. Elektronska mikroskopija u biomedicini i nauci o materijalima, 40 godina elektronske mikroskopije u Srbiji, ed. »EXCELSIOR« Novi Sad, 1997, p.33-4.

**Radovi saopšteni na skupovima nacionalnog značaja štampani u izvodu (М64)**

1. Brkušanin M, Milić Rašić V, Brankovič V, Stević Z, Nikolić D, Kosać A, Jovanović K, Pešović J, **Brajušković G**, Savić-Pavićević D. Fosforilisani težak lanac neurofilamenta u likoviru kao biomarker odgovora na terapiju Nusinersenom kod osoba sa spinalnom mišićnom atrofijom. Knjiga sažetaka: 292. Treći kongres biologa Srbije. Zlatibor, Srbija, 21-25.09.2022.
2. Pešović J, Perić S, Radovanović N, Radenković L, Brkušanin M, **Brajušković G**, Rakočević Stojanović V, Savić-Pavićević D. CpG mesta u okolini *DMPK* ekspanzija sa varijantnim motivima su heterogeno metilovana kod bolesnika sa miotoničnom distrofijom tip 1. Knjiga sažetaka: 289. Treći kongres biologa Srbije. Zlatibor, Srbija, 21-25.09.2022.
3. Radenković L, Pešović J, Radovanović N, **Brajušković G**, Savić-Pavićević D, Perić S, Rakočević Stojanović V. Klaster analiza fenotipskih karakteristika pacijenata koji boluju od miotonične distrofije tipa 2. Knjiga sažetaka: 312. Treći kongres biologa Srbije. Zlatibor, Srbija, 21-25.09.2022.
4. Filipović L, Spasojević M, Prodanović R, Korać A, Matijašević S, **Brajušković G**, Ariode M, Popović M. Developing reversible immuno-affinity capture for extracellular vesicles purification Book of abstracts:66-7. Serbian Biochemical Society Eleventh Conference Scientific meeting of an international character September 22nd and 23rd, 2022, Novi Sad, Serbia “Amazing Biochemistry”.
5. Kotarac N, Dobrijević Z, Matijašević S, Savić-Pavićević D, **Brajušković G**. Analysis of association of potentially functional genetic variants within genes encoding miR-34b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population.Book of abstracts:59. 6th Congress of the Serbian Genetic Society. Vrnjačka Banja, Serbia, October 2019.
6. Matijašević S, Vučić N, Radovanović N, Rajovski S, Dobrijević Z, Kotarac N, Djordjević M, Budimirović B, Savić-Pavićević D, **Brajušković G**. Association studies of genetic variant 10842262 with idiopatic male infertility in Serbian and North Macedonian man. Book of abstracts:61. 6th Congress of the Serbian Genetic Society. Vrnjačka Banja, Serbia, October 2019.
7. Brkušanin M, Jeftović Velkova I, Jovanović V, Perić S, Pešović J, **Brajušković G**, Stević Z, Savić-Pavićević D. *SMN1* copy number as a modifying factor of survival in Serbian patients with sporadic Amyotrophic Lateral Sclerosis. Book of abstracts:60. 6th Congress of the Serbian Genetic Society. Vrnjačka Banja, Serbia, October 2019.
8. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Variant repeats wthin *DMPK* expansions as genetic modifer of DM1 phenotype. Book of abstracts:57. 6th Congress of the Serbian Genetic Society. Vrnjačka Banja, Serbia, October 2019.
9. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Variant CCG repeats within *DPMK* expansions and surrounding CpG sites are heterogeneously methylated in blood cells of Myotonic Dystrophy type 1 patients. Abstract book:11.Immunology at the confluence of multidisciplinary approaches. Serbia, Belgrade, December 6-8, 2019.
10. Karanović J, Ivković M, Pantović M, Damjanović A, Jovanović V, **Brajušković G**, Savić Pavićević D. Association of variants in RNA editing genes, serotonergic system genes and stressful life events with suicide attempt in psychiatric patients. Book of Abstracts:85. 7th Congress of Serbian Neuroscience Society with international participation, Belgrade, Serbia, October 25-27, 2017. ISBN: 978-86-917255-1-8.
11. Pešović J, Perić S, Brkušanin M, **Brajušković G**, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Book of Apstracts [Elektronski izvor]: 91. 1st Congress of Molecular Biologists of Serbia with international participation - CoMBoS, Belgrade, Serbia, September 20 - 22, 2017. ISBN 978-86-7078-136-8.
12. Brkušanin M, Kosać A, Jovanović V, Pešović J, **Brajušković G**, Milić Rašić V, Savić-Pavićević D. Synergistic influence of the SMN2 and SERF1A gene copy number on childhood-onset spinal muscular atrophy. Book of Apstracts [Elektronski izvor]: 112. 1st Congress of Molecular Biologists of Serbia with international participation - CoMBoS, Belgrade, Serbia, September 20 - 22, 2017. ISBN 978-86-7078-136-8.
13. Karanović J, Ivkocić M, Pantović M, Damjanović A, Jovanović V, **Brajušković G**, Savić-Pavićević D. Joint effects of variants in RNA editing and serotonergic system genes and stressful life events in predisposition for suicide attempt in psychiatric patients. Book of Apstracts [Elektronski izvor]: 139. 1st Congress of Molecular Biologists of Serbia with international participation - CoMBoS, Belgrade, Serbia, September 20 - 22, 2017. ISBN 978-86-7078-136-8.
14. Kotarac N, Vučić N, Vuković I, Kanazir S, Savić-Pavićević G, **Brajušković G**. Copy number variations and microdeletions in Y-chromosomal azoospermia factor regions in patients from Serbia. Book of Apstracts [Elektronski izvor]: 145. 1st Congress of Molecular Biologists of Serbia with international participation - CoMBoS, Belgrade, Serbia, September 20 - 22, 2017. ISBN 978-86-7078-136-8.
15. Karanović J, Ivković M, Jovanović V, Pantović Stefanović M, Brkušanin M, Damjanović A**, Brajušković G**, Savić-Pavićević D. Effect of childhood general traumas on suicide attempt depends on TPH2 and ADARB1 variants in psychiatric patients. Psihijatrija danas Supplementum/2016/48/1/5-145, Book of abstracts: 80. XV kongres Udruženja psihijatara Srbije kosponzorisan od strane Svetske psihijatrijske asocijacije i Regionalni kongres Udruženja psihijatara Istočne Evrope i Balkana: Putevi i raskršća psihijatrije. Beograd, Srbija. 12-15. oktobar, 2016.
16. Karanović J, Ivković M, Jovanović V, Šviković S, Pantović Stefanović M, Damjanović A, **Brajušković G**, Romac S, Savić Pavićević D. Association of serotonin receptor 1A gene with bipolar disorder in Serbian population - a preliminary results. U: Engrami. 43. edukativni simpozijum Klinike za psihijatriju KCS - Bipolarni poremećaj - izazovi i pespektive; 12-13. novembar 2015; Beograd, Srbija. str. 82.
17. Nikolić Z, Savić-Pavićević D, Vučić N, Filipović N, Vukotić V, Romac S, **Brajušković G**. Assessment of association between rs895819 in miR-27a and prostate cancer risk in Serbian population. Book of abstracts:46. V Congress of the Serbian Genetic Society. Kladovo (Belgrade). 28. Septembra – 2. Oktobra 2014.
18. Vučić N, Nikolić Z, Savić-Pavićević D, Kanazir S, Vukotić V, Romac S, **Brajušković G**. Assessment of possible association between two genetic variants in NOS3 gene and male infertility in Serbian population. Book of abstracts:131. V Congress of the Serbian Genetic Society. Kladovo (Belgrade). 28. Septembra – 2. Oktobra 2014
19. Pešović J, Brkušanin M, Nikolić Z, Karanović J, **Brajušković G**, Romac S, Savić-Pavićević D. Repeat-primed PCR in diagnostic testing of repeat expansion diseases. Book of abstracts:232. V Congress of the Serbian Genetic Society. Kladovo (Belgrade). 28. Septembra – 2. Oktobra 2014.
20. Brkušanin M. Kosać A, Pešović J, **Brajušković G**, Romac S, Milić Rašić V, Savić-Pavićević D. Association of SMN2 gene copy number with clinical types of spinal muscular atrophy (SMA) in Serbian patients. Book of abstracts:78. V Congress of the Serbian Genetic Society. Kladovo (Belgrade). 28. Septembra – 2. Oktobra 2014.
21. Karanović J, Pantović M, Brkušanin M, **Brajušković G**, Romac S, Ivković M, Savić-Pavićević D. Interactions of TPH2 variants and childhood abuse as risk factors for suicide attempt in Serbian psychiatric patients. Book of abstracts:123. V Congress of the Serbian Genetic Society. Kladovo (Belgrade). 28. Septembra – 2. Oktobra 2014.
22. Pešović J, Vojinović D, Maksimović N, **Brajušković G**, Romac S, Novaković I, Milič Rašić V, Savić-Pavićević D. Analiza rearanžmana u genu za distrofin primenom metode multipleks amplifikacije ligiranih proba. Zbornik sažetaka: 137. IX/XV Kongres neurologa Srbije sa međunarodnim učešćem. Beograd. 14-16. Novembra 2013.
23. Šviković S, Brkušanin M, Karanović J, Pantović M, Đurica S, **Brajušković G**, Romac S, Ivković M, Savić-Pavićević D. From genotype to phenotype: *in silico* modelling of serotonergic system. Book of Abstracts:31. Theoretical Approaches to BioInformation Systems TABIS 2013. Beograd, 17-22. Septembar 2013. godine.
24. Dačković J, Radivojević M, Keckarević-Marković M, **Brajušković G**, Romac S. Pallister Hall sindrom: porodica iz Srbije. Zbornik radova:159. VIII/XIV Kongres neurologa Srbije, V kongres Društva za neuronauke Srbije, II simpozijum medicinskih sestara – tehničara. Kopaonik, 29. Septembar – 02. Oktobar, 2011.
25. Strnad M, **Brajušković G**, Strelić N, Todorić Živanović B, Stamatović D, Magić Z. Ekspresija Bcl 2 proteina i amplifikacija c-myc gena u bolesnika sa hroničnom granulocitnom lekukemijom. Zbornik apstrakata: 77. IV Kongres genetičara Srbije, Tara, Jun 1-5, 2009.
26. Radivojević M, Keckarović Marković M, Dačković J, Apostolski S, **Brajušković G**, Romac S. Molekularna analiza Gli3 gena kod pacijenata sa Palister-Halovim sindromom. Zbornik apstrakata: 104. IV Kongres genetičara Srbije, Tara, Jun 1-5, 2009.
27. Šijačić Nikolić M, Milovanović J, Savić-Pavićević D, **Brajušković G**, Diklić M. Genetička distanca različitih regiona hrasta kitnjaka u Srbiji. Zbornik apstrakata: 257. IV Kongres genetičara Srbije, Tara, Jun 1-5, 2009.
28. **Brajušković G**, Savić-Pavićević D, Romac S. Značaj otkrića varijacija u broju ponovaka u humanom genomu za nove strategije istraživanja bolesti. Materia Medica 2009; 25(2):44. XIII Kongres Udruženja patologa i citologa Srbije sa međunarodnim učešćem. Vršac, Maj 27-30, 2009.
29. Cerović S, **Brajušković G**, Vukotić Maletić V. Imunohistohemijska ekspresija ciklooksigenaze 2 u lokalizovanom karcinomu prostate. Materia Medica 2009; 25(2):76. XIII Kongres Udruženja patologa i citologa Srbije sa međunarodnim učešćem. Vršac, Maj 27-30, 2009.
30. **Brajušković G**, Cerović S, Strnad M, Marjanović S. The ultrastructural investigation of mitochondria in B-CLL cells during process of apoptosis. Materia Medica 2006; 22 (2, suppl 1):80. 12th Congress of the Association of Serbia and Montenegro pathologists with international participation. Palić, May 31 – June 3, 2006.
31. Cerović S, **Brajušković G**, Jeremić N, Maletić Vukotić V. Lymph node metastases of prostate cancer in patients with preoperative serum prostate specific antigen of ≤ 10 ng/ml. Materia Medica 2006; 22 (2, suppl 1):78. 12th Congress of the Association of Serbia and Montenegro pathologists with international participation. Palić, May 31 – June 3, 2006.
32. Strnad M, **Brajušković G**, Strelić N, Todorić Živanović B, Tatomirović Ž, Stamatović D, Magić Z. Amplification of c-myc oncogene in CML. Materia Medica 2006; 22 (2, suppl 1):81. 12th Congress of the Association of Serbia and Montenegro pathologists with international participation. Palić, May 31 – June 3, 2006.
33. Marjanović S, **Brajušković G**, Vukosavić Orolicki S, Cerović S. Ekspresija Bad proteina u limfocitima B periferne krvi bolesnika sa hroničnom limfocitnom leukemijom. Bilt. Hematol 2004; 32(1/2):3. XII Hematološki dani, Niš, oktobar 2004.
34. Strnad M, **Brajušković G**, Todorić Živanović B, Stamatović D, Magić Z, Škaro Milić A. Ekspresija Bcl 2 proteina kod bolesnika sa CML. Bilt. Hematol 2004; 32(1/2):3. XII Hematološki dani, Niš, oktobar 2004.
35. Strnad M, Strelić N, **Brajušković G**, Malešević M, Škaro Milić A, Magić Z. Study of p53 in patients with CML by immunohistochemistry and DNA analysis. Archive of Oncology 2004; 12(1):107. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, 23-26 May 2004.
36. Ušaj Knežević S, Krotilica K, Bogdanović A, **Brajušković G,** Cerović S, Ištvan K, Eri Ž. Vascular endothelial growth factor and K-ras mutation in colorectal carcinoma. Archive of Oncology 2004; 12(1):109. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, 23-26 May 2004.
37. Rafajlovski S, Stanković Z, Popović Z, Kovačević R, **Brajušković G**, Milosavljević I, Dimitrijević J. Combined myocardial infarction of left ventricule. Archive of Oncology 2004; 12(1):137. 11th Congress of Pathology Serbia and Montenegro with international participation. Zlatibor, 23-26 May 2004.
38. **Brajušković G**, Marjanović S, Vukosavić S, Romac S, Škaro Milić A. Efekat hemioterapije na ekspresiju Bcl 2 i Bax proteina u B limfocitima periferne krvi pacijenata sa *de novo* dijagnostikovanom CLL. Bilten Hematol 2002; 30(1;2/3):34. 9 Kongres hematologa Jugoslаvije sa međunarodnim učešćem, Beograd, Jugoslavija, 16-19 oktobar 2002.
39. Marjanović S, **Brajušković G**, Vukosavić S, Škaro Milić A, Malešević M. Imunohistohemijska i Western blotting analiza ekspresije kaspaze 3 u mononuklearima periferne krvi pacijenata sa hroničnom limfocitnom leukemijom. Bilten Hematol 2002; 30(1;2/3):17. 9 Kongres hematologa Jugoslavije sa međunarodnim učešćem, 16Beograd, Jugoslavija, 16-19 oktobar 2002.
40. Tomić Lj, Aleksić B, Begović V, **Brajušković G**, Dimitrijević J. Viral hemorrhagic fevers (Hantavirus – pulmonal and renal syndrome). Archive of Oncology 2002; 10(1):69. 10th Yugoslav Congress of Pathology with International Participation, Tara, Serbia, Yugoslavia,September 24 – 28, 2002.
41. Jovanović J, Dimitrijević J, Milović N, Aleksić P, Medić N, Tufegdžić I, Đukić M, Nikolajević S, **Brajušković G**, Cerović S. Double carcinoma of the left kidney – A case report. Archive of Oncology 2002; 10(1):53. 10th Yugoslav Congress of Pathology with International Participation, Tara,Serbia, Yugoslavia,September 24 – 28, 2002.
42. Đukić M, Popović L, Krstić V, Jaćević V, Knežević Ušaj S, Cerović S, **Brajušković G.** Clear cell sarcoma – A case report. Archive of Oncology 2002; 10(1):72. 10th Yugoslav Congress of Pathology with International Participation, Tara,Serbia, Yugoslavia,September 24 – 28, 2002.
43. Popović L, Tatić V, Ilić S, Jaćević V, Cerović S, Ušaj Knežević S, **Brajušković G.** Correlation between mast cells and different biological potential of fibrohistiocytic tumors. Archive of Oncology 2002; 10(1):126. 10th Yugoslav Congress of Pathology with International Participation, Tara,Serbia, Yugoslavia,September 24 – 28, 2002.
44. Popović L, Cerović S, Ušaj Knežević S, **Brajušković G**. Prisustvo i značaj različitih tipova inflamacije u površno lokalizovanim fibrohistiocitnim tumorima. Zbornik radova:52. XVI Kongresa dermatovenerologa Jugoslavije, Igalo, Jugoslavija, 20-24 Septembar 2000.
45. Marjanović S, **Brajušković G,** Škaro Milić A. Značaj detekcije aktivirane kaspaze 3 u spontanoj i terapijom indukovanoj apoptozi selektovane grupe bolesnika sa B-CLL. Bilten of Hematology 28 (1;2/3):56. XI Hematološki dani, Beograd, Septembar 2000.
46. Dimitrijević J, Škaro-Milić N, Knežević-Ušaj S, **Brajušković G**, Aleksić A. Uloga kliničke patologije u savremenom lečenju bolesti jetre i bubrega. XIV Kongres lekara otadžbine i dijaspore, Beograd, Jugoslavija, 21-24 Maj, 2000.
47. **Brajušković G,** Spasić P, Bumbaširević V, Marjanović S, Škaro Milić A. In Vivo Follow up on Effects of Chemotherapy in Patients with Hematologic Neoplasms. Annals of the Academy of Studenica 1/1998:48.
48. **Brajušković G,** Spasić P, Bumbaširević V, Marjanović S, Knežević Ušaj S, Škaro Milić A. Expression of Bcl 2 and mut p53 Proteins and Chemotherapy Induced Apoptosis. Annals of the Academy of Studenica 1/1998:23.
49. **Brajušković G**, Spasić P, Bumbaširević V, Marjanović S, Knežević Ušaj S, Škaro Milić A. Immunohistochemical Detection of Bcl 2 and Mut. P53 Proteins – Correlation With Apoptotic response to Therapy. Archive of Oncology 1998; 6 (Suppl 2): 126. 8th Yugoslav Congress on Pathology with Internatonal Participation, Sremska Kamenica, Yugoslavia,June 10-13, 1998.
50. Cerović S, Tatić V, Knežević Ušaj S, Popović L, Elaković D, **Brajušković G.** Pathological Changes in Bening and Malignant Prostatic Tissue Following Androgen Deprivation Therapy. Archive of Oncology 1998; 6 (Suppl 2):110. 8th Yugoslav Congress on Pathology with Internatonal Participation, Sremska Kamenica, Yugoslavia,June 10-13, 1998.
51. Bogdanović Z, Kandolf L, **Brajušković G.** Malignant Eccrine Poroma (Porocarcinoma). Archive of Oncology 1998; 6 (Suppl 2): 135. 8th Yugoslav Congress on Pathology with Internatonal Participation, Sremska Kamenica, Yugoslavia,June 10-13, 1998.
52. Škaro Milić A, Marjanović S, **Brajušković G.** Chemotherapy and Induction of Ultrastructural Alternations of Leukemic Cells (CLL, ANNL). Archive of Oncology 1998; 6 (Suppl 2): 127. 8th Yugoslav Congress on Pathology with Internatonal Participation, Sremska Kamenica, Yugoslavia,June 10-13, 1998.
53. Knežević Ušaj S, Magić Z, Krtolica K, Cerović S, **Brajušković G**, Tarabar D, Ćuk V, Jović M. The pattern of proliferative activity and p53 protein over – expression in neoplastic and nonneoplastic lesions in longstanding ulcerative colitis. Archive of Oncology 1998; 6(2):61. 8th Yugoslav Congress on Pathology with Internatonal Participation, Sremska Kamenica, Yugoslavia,June 10-13, 1998.
54. Cerović S, Tatić V, Knežević Ušaj S, Bogdanović Z, **Brajušković G,** Milosavljević I, Milović N, Aleksić P, Elaković D. Korelacija preoperativnih vrednosti serumskih PSA sa prognostičkim parametrima adenokarcinoma prostate u radikalnim prostatektomijama (pilot studija). Abstracts Book: 33. 14th Yugoslavian Urological Congress with international participation Podgorica, Yugoslavia,11-14 June 1997, Yugoslavia.
55. Knežević Ušaj S, Krtolica K, Cerović S, Bogdanović Z, Ćuk V, Rabrenović Lj, Škaro Milić A, Tatić V, **Brajušković G.** Korelacija ekspresije K-ras i p53 mutacije sa proliferativnom aktivnosti kolorektalnog karcinoma. Arch. Gastroenteropatol. 1996; 15(7):S63. III Jugoslovenska gastroenterološka nedelja i XVI gastroenterološki dani srpskog lekarskog društva, Igalo – Herceg Novi, 17 – 21 Septembar 1996.
56. Marjanović S, **Brajušković G,** Stamatović D, Škaro Milić A, Malešević M. Efekat terapije u bolesnika sa CLL i ALL procenjivan maksimalnim odgovorom apoptoze. X Jugoslovenski hematološki dani sa međunarodnim učešćem. Knjiga abstarkta i radova:65. Niš – Niška Banja, 10-12 oktobar, 1996.
57. **Brajušković G,** Bumbaširević V, Marjanović S, Obradović S, Škaro Milić A. Indukcija apoptoze dejstvom hemioterapije kod pacijenata sa hematološkim neoplazmama. Acta Medianae 1996; XXXV(1):163. VII Congress of pathology of Yugoslavia with international participation. Podgorica – Budva 13-15 June 1996.
58. Knežević Ušaj S, Cerović S, Bogdanović Z, Ćuk V, Škaro Milić A, Dimitrijević J, **Brajušković G**, Todorović V, Marković Lipkoviski J, Tatić V. Korelacija ekspresije p53 i PCNA u kolorektalnim karcinomima. Acta Medianae 1996; XXXV(1):40. VII Congress of pathology of Yugoslavia with international participation. Podgorica – Budva 13-15 June 1996.

**Uređivanje zbornika saopštenja skupa nacionalnog značaja (M66)**

1. Book of Apstracts. 1st Congress of Molecular Biologists of Serbia [with international participation] – CoMBoS, Belgrade, Serbia, September 20 – 22, 2017. Editors: Goran Brajušković, Ana Đorđević ISBN 978-86-7078-136-8.

**Stručni radovi, naučno-popularni i popularni radovi (M66a)**

1. Djordjević A, **Brajušković G**. First Winner of the MolBioS Award. Gordana Matić: distinquished dedication, constancy and motivation. Biologica Serbica 2017; 39(1):6-8.
2. Fira Dj, Savić-Pavićević D, **Brajušković G**. 40 godina molekularne biologije. Biološki fakultet Univerzitet u Beogradu: 140 godina biologije, 40 godina molekularne biologije i 15 godina ekologije i zaštite životne sredine. 2013. pp. 10-11.

**Disertacije i teze (M70)**

**Doktorska disertacija (M71)**

1. **Brajušković Goran**. Ekspresija i interakcija proteina programirane ćelijske smrti kao mogući prognostički parametar hronične limfocitne leukemije. Doktorska disertacija. Biološki fakultet, Univerzitet u Beogradu, 2001.

Komisija: dr Vukosavić Slobodanka (mentor), dr Škaro-Milić Anđelija (mentor), dr Romac Stanka (član), dr Čuljković Biljana (član), dr Marjanović Slobodan (član)

**Magistarska teza (M72)**

1. **Brajušković Goran**. Indukcija apoptoze hemioterapijom u hematološkim neoplazmama. Magistarski rad*.* Biološki fakultet, Univerzitet u Beogradu, 1997.

Komisija: dr Romac Stanka (mentor), dr Škaro-Milić Anđelija (mentor), dr Bumbaširević Vladimir (član)

**Diplomski rad**

1. **Brajušković G.** Ultrastrukturne promene nukleusa tumorskih ćelija kolona u raznim fazama maligniteta. Diplomski rad. Biološki fakultet, Univerzitet u Beogradu, 1994.

Komisija: dr Škaro-Milić Anđelija (mentor), dr Nada Šerban (mentor)

**Angažovanje na projektima**

*domaći projekti*

* Projekat „Analiza promena u strukturi genoma kao dijagnostički i prognostički parametar humanih bolesti“ broj 173016. Finansijer i trajanje: Ministarstvo za prosvetu i nauku Republike Srbije, 2011−2019.
* Projekat „Molekularna genetika naslednih neurodegenerativnih i psihijatrijskih oboljenja” broj 143013. Finansijer i trajanje: Ministarstvo za nauku i tehnološki razvoj Republike Srbije, 2006−2010.
* Projekat “Molekularni mehanizmi regulacije apoptoze / ćelijske smrti u normalnim i malignim ćelijama” (2002).

*međunarodni projekti*

* Rukovodilac grupe PROSTATSERBIA u okviru*Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium* (http://practical.ccge.medschl.cam.ac.uk/) kojim rukovodi Centre for Cancer Genetic Epidemiology University of Cambridge, UK.
* C.O.S.T. Action. COST-BM1003. *Microbial cell surface determinants of virulence as targets for new therapeutics in Cystic Fibrosis*. 2014. Management Committee Substitute. (http://www.cost.eu /about\_cost/ who/ (type)/5/(wid)/40805)

**Članstvo u uredništvu međunarodnog časopisa**

2017 –2019 Srpski arhiv za celokupno lekarstvo (M23)

http://www.srpskiarhiv.rs/en/editorial-board/

2017 – Review Editor za Bioinformatics and Computational Biology, kao deo naučnih časopisa Frontiers in Genetics, Plant Science i Bioengineering and Biotechnology.

(https://www.frontiersin.org/journals/all/sections/bioinformatics-and-computational-biology#editorial-board)

**Recenzije publikacija kategorije M20**

1. Genetically predicted benign prostate hyperplasia causally affects prostate cancer: a two-sample Mendelian randomization. Reject. HELIYON 2023. Manuscript Number: HELIYON-D-23-06727. M23
2. Association Study of rs323344 In TEX15 With Non-Obstractive Azoospermia In Iranian Population. Genetika 2023. (M23)
3. Practical Utility of Liquid Biopsy for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer. Cancers 2023. Manuscript ID: cancers-2330503. (M21)
4. Application value of miRNA-182 as a biomarker for cancer diagnosis: a systematic review with meta-analysis. Biomarkers in Medicine 2023. Manuscript ID BMM-2023-0176. (M23).
5. Mitochondrial alterations in prostate cancer: roles in pathobiology and racial disparities. IJMS 2023. Manuscript ID: ijms-2161916.
6. Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: an Updated Systematic Review and Meta-analysis. Cancers 2023. Manuscript ID: cancers-2264594 (M21, IF2021=6,575)
7. Interactions of SNPs in Folate Metabolism Related Genes on Prostate Cancer Aggressiveness in European Americans and African Americans. Cancers 2023. Manuscript ID: cancers-2237748.Hsa\_circ\_0063329 inhibits prostate cancer growth and metastasis by modulating the miR-605-5p/TGIF2 axis. *Cell Cycle 2023*. Ref.: Ms. No. KCCY-2022-0691.
8. Tumor-suppressor and tumor-promoting miRNAs in prostate cancer: A roadmap to clinical course. *Gene 2022*. Ms. Ref. No.: GENEJOURNAL-D-22-02753.
9. GeneComplexities of Prostate Cancer*. International Journal of Molecular Sciences 2022*. Manuscript ID: ijms-2026494.
10. The association among TP53 rs1042522, pri-miR 34b/c rs4938723 polymorphisms and daily dietary fatty acids in patients with premalignant and malignant oral lesions. *Meta Gene 2022.* Manuscript ID:MGENE-D-22-00166.
11. Transcriptomic profiling analysis of castration resistant pros-tate   
    cancer cell lines treated with chronic intermittent hypoxia. *Cancers 2022*. Manuscript ID: cancers-1821639 (M21, IF2021=6,575)
12. Analysis of the correlation between gene copy deletion in the AZFc region and male infertility in Japanese men. *Reproductive Biology 2022*. Manuscript Number: REPBIO-D-22-00258. (M23, IF2020=2,376)
13. Analyzing the endothelial nitric oxide synthase  gene VNTR variant  in Turkish FMF Patients. *Meta Gene 2022.* Manuscript ID: MGENE-D-22-00162.
14. Decoding the Role of Tandem Repeats in DNA Repair Genes – A Pilot Study in Haematologic Cancer Cell Lines. *Frontiers in Genetics 2022.* Manuscript ID: 847511. (M21, IF2020=4,559)
15. The Crosstalk of Long Non-coding RNA and MicroRNA in Castration-resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance. *International Journal of Molecular Sciences 2021;* Manuscript ID: ijms-1463863. (M21, IF2020=5,924)
16. A mutation-related long noncoding RNA signature of genome instability predicts immune infiltration and hepatocellular carcinoma prognosis". *Frontiers in Genetics 2021.* Manuscript ID: 779554(M21, IF2020=4,559)
17. Linc-ROR has a potential ceRNA activity for OCT4A by sequestering miR-335-5p in Hek-293T cell line. *Biochemical Genetics 2021*. Manuscript Number BIGI-D-21-00077. (M23, IF2019=2,027)
18. Replication study and meta-analysis of selected genetic variants and polycystic ovary syndrome susceptibility in Asian population. *Journal of Assisted Reproduction and Genetics* 2021. Ms. No. JARG-D-21-00285 (M21, IF2019=2,829)
19. Construction and validation of prognostic regulation network based on RNA-binding protein genes in lung squamous cell carcinoma. *DNA and Cell Biology* 2021. Manuscript ID DNA-2021-0145 (M22, IF2019=3,314)
20. A pan-cancer atlas of somatic mutations in miRNA biogenesis genes. Nucleic Acids Research 2020. NAR-02397-N-2020. (M21a, IF2019= 11,501)
21. CircRNAs as promising biomarkers in diagnosis and prognosis of lung cancer: an updated meta-analysis. Genomics 2020. GENO\_2020\_998 (M21, IF2019= 6,205)
22. Association of TERT gene polymorphisms with clinical benign prostatic hyperplasia in Northwest Chinese Han population. *Translational Andrology and Urology* 2020. Ms. No. TAU-20-1032-R1 (M22, IF2019=2,455)
23. Clinical impact of circulating tumor cells in patients with localized   
    prostate cancer. *Cells* 2019. Manuscript ID: cells-530925. (M21, IF2017=4,829)
24. The cancer-associated genetic variant rs3903072 modulates immune cells in the tumor microenvironment. *Frontiers in Genetics* 2019. #470802 (M21, IF2017=4,151)
25. Association between two polymorphisms in the promoter region of miR-143/miR 145 and the susceptibility of lung cancer in Northeast Chinese non-smoking females. *DNA and Cell Biology* 2019.  # DNA-2019-4796 (M22, IF2017=2,634)
26. Enrichment of Cxcl12 promoter with TET2: a possible link between promoter demethylation and enhanced gene expression in the absence of PARP-1. *Archives of Biological Sciences* 2019. #2471(M23, IF2017=0,648)
27. Associations of single nucleotide polymorphisms in hsa-miR-499 and hsa-miR-196a2 and the risk of prostate cancer. *International Journal of Experimental Pathology* 2018;ms no. IJEP-2018-11-2875. (M22, IF2017=1,983)
28. Lack of associations between the has-miR-27a and hsa-miR-125a gene variations and prostate cancer risk.*Experimental and Molecular Pathology* 2018; Ref: EMP\_2018\_548. (M23, IF2017=2,556)
29. *In-silico* analysis of novel p.(Gly14Ser) variant of ATOX1 gene: Plausible role in modulating ATOX1-ATP7B interaction. *Biochemical Genetics* 2018; #BIGI-D-18-00295. (M23, IF2017=1,927)
30. Somatic Copy Number Alteration Burden Predicts Survival Prognosis in Breast Cancer. *Frontiers in Genetics* 2018; #409435. (M21, IF2017=4,151)
31. Determination of endothelial nitric oxide synthase gene polymorphism and plasma asymmetric dimethyl arginine concentrations in patients with lung cancer. *Biochemistry and Cell Biology* 2018; # bcb-2018-0174. (M23, IF2017=2,250)
32. The association between three genetic variants in microRNAs (rs11614913, rs2910164, rs3746444) and prostate cancer risk. *Cellular Physiology and Biochemistry* 2018; MS-N°:2018MS129 (M21a, IF2016=5,107)
33. A meta-analysis of miR-499 rs3746444 polymorphism for cancer risk of different systems: evidence from 65 case-control studies.*Frontiers Physiology* 2018; Manuscript ID: 357297 (M21, IF2016=4,134)
34. AGO2 expression levels and related genetic polymorphism in renal cell carcinoma. *Tumor Biology* 2018; TUB-18-0044 (M21, IF2016=3,650)
35. Renal immature teratoma in a male adult –a case report and literature review. *Urology Journal* 2018; Manuscript Code: 4455-02-03-2018 (M23, IF2016=0,824)
36. Methylation status of p16 and p14 genes in locally advanced rectal cancer treated with preoperative chemoradiotherapy: potential clinical implication. *Archives of Biological Sciences* 2018. #2771(M23, IF2016=0,352)
37. An updated meta-analysis of miR-499 rs3746444 polymorphism for cancer risk evidence from 57 case-control studie. *Oncotarget* 2017; Paper#041381 (M21, IF2016=5,168)
38. SOX4 is Activated by C-MYC Oncogene in Prostate Cancer. *Internatonal Journal of Experimental Pathology* 2017; IJEP-2017-09-2642 (M22, IF2016=1,780)
39. A functional variant (rs35592567) in TP63 at 3q28 is associated with gastric cancer risk via modifying its regulation by microRNA-140. *Cellular Physiology and Biochemistry* 2017; 2017MS1139 (M21a, IF2016=5,104)
40. Polymorphisms in four microRNAs and risk of oral squamous cell cancer: a meta-analysis. *Oncotarget* 2017; Paper#038297 (M21, IF2016=5,168)
41. Next generation sequencing as a tool for pharmacogenomic profiling: nine novel potential genetic markers for targeted therapy in childhood acute lymphoblastic leukemia. *Srpski arhiv za celokupno lekarstvo* 2017; Rad 152/2017 (M23, IF2016=0,253)
42. Minor allele of rs1057317 polymorphism is associated with increased risk of H.Pylori-induced gastric cancer by alternating the interaction between microRNA-34a and TLR4. *Cellular Physiology and Biochemistry* 2017; Manuscript Code: 2017MS361 (M21, IF2015=4,652)
43. Genetic Variants Are Associated With Treatment for BPH with α-blocker. *The Aging Male* 2017; Manuscript ID: DAGM-2017-0040. (M22, IF2015=1,493)
44. Comprehensive Review of Genetic Association Studies and Meta-Analysis on polymorphisms in microRNAs and Urological Neoplasms Risk. *Scientific Reports* 2017; Manuscript Code: SREP-16-43211. (M21, IF2015=5,228)
45. Functional polymorphism at the miR-502-binding site in the 3′ untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian Population. *Gene* 2017; Ms. Ref. No.: GENE-D-17-00513. (M22, IF2015=2,319)
46. The effects of sodium nitrite on cytotoxicity of ovary and changes in ovary cancer ca125 and spp1 genes expression in adult and immature rats. *Srpski arhiv za celokupno lekarstvo* 2017; Broj 225/16. (M23, IF2015=0,277)
47. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. *Gene* 2017; Ms. Ref. No.: GENE-D-17-00093. (M22, IF2015=2,319)
48. Association between eNOS G894T, 4b/a and T786C Polymorphisms and Risk of Prostate Cancer: a Meta-Analysis of 15 Studies. *Molecular Diagnosis & Therapy* 2016; Manuscript Number: MDTA-D-16-00203R1. (M22, IF2014=2,891)
49. Daucusol, a new guaiane-type sesquiterpenoids from Daucus carota L, promotes cytoplasmic vacuolation-mediated cell death of human prostate cancer PC-3 cells by triggering oxidative stress. *Archives of Biological Sciences* 2016. #960. (M23, IF2014=0,718)
50. Polymorphism in Exon 7 (G894T) and 5' Flanking Region (T786C) of Endothelial Nitric Oxide Synthase gene effect Serum Nitrate Levels; a Predictive Markers of Myocardial Infarction in Pakistan. *BMC Medical Genetics* 2016. Manuscript Code: MGTC-D-16-00011. (M23, IF2015=2,094)
51. miRNA-340 suppress cell proliferation, invasion and induced apoptosis by targeting ras homolog gene family, member A (RhoA) in colorectal cancer. *Archives of Biological Sciences* 2016. #336. (M23, IF2014=0,718)
52. Discrepancies between biosy Gleason score nad radical prostatectomy specimen gleason score: an Iranian experience. *Urology Journal* 2016. Manuscript Code: 3520-01-04-2016. (M23, IF2014=0,565)
53. Association between pre-miR-27A polymorphism and lung cancer. *Egyptian Journal of Medical Human Genetics* 2016. EJMHG-D-16-00052 (M23)
54. Genetic variant of miR-146a and gastric cancer risk in an eastern Chinese population. *Oncotarget* 2016. Paper #015510. (M21, IF2014=6,359)
55. Polymorphism at PCA3 and prostate cancer risk in an eastern Chinese population. *Oncotarget* 2016. Paper #012553. (M21, IF2014=6,359)
56. Comparative Analysis Reveals Different Properties of Mouse CDC25Bs. *Archives of Biological Sciences* 2016. #340. (M23, IF2014=0,718)
57. EPCA2.22: A silver lining for early diagnosis of prostate cancer. *Urology Journal* 2016. Manuscript Code: 3443-01-03-2016. (M23, IF2014=0,565)
58. Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian Population. *Journal of Advanced Research 2016;* Ms. Ref. No.:JARE-D-16-00065.(M23)
59. Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing biopsy for elevated psa levels. *Urology Journal 2015*; Mauscript ID:3291. (M23, IF2014=0,565)
60. Expression profiling of miR-96, miR-584 and miR-422a in colon cancer and their potential involvement in colon cancer pathogenesis. *Archives of Biological Sciences 2016*. Manuscript ID: 2015ABS0113\_Lu et al (M23, IF2014=0,718)
61. Positive Association Between IL1A rs3783553 Polymorphism and Cancer Risk: a Meta-analysis. *OncoTargets and Therapy* 2015; Submission ID: 101455. (M22, IF2014=2,331)
62. Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: An updated meta-analysis. *OncoTargets and Therapy* 2015; Submission ID: 96738. (M22, IF2014=2,331)
63. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer. *World Journal of Gastroenterology* 2015; Manuscript NO: 17709. (M22, IF2013=2,433)
64. Association between L55M polymorphism in Paraoxonase 1 (PON1) and cancer risk: a meta-analysis based on 21 studies. *OncoTargets and Therapy* 2015; Submission ID: 96990. (M22, IF2014=2,331)
65. Current role of spacers for prostate cancer radiotherapy. *World Journal of Clinical Oncology* 2015; ESPS Manuscript NO: 20105. (M23).
66. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. *Research and Reports in Urology* 2015. Submission ID: 98877. (M23)
67. Differential blood based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score or TNM status.TUBI-D-15-03428. *Tumor Biology* 2015.(M22, IF2014=3,611)
68. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.Manuscript ID: AJA-5331. *Asian Journal of Andrology* 2015. (M21, IF2014=2,596)
69. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. *Tumor Biology* 2014. TUBI-D-15-00699R. (M22, IF2014=3,611)
70. SOX 1, contrary to SOX 2, suppresses proliferation and metastasis in human laryngeal squamous cell carcinoma by inhibiting the Wnt/β-catenin pathway. *Tumor Biology* 2014.TUBI-D-15-00550. (M22, IF2014=3,611)
71. MDM2 SNP309 Polymorphism with Skin Cancer Risk: A Meta-analysis. *Journal of Dermatological Science* 2014. Reference: JDS-14-401. (M21, IF2014=3,419)
72. Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis. *Tumor Biology* 2014.TUBI-D-13-01641. (M22, IF2014=3,611)
73. Endothelial nitric oxide synthase 3 gene variants are significantly associated with Prostate Cancer risk.*Tumor Biology* 2014.TUBI-D-13-01739R1. (M22, IF2014=3,611)
74. Relationship between CIP2A expression, and prognosis and MDR-related proteins in patients with advanced gastric cancer. *Cancer Investigation* 2014. LCNV-2014-​0038. (M23, IF2014= 2,218)
75. Endothelial nitric oxide synthase 3 gene variants are significantly associated with Prostate Cancer risk. *International Journal of Biological Markers* 2014. Ref.:Ms. No. JBM-D-14-00048. (M23, IF2014= 1,371)
76. Identification of osteosarcoma metastasis genes and its functional studies. *Archives of Biological Sciences*. 09032014AB​S. (M23, IF2014=0,718)
77. Effect of berberine on enhancer of zeste homolog 2 (Ezh2) in esophageal cell motility. *Archives of Biological Sciences*. 12122014ABS. (M23, IF2014=0,718)
78. Prognostic value of HMGB3 expression in cancer：a meta-analysis. *International Journal of Biological Markers* 2014. Ref.: Ms. No. JBM-D-15-00162. (M23, IF2014= 1,371)
79. *Cell Biology International* (M23);
80. *Cell Biology International* (M23);
81. *Cell Biology International* (M23);
82. *Archives of Biological Sciences, Belgrade* (M23);

*Kategorije M50*

1. – 86. Vojnosanitetski pregled - recenzent šest radova iz oblasti molekularne biologije i patologije) (Dobrić S. Vojnosanit Pregl 2009; 66(1):5–7.) (M50)
2. Kategorije M60
3. „TransEpiGen-omics” in research of cardiovascular diseases: Unraveling the genetic basis of complex diseases. Biologica Serbica 2017. (M60)

Bio je recezent i jednog bilateralnog projekta između Republike Srbije i Republike Slovenije za period 2020-2021.

1. **CITIRANOST RADOVA -** *izvori Web of Science, Scopus and Google Scholar*

Radovi G. Brajuškovića citirani su 500 puta od čega 56 rada **359** puta u časopisima sa SCI liste

1. **Rad: *Savić Pavićević D, Miladinović J, Brkušanin S, Šviković S, Brajušković G, Romac S, Djurica S. Molecular genetics and genetic testing in myotonic dystrophy type 1 (DM1). BioMed Research International (Journal of Biomedicine and Biotechnology) 2013.***

**citiraju: 40x**

1. Ivanovic V, Peric S, Pesovic J, Tubic R, Bozovic I, Petrovic Djordjevic I, Savic-Pavicevic D, Meola G, Rakocevic-Stojanovic V. Clinical score for early diagnosis of myotonic dystrophy type 2. Neurol Sci. 2023; 44(3):1059-67. (M22)
2. Tsai YC, de Pontual L, Heiner C, Stojkovic T, Furling D, Bassez G, Gourdon G, Tomé S. Identification of a CCG-Enriched Expanded Allele in Patients with Myotonic Dystrophy Type 1 Using Amplification-Free Long-Read Sequencing. J Mol Diagn. 2022; 24(11):1143-54. (M21)
3. Peric S, Zlatar J, Nikolic L, Ivanovic V, Pesovic J, Petrovic Djordjevic I, Sreckovic S, Savic-Pavicevic D, Meola G, Rakocevic-Stojanovic V. Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2. Front Neurol. 2022;13:932883. (M22)
4. Mateus T, Costa A, Viegas D, Marques A, Herdeiro MT, Rebelo S. Outcome measures frequently used to assess muscle strength in patients with myotonic dystrophy type 1: a systematic review. Neuromuscul Disord. 2022;32(2):99-115. (M22)
5. López-Martínez A, Soblechero-Martín P, de-la-Puente-Ovejero L, Nogales-Gadea G, Arechavala-Gomeza V. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I. Genes (Basel). 2020;11(9):1109. (M23)
6. Rasmussen A, Hildonen M, Vissing J, Duno M, Tümer Z, Birkedal U. High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in Myotonic Dystrophy Type 1. Genes (Basel). 2022;13(6):970. (M23)
7. Valor LM, Morales JC, Hervás-Corpión I, Marín R. Molecular Pathogenesis and Peripheral Monitoring of Adult Fragile X-Associated Syndromes. Int J Mol Sci. 2021; 22(16):8368. (M21)
8. Pegoraro V, Cudia P, Baba A, Angelini C. MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy. Neurol Sci. 2020;10. (M22)
9. Urata Y, Nakamura M, Shiokawa N, et al. Sleep Disorders in Four Patients With Myotonic Dystrophy Type 1. Front Neurol. 2020;11:12. (M22)
10. Claerhout S, Van der Haegen M, Vangeel L, Larmuseau MHD, Decorte R. A game of hide and seq: Identification of parallel Y-STR evolution in deep-rooting pedigrees. Eur J Hum Genet. 2019; 27(4):637-646(M22).
11. Taylor S, Rodrigues M, Poke G, Wake S, McEwen A. Family communication following a diagnosis of myotonic dystrophy: To tell or not to tell? J Genet Couns. 2019; 28(5):1029-1041. (M21)
12. Yamamoto T, Miura A, Itoh K, Takeshima Y, Nishio H. RNA sequencing reveals abnormal LDB3 splicing in sudden cardiac death. Forensic Sci Int. 2019;302:109906. (M21)
13. Leferink M, Wong DPW, Cai S, Yeo M, Ho J, Lian M, Kamsteeg EJ, Chong SS, Haer-Wigman L, Guan M. Robust and accurate detection and sizing of repeats within the DMPK gene using a novel TP-PCR test. Sci Rep. 2019;9(1):8280. (M21)
14. Solbakken G, Bjørnarå B, Kirkhus E, Nguyen B, Hansen G, Frich JC, Ørstavik K. MRI of trunk muscles and motor and respiratory function in patients with myotonic dystrophy type 1. BMC Neurol. 2019;19(1):135.(M23)
15. Peric S, Bozovic I, Nisic T, Banovic M, Vujnic M, Svabic T, Pesovic J, Brankovic M, Basta I, Jankovic M, Savic-Pavicevic D, Rakocevic-Stojanovic V. Body composition analysis in patients with myotonic dystrophy types 1 and 2. Neurol Sci. 2019;40(5):1035-1040. (M22)
16. Dastidar S, Ardui S, Singh K, Majumdar D, Nair N, Fu Y, Reyon D, Samara E, Gerli MFM, Klein AF, De Schrijver W, Tipanee J, Seneca S, Tulalamba W, Wang H, Chai YC, In't Veld P, Furling D, Tedesco FS, Vermeesch JR, Joung JK, Chuah MK, VandenDriessche T. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res. 2018; 46(16):8275-8298. (M21a)
17. Van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, Vandenberghe R, Van Langenhove T, Baets J, Deryck O, Santens P, Ivanoiu A, Willems C, Bäumer V, Van den Broeck M, Peeters K, Mattheijssens M, De Jonghe P, Cras P, Martin JJ, Cruts M, De Deyn PP, Engelborghs S, Van Broeckhoven C; Belgian Neurology (BELNEU) Consortium. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurol. 2017;74(4):445-452. (M21a)
18. Lan X, Li N, Wan H, Luo L, Wu Y, Li S, An Y, Wu BL. Developing a one-step triplet-repeat primed PCR assay for diagnosing myotonic dystrophy. J Genet Genomics. 2018; 45(10):549-552. (M21)
19. Conlon EG, Manley JL. RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017;31(15):1509-28. (M21a)
20. Heringer JF, Santo RM, Barbosa LJ, Avakian A, Carricondo PC. Corneal Endothelial Dystrophy Associated With Myotonic Dystrophy: A Report of 2 Cases. Cornea. 2017;36(10):e24-e25. (M22)
21. Koutsoulidou A, Photiades M, Kyriakides TC, Georgiou K, Prokopi M, Kapnisis K, Łusakowska A, Nearchou M, Christou Y, Papadimas GK, Anayiotos A, Kyriakou K, Kararizou E, Papanicolaou EZ, Phylactou LA. Identification of Exosomal Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relating to Muscle Disease Progress. Hum Mol Genet. 2017; 26(17):3285-302. (M21a)
22. Peric S, Maksimovic R, Banko B, Durdic M, Bjelica B, Bozovic I, Balcik Y, Pesovic J, Savic-Pavicevic D, Rakocevic-Stojanovic V. Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies. J Neurol. 2017; 136(6):694-697. (M22)
23. Peric S, Heatwole C, Durovic E, Kacar A, Nikolic A, Basta I, Marjanovic A, Stevic Z, Lavrnic D, Rakocevic Stojanovic V. Prospective measurement of quality of life in myotonic dystrophy type 1. Acta Neurol Scand. 2017; 136(6):694-7. (M22)
24. van Mossevelde S, van der Zee J, Gijselinck I, Sleegers K, De Bleecker J, Sieben A, Vandenberghe R, Van Langenhove T, Baets J, Deryck O, Santens P, Ivanoiu A, Willems C, Bäumer V, Van den Broeck M, Peeters K, Mattheijssens M, De Jonghe P, Cras P, Martin JJ, Cruts M, De Deyn PP, Engelborghs S, Van Broeckhoven C; Belgian Neurology (BELNEU) Consortium.. Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurol. 2017; 74(4): 445-52. (M21a)
25. Santoro M, Masciullo M, Silvestri G, Novelli G, Botta A. Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis. Clin Genet. 2017; 92(4):355-64. (M21)
26. Cona F, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C. Cutaneous manifestations in Steinert’s disease. Apropos of four clinical cases. J Biol Regul Homeost Agents. 2017; 31(2 Suppl. 2):23-33. (M23)
27. Peric S, Vujnic M, Dobricic V, Marjanovic A, Basta I, Novakovic I, Lavrnic D, Rakocevic-Stojanovic V. Five-year study of quality of life in myotonic dystrophy. Acta Neurologica Scandinavica. 2016; 134 (5):346-51. (M22)
28. Lee YC, Tsai PC, Guo YC, Hsiao CT, Liu GT, Liao YC, Soong BW. Spinocerebellar ataxia type 36 in the Han Chinese. Neurol Genet. 2016; 2(3):e68.(M23)
29. Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M, Nikolic A, Lavrnic D, Savic Pavicevic D. Quality of life in patients with myotonic dystrophy type 2. Journal of the Neurological Sciences 2016; 365:158-61. (M22)
30. Koutsoulidou A, Kyriakides TC, Papadimas GK, Christou Y, Kararizou E, Papanicolaou EZ, Phylactou LA. Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress. PLoS One. 2015; d10(4):e0125341. (M21)
31. Liu Q, Zheng YF, Zhu YP, Ling SQ, Li WR. Clinical, pathological and genetic characteristics of a pedigree with myotonic dystrophy type 1. Exp Ther Med. 2015;10(5):1931-1936 (M23).
32. Vujnic M, Peric S, Popovic S, Raseta N, Ralic V, Dobricic V, Novakovic I, Rakocevic-Stojanovic V. Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve 2015;52(2):273-7. (M22)
33. Klein AF, Dastidar S, Furling D, Chuah MK. Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy. Curr Gene Ther. 2015;15(4):329-37. (M21)
34. Tejada MI, Glover G, Martínez F, Guitart M, de Diego-Otero Y, Fernández-Carvajal I, Ramos FJ, Hernández-Chico C, Pintado E, Rosell J, Calvo MT, Ayuso C, Ramos-Arroyo MA, Maortua H, Milà M. Molecular testing for fragile X: analysis of 5062 tests from 1105 fragile X families--performed in 12 clinical laboratories in Spain. Biomed Res Int. 2014; 2014:195793. (M22)
35. Gattey D, Zhu AY, Stagner A, Terry MA, Jun AS. Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case series. Cornea. 2014; 33(1):96-8. (M22)
36. Michalova E, Vojtesek B, Hrstka R. Impaired Pre-mRNA Processing and Altered Architecture of 3' Untranslated Regions Contribute to the Development of Human Disorders. Int J Mol Sci. 2013; 14(8):15681-94. (M22)
37. Finsterer J, Rudnik-Schöneborn S. [Myotonic dystrophies: clinical presentation, pathogenesis, diagnostics and therapy]. Fortschr Neurol Psychiatr. 2015; 83(1):9-17. (M23)
38. Dryland PA, Hughes K, Han DY, Aziz A, Zhu D, Doherty E, Love DR. Myotonic Dystrophy: Accurately Scoring the Boundaries that Define Regions of Triplet Repeat. British Journal of Medicine & Medical Research 2015; 8(8): 724-31 (M23).
39. Rakocevic-Stojanovic V, Peric S, Madzarevic R, Dobricic V, Ralic V, Ilic V, Basta I, Nikolic A, Stefanova E. Significant impact of behavioral and cognitive impairment on quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg. 2014;126C:76-81. (M23)
40. Balasubramanian M, Sayers R, Martindale J. Congenital myotonic dystrophy: natural disease progression and facial dysmorphology. Clin Dysmorphol. 2014; 23(4):127-9. (M23)
41. **Rad: *Nikolić Z, Savić Pavićević D, Vučić N, Cidilko S, Filipović N, Cerović S, Vukotić V, Romac S, Brajušković G. Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Experimental and Molecular Pathology 2015; 99:145-50.***

**citiraju: 30x**

1. Mir R, Saeedi NH, Jalal MM, Altayar MA, Barnawi J, Hamadi A, Tayeb FJ, Alshammari SE, Mtiraoui N, M Ali ME, Abuduhier FM, Ullah MF. Clinical Implications of Krüpple-like Transcription Factor KLF-14 and Certain Micro-RNA (miR-27a, miR-196a2, miR-423) Gene Variations as a Risk Factor in the Genetic Predisposition to PCOS. J Pers Med. 2022; 12(4):586.(M21)
2. Aziz MA, Akter T, Islam MS. Effect of miR-196a2 rs11614913 Polymorphism on Cancer Susceptibility: Evidence From an Updated Meta-Analysis. Technol Cancer Res Treat. 2022; 21:15330338221109798. (M23)
3. Yang X, Li X, Hao X, Tian W, Zhou B. Association of miR-27a polymorphism with the risk of digestive system cancers. Pathology Research and Practice 2020; 216(10),153115 (M22)
4. Hakimian M, Ghorbian S. Negative associations between the has-miR-27a and hsa-miR-125a gene variations and prostate cancer susceptibility. Mol Biol Rep. 2020;10.(M23)
5. Dai J, Chen Y, Gong Y, Gu D, Chen J. Association of microRNA-27a rs895819 polymorphism with the risk of cancer: An updated meta-analysis. Gene. 2020; 728:144185. (M22)
6. McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. Cancer Manag Res. 2020; 12:5225-5241. (М22)
7. Greco F, Inferrera A, La Rocca R, et al. The Potential Role of MicroRNAs as Biomarkers in Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019;5(3):497‐507. (M23)
8. Torruella-Loran I, Ramirez Viña MK, Zapata-Contreras D, Muñoz X, Garcia-Ramallo E, Bonet C, Gonzalez CA, Sala N, Espinosa-Parrilla Y; EPIC gastric cancer working group. rs12416605:C>T in MIR938 associates with gastric cancer through affecting the regulation of the CXCL12 chemokine gene. Mol Genet Genomic Med. 2019;7(8):e832. (M22)
9. Yang X, Li X, Quan X, Li H, Hao X, Jiang M, Zhou B. Association Between Two Polymorphisms in the Promoter Region of miR-143/miR-145 and the Susceptibility of Lung Cancer in Northeast Chinese Nonsmoking Females. DNA and Cell Biology 2019; 38(8):814-823. (M22)
10. Darabi H, Salmaninejad A, Jaripour ME, Azarpazhooh MR, Mojarrad M, Sadr-Nabavi A. Association of the genetic polymorphisms in immunoinflammatory microRNAs with risk of ischemic stroke and subtypes in an Iranian population. J Cell Physiol. 2019; 234(4):3874-3886. (M21)
11. Choupani J, Nariman-Saleh-Fam Z, Saadatian Z, Ouladsahebmadarek E, Masotti A, Bastami M. Association of mir-196a-2 rs11614913 and mir-149 rs2292832 Polymorphisms With Risk of Cancer: An Updated Meta-Analysis. Front Genet. 2019;10:186. (M21)
12. Nouri R, Ghorbian S. Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer. Int Urol Nephrol. 2019; 51:811–6. (M23).
13. Yang X, Li X, Zhou B. A Meta-Analysis of miR-499 rs3746444 Polymorphism for Cancer Risk of Different Systems: Evidence From 65 Case-Control Studies. Front Physiol. 2018; 9:737. (M21)
14. Mi Y, Ren K, Zou J, Bai Y, Zhang L, Zuo L, Okada A, Yasui T. The Association Between Three Genetic Variants in MicroRNAs (Rs11614913, Rs2910164, Rs3746444) and Prostate Cancer Risk. Cell Physiol Biochem. 2018; 48(1):149-157. (M21a)
15. Qiu D, Han F, Zhuang H. MiR-499 rs3746444 polymorphism and hepatocellular carcinoma risk: A meta-analysis. J Cancer Res Ther. 2018; 14(Supplement):S490-S493 (M23)
16. Fang C, Li XP, Chen YX, Wu NY, Yin JY, Zhang W, Zhou HH, Liu ZQ. Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. J Thorac Dis. 2018; 10(6):3329-3340. (M23)
17. Qiu D, Han F, Zhuang H. MiR-499 rs3746444 polymorphism and hepatocellular carcinoma risk: A meta-analysis. J Cancer Res Ther. 2018; 14(Supplement):S490-S493 (M23)
18. Liu Y, He A, Liu B, Zhong Y, Liao X, Yang J, Chen J, Wu J, Mei H. rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis. Onco Targets Ther. 2018; 11:1121-39. (M23)
19. Zhang L, Zhang M, Wang H, Wang Y, Zhou J, Hao Z, Zhang L, Liang C. Comprehensive Review of Genetic Association Studies and Meta-Analysis on polymorphisms in microRNAs and Urological Neoplasms Risk. Sci Rep. 2018; 8(1):3776. (M21)
20. Wang YH, Hu HN, Weng H, Chen H, Luo CL, Ji J, Yin CQ, Yuan CH, Wang FB. Association between Polymorphisms in MicroRNAs and Risk of Urological Cancer: A Meta-Analysis Based on 17,019 Subjects. Front Physiol. 2017; 8:325. (M21)
21. Zhang H, Zhang Y, Zhao X, Ma X, Yan W, Wang W, Zhao Z, Yang Q, Sun X, Luan H, Gao X, Zhang S. Association of two microRNA polymorphisms miR-27 rs895819 and miR-423 rs6505162 with the risk of cancer. Oncotarget. 2017; 8(29): 46969-80. (M21)
22. Chen M, Fang W, Wu X, Bian S, Chen G, Lu L, Weng Y. Distinct effects of rs895819 on risk of different cancers: an update meta-analysis. Oncotarget. 2017; 8(43):75336-49. (M21)
23. Yan W, Gao X, Zhang S. Association of miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms with cancer risk: a meta-analysis. Oncotarget. 2017; 8(69):114344-114359. (M21)
24. Liu X, Han Z, Yang C. Associations of microRNA single nucleotide polymorphisms and disease risk and pathophysiology. Clin Genet. 2017; 92(3): 235-42. (M21)
25. Li D, Zhu G, Di H, Li H, Liu X, Zhao M, Zhang Z, Yang Y. Associations between genetic variants located in mature microRNAs and risk of lung cancer. Oncotarget 2016; 7(27):41715-24. (M21a)
26. Ni J, Huang Y. Role of polymorphisms in miR-146a, miR-149, miR-196a2 and miR-499 in the development of ovarian cancer in a Chinese population. Int J Clin Exp Pathol 2016; 9(5):5706-11. (M22)
27. Wang J, Zhang Y, Zhang Y, Chen L. Correlation between miRNA-196a2 and miRNA-499 polymorphisms and bladder cancer. Int J Clin Exp Pathol 2016; (M22)
28. Sun XC, Zhang AC, Tong LL, Wang K, Wang X, Sun ZQ, Zhang HY. miR-146a and miR-196a2 polymorphisms in ovarian cancer risk. Genet Mol Res. 2016;15(3). (M23)
29. Hashemi M, Moradi N, Ziaee SAM, Narouie B, Soltani MH, Rezaei M, Shahkar G, Taheri M. Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. Journal of Advanced Research 2016; 7(3): 491-8. (M23)
30. Li M, Li RJ, Bai H, Xiao P, Liu GJ, Guo YW, Mei JZ. Association between the pre-miR-196a2 rs11614913 polymorphism and gastric cancer susceptibility in a Chinese population. Genetics and Molecular Research 2016; 15 (2): gmr.15027516. (M23)
31. ***Rad: Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. Front. Genet. 2018.***

**citiraju: 24x**

1. Tsai YC, de Pontual L, Heiner C, Stojkovic T, Furling D, Bassez G, Gourdon G, Tomé S. Identification of a CCG-Enriched Expanded Allele in Patients with Myotonic Dystrophy Type 1 Using Amplification-Free Long-Read Sequencing. J Mol Diagn. 2022; 24(11):1143-1154. (M21)
2. Alfano M, De Antoni L, Centofanti F, Visconti VV, Maestri S, Degli Esposti C, Massa R, D'Apice MR, Novelli G, Delledonne M, Botta A, Rossato M. Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing. Elife. 2022;11:e80229. (M21a)
3. Mohiuddin M, Kooy RF, Pearson CE. De novo mutations, genetic mosaicism and human disease. Front Genet. 2022;13:983668. (M21)
4. García-Puga M, Saenz-Antoñanzas A, Matheu A, López de Munain A. Targeting Myotonic Dystrophy Type 1 with Metformin. Int J Mol Sci. 2022;23(5):2901. (M21)
5. Zhang N, Ashizawa T. Mechanistic and Therapeutic Insights into Ataxic Disorders with Pentanucleotide Expansions. Cells. 2022;11(9):1567. (M21)
6. de Pontual L, Tomé S. Overview of the Complex Relationship between Epigenetics Markers, CTG Repeat Instability and Symptoms in Myotonic Dystrophy Type 1. Int J Mol Sci. 2022; 23(7):3477. (M21)
7. Fan Y, Xu Y, Shi C. NOTCH2NLC-related disorders: the widening spectrum and genotype-phenotype correlation. J Med Genet. 2022; 59(1):1-9. (M21)
8. Fourier A, Quadrio I. Proteinopathies associated to repeat expansion disorders. J Neural Transm (Vienna) 2022;129(2):173-185. (M22)
9. Arning L, Nguyen HP. Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. Medizinische Genetik 2022; 33(4). (M23)
10. Rasmussen A, Hildonen M, Vissing J, Duno M, Tümer Z, Birkedal U. High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in Myotonic Dystrophy Type 1. Genes (Basel). 2022; 13(6):970. (M23)
11. Peric S, Pesovic J, Savic-Pavicevic D, Rakocevic Stojanovic V, Meola G. Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1. Int J Mol Sci. 2021; 23(1):354. (M21)
12. Mangin A, de Pontual L, Tsai YC, Monteil L, Nizon M, Boisseau P, Mercier S, Ziegle J, Harting J, Heiner C, Gourdon G, Tomé S. Robust Detection of Somatic Mosaicism and Repeat Interruptions by Long-Read Targeted Sequencing in Myotonic Dystrophy Type 1. Int J Mol Sci. 2021; 22(5):2616. (M21)
13. Chiu R, Rajan-Babu IS, Friedman JM, Birol I. Straglr: discovering and genotyping tandem repeat expansions using whole genome long-read sequences. Genome Biol. 2021;22(1):224. (M21a)
14. Cumming SA, Oliwa A, Stevens G, Ballantyne B, Mann C, Razvi S, Longman C, Monckton DG, Farrugia ME. A DM1 patient with CCG variant repeats: Reaching the diagnosis. Neuromuscul Disord. 2021 Mar;31(3):232-238. (M22)
15. Wenninger S, Cumming SA, Gutschmidt K, Okkersen K, Jimenez-Moreno AC, Daidj F, Lochmüller H, Hogarth F, Knoop H, Bassez G, Monckton DG, van Engelen BGM, Schoser B. Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1. Neurol Genet 2021; 7(2):e572; (M21)
16. Ballester-Lopez A, Koehorst E, Almendrote M, Martínez-Piñeiro A, Lucente G, Linares-Pardo I, Núñez-Manchón J, Guanyabens N, Cano A, Lucia A, Overend G, Cumming SA, Monckton DG, Casadevall T, Isern I, Sánchez-Ojanguren J, Planas A, Rodríguez-Palmero A, Monlleó-Neila L, Pintos-Morell G, Ramos-Fransi A, Coll-Cantí J, Nogales-Gadea G. A DM1 family with interruptions associated with atypical symptoms and late onset but not with a milder phenotype. Hum Mutat. 2020.(M21)
17. Hildonen M, Knak KL, Dunø M, Vissing J, Tümer Z. Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat of *DMPK* in Patients with Myotonic Dystrophy Type 1. Genes (Basel). 2020 Aug 13;11(8):936. (M22)
18. Morales F, Vásquez M, Corrales E, Vindas-Smith R, Santamaría-Ulloa C, Zhang B, Sirito M, Estecio MR, Krahe R, Monckton DG. Longitudinal increases in somatic mosaicism of the expanded CTG repeat in myotonic dystrophy type 1 are associated with variation in age-at-onset. Hum Mol Genet. 2020 ; 29(15):2496-2507. (M21)
19. Wansink DG, Gourdon G, van Engelen BGM, Schoser B; DM workshop study group. 248th ENMC International Workshop: Myotonic dystrophies: Molecular approaches for clinical purposes, framing a European molecular research network, Hoofddorp, the Netherlands, 11-13 October 2019. Neuromuscul Disord. 2020 Jun;30(6):521-531. (M22)
20. Khristich AN, Mirkin SM. On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability. J Biol Chem. 2020; 295(13):4134-4170. (M21)
21. Westenberger A, Klein C. Essential phenotypes of NOTCH2NLC-related repeat expansion disorder. Brain. 2020;143(1):5-8. (M21a)
22. Miller JN, van der Plas E, Hamilton M, Koscik TR, Gutmann L, Cumming SA, Monckton DG, Nopoulos PC. Variant repeats within the DMPK CTG expansion protect function in myotonic dystrophy type 1. Neurol Genet. 2020; 6(5):e504. (M21)
23. Leferink M, Wong DPW, Cai S, Yeo M, Ho J, Lian M, Kamsteeg EJ, Chong SS, Haer-Wigman L, Guan M. Robust and accurate detection and sizing of repeats within the DMPK gene using a novel TP-PCR test. Sci Rep. 2019; 9(1):8280. (M21)
24. Corrales E, Vásquez M, Zhang B, Santamaría-Ulloa C, Cuenca P, Krahe R,Monckton DG, Morales F. Analysis of mutational dynamics at the DMPK (CTG)n locus identifies saliva as a suitable DNA sample source for genetic analysis in myotonic dystrophy type 1. PLoS One. 2019; 14(5):e0216407. (M21)
25. **Rad: *Karanović J, Šviković S, Pantović M, Đurica S, Brajušković G, Damjanović A, Jovanović V, Ivković M, Romac S, Savić Pavićević D. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. World Journal of Biological Psychiatry 2015; 1-11.***

**citiraju: 23x**

1. Butchbach MER. Genomic Variability in the Survival Motor Neuron Genes (*SMN1* and *SMN2*): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. Int J Mol Sci. 2021; 22(15):7896. (M21)
2. Costa-Roger M, Blasco-Pérez L, Cuscó I, Tizzano EF. The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int J Mol Sci. 2021;22(16):9029. (M21)
3. Wu H, Chen HL. Insufficient evidential basis for the association between Toxoplasma gondii and suicide attempts. Transbound Emerg Dis. 2021; 68(6):2993-2994. (M21a)
4. Fakhari A, Allahverdipour H, Esmaeili ED, Chattu VK, Salehiniya H, Azizi H. Early marriage, stressful life events and risk of suicide and suicide attempt: a case-control study in Iran. BMC Psychiatry. 2022;22(1):71. (M22)
5. Zhang X, Yan W, Xue Y, Xu H, Li J, Zhao Z, Sun Y, Wang Y, He J, Huang Y, Yu D, Xiao Z, Yin S. Roles of miR-432 and circ\_0000418 in mediating the anti-depressant action of ADAR1. Neurobiol Stress. 2021;15:100396. (M21a)
6. Warhaftig G, Sokolik CM, Khermesh K, Lichtenstein Y, Barak M, Bareli T, Levanon EY, Yadid G. RNA editing of the 5-HT2C receptor in the central nucleus of the amygdala is involved in resilience behavior. Transl Psychiatry 2021; 11(1):137. (M21)
7. Nascimento FP, Macedo-Júnior SJ, Lapa-Costa FR, Cezar-Dos-Santos F, Santos ARS. Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor? Front Neurosci. 2021; 15:703783. (M23)
8. Levchenko A, Vyalova NM, Nurgaliev T, Pozhidaev IV, Simutkin GG, Bokhan NA, Ivanova SA. *NRG1*, *PIP4K2A*, and *HTR2C* as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. Front Genet. 2020;11:936. (M21)
9. Plonski NM, Johnson E, Frederick M, Mercer H, Fraizer G, Meindl R, Casadesus G, Piontkivska H. Automated Isoform Diversity Detector (AIDD): a pipeline for investigating transcriptome diversity of RNA-seq data. BMC Bioinformatics. 2020; 21(Suppl 18):578. (M21)
10. Chen JX, Feng JH, Zhang LG, Liu Y, Yang FD, Wang SL, Tan YL, Su YA. Association of serum uric acid levels with suicide risk in female patients with major depressive disorder: a comparative cross-sectional study. BMC Psychiatry 2020; 20(1):477. (M23)
11. Barbon A, Magri C. RNA Editing and Modifications in Mood Disorders. Genes (Basel). 2020; 11(8):E872. (22)
12. Chimienti F, Cavarec L, Vincent L, Salvetat N, Arango V, Underwood MD, Mann JJ, Pujol JF, Weissmann D. Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents. Transl Psychiatry 2019; 9(1):91. (M21)
13. Xiang C, Liu S, Fan Y, Wang X, Jia Y, Li L, Cong S, Han F. Single nucleotide polymorphisms, variable number tandem repeats and allele influence on serotonergic enzyme modulators for aggressive and suicidal behaviors: A review. Pharmacol Biochem Behav. 2019; 180:74-82. (M22)
14. Lutz PE, Mechawar N, Turecki G. Neuropathology of suicide: recent findings and future directions. Mol Psychiatry. 2017; 22(10):1395-1412. (M21a)
15. Sudol K, Mann JJ. Biomarkers of Suicide Attempt Behavior: Towards a Biological Model of Risk. Curr Psychiatry Rep. 2017; 19(6):31. (M21)
16. Stamm S, Gruber SB, Rabchevsky AG, Emeson RB. The activity of the serotonin receptor 2C is regulated by alternative splicing. Hum Genet. 2017; 136(9):1079-91. (M21)
17. Yao J, Wang X, Yan H, Cai X, Wang M, Tu Y, Yang C. Enhanced Expression of Serotonin Receptor 5-Hydroxytryptamine 2C is Associated with Increased Feather Damage in Dongxiang Blue-Shelled Layers. Behav Genet. 2017; 47(3):369-374.(M21)
18. van der Laan S, Salvetat N, Weissmann D, Molina F. Emerging RNA editing biomarkers will foster drug development. Drug Discov Today. 2017; 22(7):1056-63. (M21a)
19. González-Castro TB, Hernandez-Diaz Y, Juárez-Rojop IE, López-Narváez L, Tovilla-Zárate CA, Rodriguez-Perez JM, Sánchez-de la Cruz JP. The role of the Cys23Ser (rs6318) polymorphism of the HTR2C gene in suicidal behavior: systematic review and meta-analysis. Psychiatr Genet. 2017; 27(6):199-209. (M22)
20. Molina-Guzman G, González-Castro TB, Hernández Díaz Y, Tovilla-Zárate CA, Juárez-Rojop IE, Guzmán-Priego CG, Genis A, Pool García S, López-Narvaez ML, Rodriguez-Perez JM. Gender differences in the association between HTR2C gene variants and suicidal behavior in a Mexican population: a case-control study. Neuropsychiatr Dis Treat. 2017;13:559-66. (M22)
21. Weissmann D, van der Laan S, Underwood MD, Salvetat N, Cavarec L, Vincent L, Molina F, Mann JJ, Arango V, Pujol JF. Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl Psychiatry. 2016;6(8):e878. (M21a)
22. Kim JS, Lee SH. Influence of interactions between genes and childhood trauma on refractoriness in psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2016; S0278-5846(16)30013-6. (M21a)
23. Gasparini CF, Smithb RA, Griffiths LR. Genetic insights into migraine and glutamate: a protagonist driving the headache. Journal of the Neurological Sciences 2016; 367:258–268. (M22)
24. **Rad: *Branković A, Brajušković G, Nikolić Z. Vukotić V, Cerović S, Savić Pavićević D, Romac S. Endothelial nitric oxide synthase gene polymorphism and prostate cancer risk in Serbian population. Int. J. Exp. Path. 2013;94(6):355-61.***

**citiraju: 17x**

1. Salihi A, Al-Naqshabandi MA, Khudhur ZO, Housein Z, Hama HA, Abdullah RM, Hussen BM, Alkasalias T. Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review). Mol Med Rep. 2022; 26(1):233. (M23)
2. Abedinzadeh M, Dastgheib SA, Maleki H, Heiranizadeh N, Zare M, Jafari-Nedooshan J, Kargar S, Neamatzadeh H. Association of Endothelial Nitric Oxide Synthase Gene Polymorphisms with Susceptibility to Prostate Cancer: a Comprehensive Systematic Review and Meta-Analysis. Urol J. 2020; 17(4):329-337. (M23)
3. Nan J, Liu Y, Xu C, Ge D. Effects of eNOS gene polymorphisms on individual susceptibility to cancer: A meta-analysis. Nitric Oxide. 2019; 84:1-6. (M21)
4. Chen JB, Zhang M, Cui Y, Liu PH, Qi YW, Li C, Cheng X, Ren WB, Li QQ, Liu LF, Chen MF, Chen HQ, Zu XB. Association Between 12 Polymorphisms of VEGF/Hypoxia/Angiogenesis Pathway Genes and Risk of Urogenital Carcinomas: A Meta-Analysis Based on Case-Control Studies. Front. Physiol. 2018. doi.org/10.3389/fphys.2018.00715 (M21)
5. Diler SB, Öden A, The T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene in prostate cancer cases, Russian Journal of Genetics, 2016, 52, 2, 220 (M23)
6. Gao X, Wang J, Wang W, Wang M, Zhang J. eNOS Genetic Polymorphisms and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer. Medicine (Baltimore) 2015; 94(26):e972. (M21)
7. Yanar K, Çakatay U, Aydjn S, Verim A, Atukeren P, Özkan NE, Karatoprak K, Cebe T, Turan S, Ozkök E, Korkmaz G, Cacjna C, Küçükhüseyin O, Yayljm E. Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. Oxidative Medicine and Cellular Longevity 2016; Article number 4985063. (M22)
8. Haque S, Mandal RK, Akhter N, Panda AK, Hussain A, Khan S, Lohani M. G894T and 4a/b Polymorphisms of NOS3 Gene are Not Associated with Cancer Risk: a Meta-analysis. Asian Pac J Cancer Prev. 2015; 16(7):2929-37. (М23)
9. Arjmand Kolukhi Z, Salehi Z , Mashayekhi F, Najafi B, Mirpoor SH. Analysis of Glu298Asp eNOS Gene polymorphism in patients with Gastric Cancer in the Guilan population. Arak Medical University Journal (AMUJ) 2014; 17(89): 53-62. (M23)
10. Zhang Y, Jia Q, He Q, Shen J, Yang J, Xue P, Ma M, Xu R, Du L. The Glu298Asp polymorphism in the NOS3 gene and the risk of prostate cancer. Tumor Biol. 2014; 35(5):4735-9. (M22)
11. Wu JH, Yang K, Ma HS, Xu Y. Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis. Tumor Biol. 2014; 35(7):7057-62. (M22)
12. Zhang Y, Jia Q, Xue P, Liu Y, Xiong T, Yang J, Song C, He Q, Du L. The -786T > C polymorphism0 in the NOS3 gene is associated with increased cancer risk. Tumor Biol. 2014; 35(4):3535-40. (M22)
13. Zhao C, Yan W, Zu X, Chen M, Liu L, Zhao S, Liu H, Hu X, Luo R, Xia Y, Qi L. Association between endothelial nitric oxide synthase 894G>T polymorphism and prostate cancer risk: a meta-analysis of literature studies. Tumor Biol. 2014; 35(12):11727-33. (M22)
14. Wu X, Wang ZF, Xu Y, Ren R, Heng BL, Su ZX. Association between three eNOS polymorphisms and cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(13): 5317-24. (M23)
15. Chen Y, Li J, Guo Y, Guo XY. Nitric oxide synthase 3 gene variants and colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(8):3811-5. (M23)
16. Qiao G, Zheng S, Shen Z, Yao Y Association between 894G>T polymorphism of nitric oxide synthase 3 (NOS3) gene and genetic susceptibility to prostate cancer: a Meta-analysis. TUMOR 2014 (M23)
17. Zhang L, Chen LM, Wang MN, Chen XJ, Li N, Huang YD, Chen M. The G894T, T-786C and 4b/a polymorphisms in eNOS gene and cancer risk: a meta-analysis. Journal of Evidence-Based Medicine 2014; 7(4):263-9. (M23)
18. **Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Neurogenetics 2017; 18(4):207-18.***

**citiraju: 16x**

1. Ivanovic V, Peric S, Pesovic J, Tubic R, Bozovic I, Petrovic Djordjevic I, Savic-Pavicevic D, Meola G, Rakocevic-Stojanovic V. Clinical score for early diagnosis of myotonic dystrophy type 2. Neurol Sci. 2023;44(3):1059-1067. (M22)
2. Han JY, Jang W, Park J. Intergenerational Influence of Gender and the DM1 Phenotype of the Transmitting Parent in Korean Myotonic Dystrophy Type 1. Genes (Basel). 2022; 13(8):1465.
3. de Pontual L, Tomé S. Overview of the Complex Relationship between Epigenetics Markers, CTG Repeat Instability and Symptoms in Myotonic Dystrophy Type 1. Int J Mol Sci. 2022; 23(7):3477. (M21)
4. Rasmussen A, Hildonen M, Vissing J, Duno M, Tümer Z, Birkedal U. High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in Myotonic Dystrophy Type 1. Genes (Basel). 2022; 13(6):970. (M23)
5. Peric S, Pesovic J, Savic-Pavicevic D, Rakocevic Stojanovic V, Meola G. Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1. Int J Mol Sci. 2021; 23(1):354.
6. Butterfield RJ, Imburgia C, Mayne K, Newcomb T, Dunn DM, Duval B, Feldkamp ML, Johnson NE, Weiss RB. High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis. Mol Genet Genomic Med. 2021; 9(4):e1619. (M23)
7. Cumming SA, Oliwa A, Stevens G, Ballantyne B, Mann C, Razvi S, Longman C, Monckton DG, Farrugia ME. A DM1 patient with CCG variant repeats: Reaching the diagnosis. Neuromuscul Disord. 2021 Mar;31(3):232-238. (M22)
8. Joosten IBT, Hellebrekers DMEI, de Greef BTA, et al. Parental repeat length instability in myotonic dystrophy type 1 pre- and protomutations [published online ahead of print, 2020 Eur J Hum Genet. 2020;10. (M21)
9. Ballester-Lopez A, Koehorst E, Almendrote M, Martínez-Piñeiro A, Lucente G, Linares-Pardo I, Núñez-Manchón J, Guanyabens N, Cano A, Lucia A, Overend G, Cumming SA, Monckton DG, Casadevall T, Isern I, Sánchez-Ojanguren J, Planas A, Rodríguez-Palmero A, Monlleó-Neila L, Pintos-Morell G, Ramos-Fransi A, Coll-Cantí J, Nogales-Gadea G. A DM1 family with interruptions associated with atypical symptoms and late onset but not with a milder phenotype. Hum Mutat. 2020; 41(2):420-31. (M21)
10. Hildonen M, Knak KL, Dunø M, Vissing J, Tümer Z. Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat of *DMPK* in Patients with Myotonic Dystrophy Type 1. Genes (Basel). 2020;11(8):936. (M22)
11. Tomé S, Gourdon G. Fast Assays to Detect Interruptions in CTG.CAG Repeat Expansions. Methods Mol Biol. 2020;2056:11-23. (M23)
12. Tomé S, Gourdon G. DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies. Int J Mol Sci. 2020;21(2). (M21)
13. Overend G, Légaré C, Mathieu J, Bouchard L, Gagnon C, Monckton DG. Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. Hum Mol Genet. 2019; 28(13):2245-2254. (M21)
14. Loureiro JR, Oliveira CL, Mota C, Castro AF, Costa C, Loureiro JL, Coutinho P, Martins S, Sequeiros J, Silveira I. Mutational mechanism for DAB1 (ATTTC)(n) insertion in SCA37: ATTTT repeat lengthening and nucleotide substitution. Hum Mutat. 2019; (M21)
15. Cumming SA, Hamilton MJ, Robb Y, Gregory H, McWilliam C, Cooper A, Adam B, McGhie J, Hamilton G, Herzyk P, Tschannen MR, Worthey E, Petty R, Ballantyne B; Scottish Myotonic Dystrophy Consortium, Warner J, Farrugia ME, Longman C, Monckton DG. De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1. Eur J Hum Genet. 2018; 26(11):1635-1647. (M21)
16. Tomé S, Dandelot E, Dogan C, Bertrand A, Geneviève D, Péréon Y; DM contraction study group, Simon M, Bonnefont JP, Bassez G, Gourdon G. Unusual association of a unique CAG interruption in 5' of DM1 CTG repeats with intergenerational contractions and low somatic mosaicism. Hum Mutat. 2018; 39(7):970-982. (M21)
17. **Rad: *Nikolić Z, Savić-Pavićević D, Vučić N, Cerović S, Vukotić V, Brajušković G. Genetic variants in RNA-induced silencing complex genes and prostate cancer. World J Urol. 2017; 35(4):613-24.***

**citiraju: 15x**

1. Juárez-Luis J, Canseco-Ocaña M, Cid-Soto MA, Castro-Martínez XH, Martínez-Hernández A, Orozco L, Hernández-Zavala A, Córdova EJ. Single nucleotide variants in microRNA biosynthesis genes in Mexican individuals. Front Genet. 2023;14:1022912. (M21)
2. Elshazli RM, Toraih EA, Hussein MH, Ruiz EM, Kandil E, Fawzy MS. Pan-Cancer Study on Variants of Canonical miRNA Biogenesis Pathway Components: A Pooled Analysis. Cancers (Basel). 2023; 15(2):338. (M21)
3. Teixeira AL, Patrão AS, Dias F, Silva C, Vieira I, Silva JF, Ferreira M, Morais A, Maurício J, Medeiros R. AGO2 expression levels and related genetic polymorphisms: influence in renal cell progression and aggressive phenotypes. Pharmacogenomics. 2021; 22(16):1069-79. (M23)
4. Cardoso JV, Medeiros R, Dias F, Costa IA, Ferrari R, Berardo PT, Perini JA. DROSHA rs10719 and DICER1 rs3742330 polymorphisms in endometriosis and different diseases: Case-control and review studies. Exp Mol Pathol. 2021. (M21)
5. Galka-Marciniak P, Urbanek-Trzeciak MO, Nawrocka PM, Kozlowski P. A pan-cancer atlas of somatic mutations in miRNA biogenesis genes. Nucleic Acids Res. 2021; 49(2):601-620. (M21)
6. Nowak I, Sarshad AA. Argonaute Proteins Take Center Stage in Cancers. Cancers (Basel). 2021; 13(4):788. (M21)
7. Fawzy MS, Abu AlSel BT, Toraih EA. Analysis of microRNA processing machinery gene (DROSHA, DICER1, RAN, and XPO5) variants association with end-stage renal disease. J Clin Lab Anal. 2020: (M23)
8. Bermisheva MA, Takhirova ZR, Gilyazova IR, Khusnutdinova EK. MicroRNA Biogenesis Pathway Gene Polymorphisms Are Associated with Breast Cancer Risk. [Russian Journal of Genetics](https://www.scopus.com/sourceid/19021?origin=recordpage) 2018; 54(5):568-75.(M23)
9. Curmi F, Cauchi RJ. The multiple lives of DEAD-box RNA helicase DP103/DDX20/Gemin3. Biochem Soc Trans. 2018; 46(2):329-341. (M22)
10. Huang SQ, Zhou ZX, Zheng SL, Liu DD, Ye XH, Zeng CL, Han YJ, Wen ZH, Zou XQ, Wu J, Liu YM, Huang CC, Wang Y, Yang G, Jing CX. Association of variants of miRNA processing genes with cervical precancerous lesion risk in a southern Chinese population. Biosci Rep. 2018;38(3). (M22)
11. Wen J, Lv Z, Ding H, Fang X, Sun M. Association of microRNA biosynthesis genes DROSHA and DGCR8 polymorphisms with cancer susceptibility: a systematic review and meta-analysis. Biosci Rep. 2018. pii: BSR20180072. (M23)
12. Song X, Zhong H, Wu Q, Wang M, Zhou J, Zhou Y, Lu X, Ying B. Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population. Oncotarget 2017; 8 (49): 86435-46. (M21)
13. Curmi F, Cauchi RJ. The multiple lives of DEAD-box RNA helicase DP103/DDX20/Gemin3. Biochem Soc Trans. 2018 Mar 9. pii: BST20180016. doi: 10.1042/BST20180016.(M23)
14. Wu N, Zhang X, Tian J, Yu S, Qiao Y. Association of GEMIN4 gene polymorphism and the risk of cancer: a meta-analysis. Onco Targets Ther. 2017;10:5263-5271. (M22)
15. Nwanaji-Enwerem JC, Colicino E, Dai L, Di Q, Just AC, Hou L, Vokonas P, DeVivo I, Lemos B, Lu Q, Weisskopf MG, Baccarelli AA, Schwartz JD. miRNA processinggene polymorphisms, blood DNA methylation age and long-term ambient PM(2.5) exposure in elderly men. Epigenomics. 2017; 9(12):1529-1542. (M21)
16. **Rad: *Nikolić Z, Brajušković G, Savić Pavićević D, Kojić A, Vukotić V, Tomović S, Cerović S, Filipović F, Mišljenović Đ, Romac S. Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population. Int J Clin Exp Med 2013; 6(1):57-66.***

**citiraju: 13x**

1. Zhang YK, Wu LL, Li TT, Cao DY, Zheng Q, Liu L. The POLR2E rs3787016 polymorphism is associated with susceptibility to and prognosis of gastric cancer. Neoplasma. 2021; 68(3):665-71. (M23)
2. Sattarifard H, Hashemi M, Hassanzarei S, Basiri A, Narouie B, Ghavami S. Long non-coding RNA POLR2E gene polymorphisms increased the risk of prostate cancer in a sample of the Iranian population. Nucleosides Nucleotides Nucleic Acids. 2018:1-11. (M23)
3. Chen B, Wang S, Ma G, Han J, Zhang J, Gu X, Feng X. The association of POLR2E rs3787016 polymorphism and cancer risk: a Chinese case-control study and meta-analysis. Biosci Rep. 2018; 38(6). (M22)
4. Mi Y, Ren K, Zou J, Bai Y, Zhang L, Zuo L, Okada A, Yasui T. The Association Between Three Genetic Variants in MicroRNAs (Rs11614913, Rs2910164, Rs3746444) and Prostate Cancer Risk. Cell Physiol Biochem. 2018;48(1):149-157. (M21a)
5. [Huang S,](https://www.scopus.com/authid/detail.uri?authorId=55777691700&amp;eid=2-s2.0-85047094903) [Cui H](https://www.scopus.com/authid/detail.uri?authorId=57202070202&amp;eid=2-s2.0-85047094903), [Lou Z](https://www.scopus.com/authid/detail.uri?authorId=57190969704&amp;eid=2-s2.0-85047094903), [Wang X](https://www.scopus.com/authid/detail.uri?authorId=57053586300&amp;eid=2-s2.0-85047094903), [Chen L](https://www.scopus.com/authid/detail.uri?authorId=57192172417&amp;eid=2-s2.0-85047094903), [Xie Z](https://www.scopus.com/authid/detail.uri?authorId=57192172177&amp;eid=2-s2.0-85047094903), [Hehir M](https://www.scopus.com/authid/detail.uri?authorId=7003949711&amp;eid=2-s2.0-85047094903), [Yao X](https://www.scopus.com/authid/detail.uri?authorId=55180278800&amp;eid=2-s2.0-85047094903), [Ren Y,](https://www.scopus.com/authid/detail.uri?authorId=57201003964&amp;eid=2-s2.0-85047094903) [Cen D,](https://www.scopus.com/authid/detail.uri?authorId=57201995426&amp;eid=2-s2.0-85047094903) [Weng G.](https://www.scopus.com/authid/detail.uri?authorId=53982356200&amp;eid=2-s2.0-85047094903) Association of rs3787016 in long non-coding rnas polr2e and rs2910164 in mirna-146a with prostate cancer: A systematic review and meta-analysis. [Iranian Journal of Public Health](https://www.scopus.com/sourceid/21484?origin=recordpage) 2018; 47(5): 623-32. (M23)
6. Chen B, Li J, Yi C, Jiao Y, Gu X, Feng X. Long non-coding RNA POLR2E rs3787016 is associated with the risk of papillary thyroid carcinoma in Chinese population. Pathology - Research and Practice 2018; 214(7):1040-4. (M23)
7. Xu T, Hu XX, Liu, XX, Wang HJ, Lin K, Pan YQ, Sun HL, Peng HX, Chen XX, Wang SK, He BS. Association between SNPs in long non-coding RNAs and the risk of female breast cancer in a chinese population. Journal of Cancer 2017; 8(7):1162-1169 (M22)
8. Chu H, Chen Y, Yuan Q, Hua Q, Zhang X, Wang M, Tong N, Zhang W, Chen J, Zhang Z. The HOTAIR, PRNCR1 and POLR2E polymorphisms are associated with cancer risk: a meta-analysis. Oncotarget. 2017; 8(26):43271-83. (M21)
9. Gong WJ, Peng JB, Yin JY, Li XP, Zheng W, Xiao L, Tan LM, Xiao D, Chen YX, Li X, Zhou HH, Liu ZQ. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol Sin. 2017; 38(4):581-590. (M21)
10. Cartwright R, Mangera A, Tikkinen KA, Rajan P, Pesonen J, Kirby AC, Thiagamoorthy G, Ambrose C, Gonzalez-Maffe J, Bennett PR, Palmer T, Walley A, Järvelin MR, Khullar V, Chapple C. Systematic Review and Meta-analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in Men. Eur Urol. 2014; 66(4):752-68. (M21a)
11. Cao DL, Gu CY, Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP, Ma CG, Xiao WJ, Qin XJ, Lin GW, Ye DW. Polymorphisms at long non-coding RNAs and prostate cancer risk in an eastern Chinese population. Prostate Cancer Prostatic Dis. 2014, 17(4):315-9. (M21)
12. Li W, Gu M. NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Int J Clin Exp Med 2015; 8(3):3474-3481.(M23).
13. Seok H, Yoo KH, Kim YO, Chung JH. Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population. Int Neurourol J. 2013; 17(4):168-73. (M23)
14. **Rad: *Pavlica Lj, Nikolić D, Magić Z, Brajušković G, Strelić N, Miličić B, Jovelić A. Successful Treatment of Postveneral Reactive Arthritis With Synovectomy and 3' Months' Azitthromycin. J Clin Rheumatol 2005; 11(5): 257-63.***

**citiraju: 12x**

1. Carlin E, Marzo-Ortega H, Flew S. British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021. Int J STD AIDS. 2021; 32(11):986-997.
2. RihlM, Kohler L, Klos A, Zeidler H. Persistent infection of Chlamydia in reactive arthritis. Annals of the rheumatic diseases 2006; 65 (3):281-4. (M21a)
3. Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am. 2009; 35(1):21-44. (M22)
4. Rihl M, KlosA, KolherL, KuipersJG. Reactive arthritis.Best practice & research in clinical rheumatology 2006; 20(6):1119-37.(M22)
5. CarterJD. Reactive arthritis: Defined etiologies, emerging pathophysiology, and unresolved treatment. Infectious Disease Clinics of North America 2006; 20:827-47. (M22)
6. Strelić N, Bojović J, Pavlica L, Cikota-Aleksić B, Miličić B, Magić Z.Detection of bacteria and analyses of Chlamydia trachomatis viability in patients with postvenereal reactive arthritis. Intern Med J. 2014;44(12a):1247-51. (M22)
7. Carlin E, Ziza J, Keat A, Janier M. 2014 European Guideline on the management of sexually acquired reactive arthritis. Int J STD AIDS. 2014;25(13):901-12. (M23)
8. Meyer T. [Diagnosis and treatment of Chlamydia trachomatis infections] [German]. Hautarzt 2012; 63(1):16-23. (M23)
9. Kuipers JG, Sibilia J, Bas S, Gaston H, Granfors K, Vischer TL, Hajjaj-Hassouni N, Ladjouze-Rezig A, Sellami S, Wollenhaupt J, Zeidler H, Schumacher HR, Dougados M. Reactive and undifferentiated arthritis in North Africa: use of PCR for detection of Chlamydia trachomatis. Clin Rheumatol. 2009;28(1):11-6. (M23)
10. Espinoza LR, García-Valladares I. Of bugs and joints: The relationship between infection and joints. Reumatol Clin. 2013; 9 (4): 229-38. (M23)
11. Muhayidin AD, Said MSM. Septic Arthritis in Rheumatology: Review of Five Cases. J Clin Med Res 2009; 1(3):173-7. (M23)
12. Taher MT, Babaii SG. Clinical and Paraclinical Reports of 100 Cases of Infectious Arthritis in Firoozgar and Rasoul-e-Akram Hospitals, 1998-2003. Razi Journal of Medical Sciences 2007; 14(54):109-17. (M23)
13. **Rad: *Karanović J, Ivković M, Jovanović V, Šviković S, Pantović-Stefanović M, Brkušanin M, Damjanović A, Brajušković G, Savić-Pavićević D. Effect of childhood general traumas on suicide attempt depends on TPH2 and ADARB1 variants in psychiatric patients. J Neural Transm 2017; 124(5):621-9.***

**citiraju: 11x**

1. Wu H, Chen HL. Insufficient evidential basis for the association between Toxoplasma gondii and suicide attempts. Transbound Emerg Dis. 2021 (M21a)
2. Barbon A, Magri C. RNA Editing and Modifications in Mood Disorders. Genes (Basel). 2020;11(8):E872 (M21).
3. Chen JX, Feng JH, Zhang LG, Liu Y, Yang FD, Wang SL, Tan YL, Su YA. Association of serum uric acid levels with suicide risk in female patients with major depressive disorder: a comparative cross-sectional study. BMC Psychiatry. 2020; 20(1):477. (M21)
4. Fu X, Zhang X, Jiang T, et al. Association Between Lifelong Premature Ejaculation and Polymorphism of Tryptophan Hydroxylase 2 Gene in the Han Population. Sex Med. 2020; 8(2):223‐229. (M22)
5. Chimienti F, Cavarec L, Vincent L, Salvetat N, Arango V, Underwood MD, Mann JJ, Pujol JF, Weissmann D. Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents. Transl Psychiatry. 2019; 9(1):91. (M21)
6. Jiang S, Postovit L, Cattaneo A, Binder EB, Aitchison KJ. Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma. Front Psychiatry. 2019;10:808. (M21)
7. Musci RJ, Augustinavicius JL, Volk H. Gene-Environment Interactions in Psychiatry: Recent Evidence and Clinical Implications. Curr Psychiatry Rep. 2019;21(9):81. (M21)
8. Xiang C, Liu S, Fan Y, Wang X, Jia Y, Li L, Cong S, Han F. Single nucleotide polymorphisms, variable number tandem repeats and allele influence on serotonergic enzyme modulators for aggressive and suicidal behaviors: A review. Pharmacol Biochem Behav. 2019 May;180:74-82. (M22)
9. Tao S, Chattun MR, Yan R, Geng J, Zhu R, Shao J, Lu Q, Yao Z. TPH-2 Gene Polymorphism in Major Depressive Disorder Patients With Early-Wakening Symptom. Front Neurosci. 2018;12:827. (M21)
10. Ottenhof KW, Sild M, Lévesque ML, Ruhé HG, Booij L. TPH2 polymorphisms across the spectrum of psychiatric morbidity: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;92:29-42. (M21a)
11. Park CHK, Lee JW, Lee SY, Shim SH, Moon JJ, Paik JW, Cho SJ, Kim SG, Kim MH, Kim S, Park JH, You S, Jeon HJ, Ahn YM. Implications of Increased Trait Impulsivity on Psychopathology and Experienced Stress in the Victims of Early Trauma With Suicidality. J Nerv Ment Dis. 2018; 206(11):840-849. (M22)
12. **Rad: *Brkušanin M, Kosać A, Jovanović V, Pešović J, Brajušković G, Dimitrijević N, Todorović S, Romac S, Milić Rašić V, Savić-Pavićević D. Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients. J Hum Genet. 2015; 60(11):723-8.***

**citiraju: 11x**

1. Butchbach MER. Genomic Variability in the Survival Motor Neuron Genes (*SMN1* and *SMN2*): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. Int J Mol Sci. 2021; 22(15):7896. (M21)
2. Costa-Roger M, Blasco-Pérez L, Cuscó I, Tizzano EF. The Importance of Digging into the Genetics of *SMN* Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int J Mol Sci. 2021; 22(16):9029. (M21)
3. Smeriglio P, Langard P, Querin G, Biferi MG. The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. J Pers Med. 2020; 10(3):E75. (M21a)
4. Kariyawasam DST, D'Silva A, Lin C, Ryan MM, Farrar MA. Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Front Neurol. 2019;10:898. (M23)
5. Maretina MA, Zheleznyakova GY, Lanko KM, Egorova AA, Baranov VS, Kiselev AV. Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates. Current Genomics 2018:19 (M23)
6. Kariyawasam DST, D'Silva A, Lin C, Ryan MM, Farrar MA. Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Front Neurol. 2019;10:898. (M22)
7. Medrano S, Monges S, Gravina LP, Alías L, Mozzoni J, Aráoz HV, Bernal S, Moresco A, Chertkoff L, Tizzano E. Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina. Eur J Paediatr Neurol. 2016; 20(6):910-917.(M22)
8. Burns JK, Kothary R, Parks RJ. Opening the window: the case for carrier and perinatal screening for spinal muscular atrophy. Neuromuscular Disorders 2016; (M22)
9. Butchbach ME. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci. 2016; 3:7. (M23)
10. Nash LA, Burns JK, Chardon JW, Kothary R, Parks RJ. Spinal Muscular Atrophy: More than a Disease of Motor Neurons? Curr Mol Med. 2016 Nov 28. (M21)
11. Knežević M, Mladenović J, Kovačević G, Ostojić S, Milin-Lazovića J, Milić-Rašića V. Genotipe-phenotipe correlation in spinal muscle atrophy (SMA). Materia medica 2015; 31(3):1337-44 (M23).
12. **Rad: *Cerović S, Brajušković G, Vukotić Maletić V, Mićic S: Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl. 2004; 61: 513-8.***

**citiraju 11x:**

1. Gilloteaux DJ, Jamison JM, Summers JL, Taper HS. Xenografts on nude mouse diaphragm of human DU145 prostate carcinoma cells: mesothelium removal by outgrowths and angiogenesis. Ultrastruct Pathol. 2022; 46(5):413-438. (M23)
2. [Mijović M](https://www.scopus.com/authid/detail.uri?authorId=57196949431&amp;eid=2-s2.0-85077009744), [Ćorac A](https://www.scopus.com/authid/detail.uri?authorId=56027519300&amp;eid=2-s2.0-85077009744),[Smiljić S](https://www.scopus.com/authid/detail.uri?authorId=36976382100&amp;eid=2-s2.0-85077009744), [Savić S](https://www.scopus.com/authid/detail.uri?authorId=57202697040&amp;eid=2-s2.0-85077009744), [Mandić P](https://www.scopus.com/authid/detail.uri?authorId=55353544800&amp;eid=2-s2.0-85077009744), [Vitković L](https://www.scopus.com/authid/detail.uri?authorId=57212535826&amp;eid=2-s2.0-85077009744), [Leštarević S](https://www.scopus.com/authid/detail.uri?authorId=55889834900&amp;eid=2-s2.0-85077009744), [Hudomal SJ](https://www.scopus.com/authid/detail.uri?authorId=57196954825&amp;eid=2-s2.0-85077009744). Correlation of focal neuroendocrine differentiation in prostate cancer with the parameters of predictive value. Vojnosanitetski pregled 2019; 76(11):1115-26. (M23)
3. Chen S, Cheung SK, Wong KN, Wong KK, Ho CL. 68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation. Clin Nucl Med. 2016; 41(12):959-960. (M21a)
4. Surcel CI, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. Urol Oncol. 2015; 33(6):265.e1-265.e7. (M21)
5. Mijović M, Vukićević D, Đerković B, Nedeljković V, Vitković L. [Prognostic significance of Gleason score 7 (3 +4) and Gleason score 7 (4 +3) in prostatic adenocarcinoma in relation to clinical stage, androgen tissue status and degree of neuroendocrine differentiation]. Praxis medica 2014; 43(1):1-12. (M23)
6. Mijović M, Vukićević D, Đerković B, Nedeljković V, Vitković L. Značaj periacinusnih pukotina kao pomoćnog kriterijuma u dijagnozi adenokarcinoma prostate Gleason score-a 7 (3+4) i Gleason score-a 7 (4+3) i njihov odnos prema parametrima od prediktivnog značaja. Praxis medica 2014; 43(4):56-9. (M23)
7. Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM; Trans-Atlantic Prostate Group. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch. 2012;461(2):103-7. (M21)
8. Jaskulski J, Gołąbek T, Kopczyński J, Orłowski P, Bukowczan J, Dudek P, Chłosta P. Czy różnicowanie neuroendokrynne w materiale uzyskanym metodą rdzeniowej biopsji stercza może mieć znaczenie prognostyczne? (Does neuroendocrine differentiation have prognostic value in prostate core needle biopsies?). Przegląd Lekarski 2013; 70(11): 933-5. (M23)
9. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 2007; 27(5B):3651-60. (M23)
10. de Almeida JC, Raissa P. Menezes, Selma A. Kuckelhaus, Anamelia L. Bocca, Florencio Figueiredo Prognostic Value of Morphologic and Clinical Parameters in pT2 - pT3 Prostate Cancer. International Braz J Urol 2007;33 (5): 662-72. (M23)
11. Afshar Moghaddam N, Nasr M. Evaluation of Neuroendocrine and Proliferative Markers in Prostatic Adenocarcinomas. Iran J Med Sci 2006; 31(1): 18-21. (M23)
12. Rad: [*Balint B, Vučetić D, Trajković-Lakić Z, Petakov M, Bugarski D, Brajušković G, Taseski J.*](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12803111&dopt=Abstract) *Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap). 2002;32(4):363-75.*

citiaju 9x:

1. Arcila DFS, Carmona EO, Colorado SJ, Corteze AA, Arcila JCS, Leme FOP, Rezende CMF. [Morphological evaluation of the autologous platelet concentrate in dogs under refrigeration and criopreservation in 6% DMSO]. Arq. Bras. Med. Vet. Zootec. 2020; 72 (05) (M23)
2. Balint B, Pavlović M, Ostojić G, Vučetić D, Todorović M. Improved cytoreductive potential of plateletapheresis in the treatment of thrombocythemia: a single center study. Vojnosanitetski pregled 2019; 76(5):559-60. (M23)
3. Vučetić D, Ilić V, Vojvodić D, Subota V, Todorović M, Balint B. Flow cytometry analysis of platelet populations: usefulness for monitoringthe storage lesion in pooled buffy-coat platelet concentrates. Blood Transfus. 2018;16(1):83-92. (M23)
4. Balint B, PaunovicD, Vucetic D, Vojvodic D, Petakov M, Trkuljic M, StojanovicN. Controlled-rate versus uncontrolled-rate freezing as predictors for platelet cryopreservation efficacy. Transfusion 2006; 46 (2): 230-5. (M22)
5. Balint B, Vucic M, Todorovic M, Antic A, Stanojkovic Z, Vucic J, Pavlovic M, Vucetic D. Radically reduced ex vivo cell activation by using "in-line" filtered whole blood as a source of platelet concentrate. Blood Transfus. 2014;12(3):440-2. (M23)
6. Balint B, Gazivoda D, Todorovic-Balint M, Lazic Z, Pavlovic M, Kanjuh V. "Triple-way" approach for the treatment of dry socket: Surgery and drugs plus fibrin sealant - as a biomatrix for "ultra-concentrated" platelets. Transfus Apher Sci. 2014;51(2):221-2.(M23)
7. Vucic M, Tijanic I, Govedarevic N, Macukanovic L, Pavlovic Z. The effect of a leukodepletion model on the activation stage of platelets. [Central Europ Journal of Med](http://www.scopus.com/source/sourceInfo.url?sourceId=4700152844&origin=recordpage). 2011; 6(2):181-4. (M23)
8. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, Dong JF, KleimanNS, Guthikonda S. Platelet activation patterns in platelet size subpopulations:differential responses to aspirin *in vitro*. J ThrombThrombolysis. 2010; 30(3):251-62. (M23)
9. Balint B. Apheresis in donor and therapeutic settings: Recruitments vs. possibilities - a multicenter study.Transfusion and apheresis science 2005; 33 (2): 181-9.(M23)
10. Rad: *Nikolić Z, Savić Pavićević D, Vučić N, Romac S, Brajušković G. Association between genetic variant in hsa-miR-146a gene and cancer risk: an updated meta-analysis. Public Health Genomics 2015; 18(5):283-98.*

citiraju 9x:

1. Machowska M, Galka-Marciniak P, Kozlowski P. Consequences of genetic variants in miRNA genes. Comput Struct Biotechnol J. 2022;20:6443-6457. (M21)
2. Bernardes JG, Fernandes MR, Rodrigues JC, Vinagre LW, Pastana LF, Dobbin EA, Medeiros JA, Dias Junior LB, Bernardes GM, Bernardes IM, Santos NP. Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes 2022; 13(4):622. (M22)
3. Salihi A, Al‑Naqshabandi MA, Khudhur ZO, Housein Z, Hama HA, Abdullah RM, Hussen BM, Alkasalias T. Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy. Molecular Medicine Reports. 2022; 26(1):1-0. (M23)
4. Gong Z, Platek ME, Till C, Goodman PJ, Tangen CM, Platz EA, Neuhouser ML, Thompson IM, Santella RM, Ambrosone CB. Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Frontiers in oncology. 2021;11. (M21)
5. Zhang S, Chen L, Wang Y, Tang W, Chen Y, Liu L. Investigation of the Association of *miRNA-499*, *miRNA-146a*, *miRNA-196a2* Loci with Hepatocellular Carcinoma Risk: A Case-Control Study Involving 1507 Subjects. DNA Cell Biol. 2020; 39(3):379-388. (M22)
6. Lin J, Lin W, Lan B, Chen S, Wu W , Ruan J, Liu C, Tang W , Chen Y, Guo Z. Lack of association between MicroRNA-146a rs2910164 C > G polymorphism and risk of gastric carcinoma: a case-control study and a meta-analysis. Int J Clin Exp Med 2019; 12(4):3810-20.
7. Chen Y, Tang W, Liu C, Lin J, Wang Y, Zhang S, Chen G, Zheng X. miRNA-146a rs2910164 C>G polymorphism increased the risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 participants. Cancer Manag Res. 2018;10:1657-1664. (M22)
8. Sangalli A, Orlandi E, Poli A, Maurichi A, Santinami M, Nicolis M, Ferronato S, Malerba G, Rodolfo M, Gomez Lira M. Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer. Melanoma Res. 2017;27(4):309-314. (M21)
9. Garcia AI, Buisson M, Damiola F, Tessereau C, Barjhoux L, Verny-Pierre C, Sornin V, Dondon MG, Eon-Marchais S; GENESIS investigators, Caron O, Gautier-Villars M, Coupier I, Buecher B, Vennin P, Belotti M, Lortholary A, Gesta P, Dugast C, Noguès C, Fricker JP, Faivre L, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM, Mazoyer S. Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study. Eur J Hum Genet. 2016; 24(9):1324-9.(M21)
10. Rad: *Branković A, Brajušković G, Mirčetić J, Nikolić Z, Kalaba P, Vukotić V, Tomović S, Cerović S, Radojičić Z, Savić Pavićević D, Romac S. Common variants at 8q24 are associated with prostate cancer risk in Serbian population. Pathology and Oncology Research 2013; 19:559-69.*

citiraju 9x:

1. Bozkurt A, Gürbüzel M, Sayar I, Baydeniz S, Arslan YK. Qualification and quantification of plasma cell-free DNA after long-term storage conditions in patients with benign prostatic hyperplasia (BPH): a pilot study. Journal of Laboratory Medicine 2022; 46(6):383-39.(M23)
2. Du P, Zhu J, He C, Hu G, Li S, Ye MY, Liu YX, Zeng JS. The rs1447295 polymorphism in the 8q24 gene contributes to cancer risk, especially prostate cancer: a meta-analysis. Int J Clin Exp Med 2018; 11(12):13115-34. (M23)
3. Li R, Qin Z, Tang J, Han P, Xing Q, Wang F, Si S, Wu X, Tang M, Wang W, Zhang W. Association between 8q24 Gene Polymorphisms and the Risk of Prostate Cancer: A systematic review and meta-analysis. Journal of Cancer 2017; 8(16):3198-211. (M22)
4. Zhu M, Wen X, Liu X, Wang Y, Liang C, Tu J. Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects. Oncotarget. 2017;8(34):57421-57439. (M21)
5. Yang Y, Wang W, Zhang L, Zhang S, Liu G, Yu Y, Liao M. Association of single nucleotide polymorphism rs6983267 with the risk of prostate cancer. Oncotarget 2016; 7 (18): 25528-34. (M21a)
6. Yanar K, Çakatay U, Aydın S, Verim A, Atukeren P, Özkan NE, Karatoprak K, Cebe T, Turan S, Ozkök E, Korkmaz G, Cacına C, Küçükhüseyin O, Yaylım İ. Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. Oxid Med Cell Longev. 2016;2016:4985063. (M21)
7. Liu Q, Liu X, Hua RX, Wang F, An H, Zhang W, Zhu JH. Association of three 8q24 polymorphisms with prostate cancer susceptibility: evidence from a meta-analysis with 50,854 subjects. Sci Rep. 2015;5:12069. (M21a)
8. Zhu HS, Zhang JF, Zhou JD, Zhang MJ, Hu HX. Association between the 8q24 rs6983267 T/G polymorphism and prostate cancer risk: a meta-analysis. Genet Mol Res. 2015; 29;14(4):19329-41.(M23)
9. Zhao CX, Liu M, Xu Y, Yang K, Wei D, Shi XH, Yang F, Zhang YG, Wang X, Liang SY, Zhao F, Zhang YR, Wang NN, Chen X, Sun L, Zhu XQ, Yuan HP, Zhu L, Yang YG, Tang L, Jiao HY, Huo ZH, Wang JY, Yang Z. 8q24 rs4242382 Polymorphism is a Risk Factor for Prostate Cancer among Multi-Ethnic Populations: Evidence from Clinical Detection in China and a Meta-analysis. Asian Pac J Cancer Prev.2014;15(19):8311-7. (M23)
10. *Rad:* ***Kotarac N****, Dobrijević Z, Matijašević S, Savić-Pavićević D, Brajušković G. Analysis of association of potentially functional genetic variants within genes encoding miR-34/b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population. EXCLI Journal 2019; 18:515-29.*

citiraju 9x:

1. Zhao J, Zuo W, Zhang Y, He C, Zhao W, Meng T. The polymorphism rs4705342 in the promoter of miR-143/145 is related to the risk of epithelial ovarian cancer and patient prognosis. Front Oncol. 2023;13:1122284. (M23)
2. Wang SC, Tsai CW, Chang WS, Hsia NY, Mong MC, Wang YC, Hsia TC, Gu J, Bau DT. Genetic variants in miR-145 gene are associated with the risk of asthma in Taiwan. Sci Rep. 2022; 12(1):15155. (M21)
3. Kong D, Duan Y, Wang J, Liu Y. A functional polymorphism of microRNA-143 is associated with the risk of type 2 diabetes mellitus in the northern Chinese Han population. Front Endocrinol (Lausanne). 2022;13:994953. (M21)
4. Gligorijević N, Dobrijević Z, Šunderić M, Robajac D, Četić D, Penezić A, Miljuš G, Nedić O. The Insulin-like Growth Factor System and Colorectal Cancer. Life (Basel). 2022;12(8):1274. (M22)
5. Kong D, Duan Y, Wang J, Liu Y. A functional polymorphism of microRNA-143 is associated with the risk of type 2 diabetes mellitus in the northern Chinese Han population. Front Endocrinol 2022;13:994953. (M21)
6. Qi S, Wang C, Li L, Li T, Chen Q, Wang J. Association Between miR-143/145 rs4705343 Polymorphism and Risk of Congenital Heart Disease in a Chinese Tibetan Population. Genet Test Mol Biomarkers. 2021; 25(12):735-740. (M23)
7. Mishra N, Raina K, Agarwal R. Deciphering the role of microRNAs in mustard gas-induced toxicity. Ann N Y Acad Sci. 2021 May;1491(1):25-41. (M21)
8. Harati-Sadegh M, Sargazi S, Saravani M, Sheervalilou R, Mirinejad S, Saravani R. Relationship between miR-143/145 cluster variations and cancer risk: proof from a Meta-analysis. Nucleosides Nucleotides Nucleic Acids 2021; 40(5):578-91. (M23)
9. Wang Y, Zhou S, Zhao W, Li Z, Zhu J, Wei T, Song H. Association between functional polymorphisms in the flanking region of miR-143/145 and risk of papillary thyroid carcinoma: A case-control study. Medicine (Baltimore). 2020;99(49):e23560. (M22)
10. *Rad: Nikolić Z, Savić-Pavićević D, Romac S, Brajušković G. Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta-Analysis. Clinical and Translational Science 2015; 8(1):23-31.*

citiraju 8x:

1. Salihi A, Al-Naqshabandi MA, Khudhur ZO, Housein Z, Hama HA, Abdullah RM, Hussen BM, Alkasalias T. Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review). Mol Med Rep. 2022; 26(1):233. (M23)
2. Bernardes JGB, Fernandes MR, Rodrigues JCG, Vinagre LWMS, Pastana LF, Dobbin EAF, Medeiros JAG, Dias Junior LB, Bernardes GM, Bernardes IMM, Santos NPCD, Demachki S, Burbano RMR. Association of Androgenic Regulation and MicroRNAs in Acinar Adenocarcinoma of Prostate. Genes (Basel). 2022;13(4):622. (M22)
3. Gong Z, Platek ME, Till C, Goodman PJ, Tangen CM, Platz EA, Neuhouser ML, Thompson IM, Santella RM, Ambrosone CB. Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Front Oncol. 2022; 11:808715. (M22)
4. Cerqueira ARD, Fratelli CF, Duarte LCAC, Pereira ASR, Morais RM, Sobrinho AB, Silva CMS, Silva ICRD, Oliveira JR. The impact of NOS3 gene polymorphism on papillary thyroid cancer susceptibility in patients undergoing radioiodine therapy. Int J Biol Markers; 35(4):87-91. (M23)
5. Aliyari M, Elieh Ali Komi D, Kiani A, Moradi M, Tanhapour M, Rahimi Z, Mozafari H, Mohammadi-Noori E, Pourmotabbed T, Vaisi-Raygani A, Bahrehmand F. The role of caveolin-1 and endothelial nitric oxide synthase polymorphisms in susceptibility to prostate cancer. Int J Exp Pathol. 2021; 102(6):260-7. (M23)
6. Abedinzadeh M, Dastgheib SA, Maleki H, et al. Association of Endothelial Nitric Oxide Synthase Gene Polymorphisms with Susceptibility to Prostate Cancer: a Comprehensive Systematic Review and Meta-Analysis [published online ahead of print, 2020 May 14]. Urol J. 2020;10.22037 (M23)
7. Dong Q, Lv C, Zhang G, Yu Z, Kong C, Fu C, Zeng Y. Impact of RNA‑binding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study. Oncol Rep. 2018;40(4):2307-2315. (M22)
8. Soni Y, Softness K, Arora H, Ramasamy R. The Yin Yang Role of Nitric Oxide in Prostate Cancer. Am J Mens Health. 2020;14(1):1557988320903191. (M22)
9. Rad: *Šijačić Nikolić M, Milovanović J, Bobinac M, Savić Pavićević D, Brajušković G, Diklić M. Variability of the Choloroplast DNA of Seddile Oak (Quercus Petraea Agg, Enrendorfer, 1967) in Serbia. Arch Biol. Sci. Belgrade 2009; 61(3):459-65.*

citiraju 7x:

1. Popović V, Drinić SM, Milovanović J, Lučić A, Rakonjac L, Milovanović J, Drinić SM, Ristić D. Genetic structure of sessil oak (Quercus petraea (matt.) liebl) from the area of outstanding natural beauty “Avala“. Genetika 2022; 54(2): 841-56. (M23)
2. Popović V, Lučić A, Rakonjac L, Milovanović J, Drinić SM, Ristić D. Application of SSR markers for assessment of genetic differentiation of silver fir (Abies alba mill.) originating from Javor mountain. Genetika 2019; 51(3): 1103-112. (M23)
3. Galović V, Šijačić-Nikolić M, Šafhauzer R, Čortan D, Orlović S. Genetic differentiation of Norway spruce (Picea abies (L.) Karst.) trees with diferent crown types from the mountain Golija. Genetika 2015; 47(3):849-61. (M23)
4. Maksimović Z, Čortan D, Ivetić V, Mladenović Drinić S, Šijačić Nikolić M. Genetic structure of black poplar (Populus nigra L.) population in the area of great war island. Genetika 2014; 46(3):963-73. (M23)
5. Nonić M, Vettori C, Boscaleri F, Milovanović J, Šijačić-Nikolić M. Genetically modified trees - State and perspectives. Genetika 2012; 44(2):429-40. (M23)
6. Milovanović J, Šijačić Nikolić M, Nonić M, Radojević U. Šumski genetički resursi u međunarodnim procesima i zakonskoj regulativi. Šumarstvo 2012; 3-4:111-32. (M23)
7. Cvjeticanin R, Sijacic-Nikolic M, Milovanovic J, Perovic M, Novkovic-Vukovic M. Regions of Provenances of Fraxinus angustifolia Vahl. and Fraxinus pallisae Wilmott in Serbia. Šumarstvo 2014; 3-4:131-42. (M23)
8. Rad: *Nikolić Z, Savić Pavićević D, Vukotić V, Tomović S, Cerović S, Filipović N, Romac S, Brajušković G. Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population. Cancer Causes Control. 2014; 25(11):1571-5.*

citiraju 6x:

1. Mi Y, Ren K, Zou J, Bai Y, Zhang L, Zuo L, Okada A, Yasui T. The Association Between Three Genetic Variants in MicroRNAs (Rs11614913, Rs2910164, Rs3746444) and Prostate Cancer Risk. Cell Physiol Biochem. 2018; 48(1):149-157. (M21a)
2. [Huang S,](https://www.scopus.com/authid/detail.uri?authorId=55777691700&amp;eid=2-s2.0-85047094903) [Cui H](https://www.scopus.com/authid/detail.uri?authorId=57202070202&amp;eid=2-s2.0-85047094903), [Lou Z](https://www.scopus.com/authid/detail.uri?authorId=57190969704&amp;eid=2-s2.0-85047094903), [Wang X](https://www.scopus.com/authid/detail.uri?authorId=57053586300&amp;eid=2-s2.0-85047094903), [Chen L](https://www.scopus.com/authid/detail.uri?authorId=57192172417&amp;eid=2-s2.0-85047094903), [Xie Z](https://www.scopus.com/authid/detail.uri?authorId=57192172177&amp;eid=2-s2.0-85047094903), [Hehir M](https://www.scopus.com/authid/detail.uri?authorId=7003949711&amp;eid=2-s2.0-85047094903), [Yao X](https://www.scopus.com/authid/detail.uri?authorId=55180278800&amp;eid=2-s2.0-85047094903), [Ren Y,](https://www.scopus.com/authid/detail.uri?authorId=57201003964&amp;eid=2-s2.0-85047094903) [Cen D,](https://www.scopus.com/authid/detail.uri?authorId=57201995426&amp;eid=2-s2.0-85047094903) [Weng G.](https://www.scopus.com/authid/detail.uri?authorId=53982356200&amp;eid=2-s2.0-85047094903) Association of rs3787016 in long non-coding rnas polr2e and rs2910164 in mirna-146a with prostate cancer: A systematic review and meta-analysis. [Iranian Journal of Public Health](https://www.scopus.com/sourceid/21484?origin=recordpage) 2018; 47(5): 623-32. (M23)
3. Sun D, Zhang X, Zhang X. miR-146a C/G polymorphism increased the risk of head and neck cancer, but overall cancer risk: an analysis of 89 studies. Biosci Rep. 2018; 38(1).(M22)
4. Wang YH, Hu HN, Weng H, Chen H, Luo CL, Ji J, Yin CQ, Yuan CH, Wang FB. Association between Polymorphisms in MicroRNAs and Risk of Urological Cancer: A Meta-Analysis Based on 17,019 Subjects. Front Physiol. 2017; 8:325. (M21)
5. Liu HT, Fang L, Cheng YX, Sun Q. LncRNA PVT1 regulates prostate cancer cellgrowth by inducing the methylation of miR-146a. Cancer Med. 2016; 5(12):3512-9. (M22)
6. Su R, Li W, Luo R. Association between miR-146a, miR-149, miR-196a2 and miR-499 gene polymorphisms and the susceptibility to gastric cancer in a Chinese population. Int J Clin Exp Pathol 2016;9(2):2192-9. (M23)
7. Rad: *Trbojević J, Nešić D, Laušević Ž, Obradović M, Brajušković G, Stojimirović B. Histological characteristics of healthy animal peritoneum. Acta Veterinaria 2006; 56(5-6): 405-12.*

citiraju 6x:

1. Capella-Monsonís H, De Pieri A, Peixoto R, Korntner S, Zeugolis DI. Extracellular matrix-based biomaterials as adipose-derived stem cell delivery vehicles in wound healing: a comparative study between a collagen scaffold and two xenografts. Stem Cell Res Ther. 2020; 11(1):510. (M21)
2. Capella-Monsonís H, Kelly J, Kearns S, Zeugolis DI. Decellularised porcine peritoneum as a tendon protector sheet. Biomed Mater. 2019;14(4):044102. (M21)
3. Jerman LF, Hey-Cunningham AJ. The role of the lymphatic system in endometriosis: a comprehensive review of the literature. Biol Reprod. 2015;92(3):64. (M21)
4. Hey-Cunningham AJ, Peters KM, Barrera-Villa Zevallos H, Berbic M, Markham R, Fraser IS. Angiogenesis, lymphangiogenesis and neurogenesis in endometriosis. Front Biosci (Elite Ed). 2013;E5:1033-56. (M22)
5. Berbic M, Ng CH, Black K, Markham R, Russell P, Basten A, Fraser IS, Hey-Cunningham AJ. A Novel Pilot Study of Endometrial Stromal Cells and Immune Cell Populations in Sentinel Uterine-Draining Lymph Nodes during the Menstrual Cycle and in Endometriosis. Reprod Sci. 2013. (M22)
6. Stojimirovic B, Jovanovic N, Lausevic Z, Krsic S, Obradovic M. First histological findings in rabbit model of peritoneal dialysis. Acta Veterinaria (Beograd) 2010; 60(5-6):625-32. (M23)
7. Rad: ***Vučić N****, Nikolić Z, Vukotić V, Tomović S, Vuković I, Kanazir S, Savić-Pavićević D, Brajušković G. NOS3 gene variants and male infertility: association of 4a/4b with oligoasthenozoospermia. Andrologia 2018; 50(1).*

citiraju 6x:

1. Manfrevola F, Chioccarelli T, Mele VG, Porreca V, Mattia M, Cimini D, D'Agostino A, Cobellis G, Fasano S, Schiraldi C, Chianese R, Pierantoni R. Novel Insights into circRNA Saga Coming from Spermatozoa and Epididymis of HFD Mice. Int J Mol Sci. 2023; 24(7):6865. (M21)
2. Mahbouli S, Dupont C, Elfassy Y, Lameignère E, Levy R. Exploring the potential impact of nutritionally actionable genetic polymorphisms on idiopathic male infertility: a review of current evidence. Asian J Androl. 2021;23(5):441-9. (M22)
3. Gao Y, Wu F, Ren Y, Zhou Z, Chen N, Huang Y, Lei C, Chen H, Dang R. MiRNAs Expression Profiling of Bovine (Bos taurus) Testes and Effect of bta-miR-146b on Proliferation and Apoptosis in Bovine Male Germline Stem Cells. Int J Mol Sci. 2020;21(11):3846.(M21)
4. Barati E, Nikzad H, Karimian M. Oxidative stress and male infertility: current knowledge of pathophysiology and role of antioxidant therapy in disease management. Cell Mol Life Sci. 2020; 77(1):93-113. (M21)
5. Barati E, Karimian M, Nikzad H. Oxidative stress markers in seminal plasma of idiopathic infertile men may be associated with glutathione S-transferase M1 and T1 null genotypes. Andrologia. 2020;52(9):e13703. (M23)
6. Wang X, Sha YW, Wang WT, Cui YQ, Chen J, Yan W, Hou XT, Mei LB, Yu CC, Wang J. Novel IFT140 variants cause spermatogenic dysfunction in humans. Mol Genet Genomic Med. 2019; 7(9):e920. (M22)
7. Rad: *Brajušković G, Škaro Milić A, Marjanović S, Cerović S, Knežević Ušaj S. The ultrastructural investigation of mitochondria in B – CLL cells during process apoptosis. Archive of Oncology 2004; 12(3):139-41.*

citiraju 6x:

1. Nazir S, Ali MN, Tantray JA, Baba IA, Jan A, Popescu SM, Paray BA, Gulnaz A. Study of Ultrastructural Abnormalities in the Renal Cells of Cyprinus carpio Induced by Toxicants. Toxics. 2022; 10(4):177. (M21)
2. Lin C, Yuwei C, Jun L, Junlan W, Xuebo L, Tongting W, Xinglian X, Guanghong Z, Xianchao F. Apoptotic changes and myofibrils degradation in post-mortem chicken muscles by ultrasonic processing. LWT 2021; 142 (M21)
3. El-Bestawy EM, M Tolba A. Effects of titanium dioxide nanoparticles on the myocardium of the adult albino rats and the protective role of β-carotene (histological, immunohistochemical and ultrastructural study). J Mol Histol. 2020 (M23)
4. Zhukova MV, Kiseleva E. The virulent Wolbachia strain wMelPop increases the frequency of apoptosis in the female germline cells of Drosophila melanogaster. BMC Microbiol. 2012;12 Suppl 1:S15. (M22)
5. Badr G, Waly H, Eldien HM, Abdel-Tawab H, Hassan K, Alhazza IM, Ebaid H, Alwasel SH. Blocking type I interferon (IFN) signaling impairs antigen responsiveness of circulating lymphocytes and alters their homing to lymphoid organs: protective role of type I IFN. Cell Physiol Biochem. 2010; 26(6):1029-40. (M21)
6. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111(6):3190-9. (M21a)
7. Rad: *Dimitrijević J, Đukanović Lj, Kovačević Z, Bogdanović R, Maksić Đ, Hrvačević R, Aleksić A, Naumović R, Jovanović D, Brajušković G, Milosavljević I. Lupus nephritis: pathological features, classification and histologic scorning in renal biopsy. Vojnosanitetski pregled 2002; 59(6):21-33.*

citiraju 6x:

1. Akhgar A, Sinibaldi D, Zeng L, Farris AB 3rd, Cobb J, Battle M, Chain D, Cann JA, Illei GG, Lim SS, White WI. Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis. Lupus Sci Med. 2023;10(1):e000747. (M22)
2. Rong R, Wen Q, Wang Y, Zhou Q, Qiu Y, Lu M, Liu X, Chen W, Yu X. Prognostic significance of hypertension at the onset of lupus nephritis in Chinese patients: prevalence and clinical outcomes. J Hum Hypertens. 2021 (M22)
3. Hu Y, Chen T, Liu S, Liu B, Meng H, Zhang L , Sun D, Dai Y, Guo D, Jin X, Jin G, Zhang F. Gelsolin deposits in renal tissues of the patients with lupus nephritis. Int J Clin Exp Pathol 2016; 9(5):5413-5420. (M22)
4. Stanković N, Vlahović P, Savić V. [Histomorphological and clinical study of primary and secondary glomerulopathies in Southeast Serbia (20-year period of analysis)](http://www.doiserbia.nb.rs/Article.aspx?id=0042-84501300027S). Vojnosanitetski pregled 2013. (M23)
5. Wang Z, Tang Z, Zhang KT, Hu WX, Liu YH, Li LS. Clinicopathological characteristics of familial SLE patients with lupus nephritis. Lupus 2009; 18(3):243-8.(M22)
6. No author name available. The treatment of lupus nephritis in children involves corticosteroids and cytotoxic agents. Drug and Therapy Perspectives 2007; 23(3): 15-9.(M23)
7. Rad: ***Filipović L****, Spasojević M, Prodanović R, Korać A, Matijaševic S,* ***Brajušković G****, de Marco A, Popović M. Affinity-based isolation of extracellular vesicles by means of single-domain antibodies bound to macroporous methacrylate-based copolymer. N Biotechnol. 2022;69:36-48.*

citiraju 5x:

1. Neumair J, D'Ercole C, De March M, Elsner M, Seidel M, de Marco A. Macroporous Epoxy-Based Monoliths Functionalized with Anti-CD63 Nanobodies for Effective Isolation of Extracellular Vesicles in Urine. Int J Mol Sci. 2023 Mar 24;24(7):6131. (M21)
2. Richards T, Patel H, Patel K, Schanne F. Endogenous Lipid Carriers-Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes. Pharmaceuticals (Basel). 2023;16(3):421. (M21)
3. Yao X, Liao B, Chen F, Liu L, Wu K, Hao Y, Li Y, Wang Y, Fan R, Yin J, Liu L, Guo Y. Comparison of proteomic landscape of extracellular vesicles in pleural effusions isolated by three strategies. Front Bioeng Biotechnol. 2023;11:1108952. (M21)
4. Alberti G, Russo E, Corrao S, Anzalone R, Kruzliak P, Miceli V, Conaldi PG, Di Gaudio F, La Rocca G. Current Perspectives on Adult Mesenchymal Stromal Cell-Derived Extracellular Vesicles: Biological Features and Clinical Indications. Biomedicines. 2022;10(11):2822. (M23)
5. Estes S, Konstantinov K, Young JD. Manufactured extracellular vesicles as human therapeutics: challenges, advances, and opportunities. Curr Opin Biotechnol. 2022;77:102776. (M21a)
6. Rad: *Brajušković G, Vukosavić Orolicki S, Cerović S, Knežević Ušaj S, Marjanović S, Romac S. [Bcl-2 and Bax protein interaction in B-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia] [Article in Serbian]. Vojnosanitetski pregled 2005; 62(5):357-63.*

citiraju 5x:

1. Liu S, Yang P, Wang M, Zhang S, Wang J, Pan T, Zhou P. Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the ERK1/2 and COX-2 pathways. Transl Cancer Res. 2022;11(4):813-822. (M23)
2. Huang Chun-li, Zhang De-qin, Zhang Qing-xia, Wen Jing. Anti-apoptotic and uterotrophic effects of Heyan Kuntai capsules in uterus of ovariectomized rats[J]. Tianjin Journal of traditional Chinese Medicine, 2016, 33(11): 675-81. (M23)
3. Masood A, Azmi A, Mohammad R. Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy.Cancers 2011;3:1527-49. (M23)
4. Zhang YJ, Dai Q, Wu SM, Zhu HY, Shen GF, Li EL, Xiao SD. Susceptibility for NSAIDs-induced apoptosis correlates to p53 gene status in gastric cancer cells. Cancer Invest. 2008; 26(9):868-77. (M23)
5. Zhang Y, Wu S, Luo H, Jaing H, XIAO S. Relationship between the level of Bax-Bcl-2 heterodimer and apoptosis of gastric cancer cells. Tumor 2006; 26(11). (M23)
6. Rad: *Kotarac N, Dobrijević Z, Matijašević S, Savić-Pavićević D, Brajušković G. Association of KLK3, VAMP8 and MDM4 genetic variants within microRNA binding sites with prostate cancer: evidence from Serbian population. Pathology and Oncology Research 2020; 26(4):2409-23.*

citiraju 4x:

1. Almeida GM, Castilho AC, Adamoski D, Braun-Prado K. MDM4: What do we know about the association between its polymorphisms and cancer? Med Oncol. 2022;40(1):61 (M22)
2. Chen J, Li X, Liu R, Xie Y, Liu Z, Xiong H, Li Y. The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis. Med Sci Monit. 2022;28:e935671. (M23)
3. Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K; UKGPCS collaborators, Schleutker J, Pashayan N; APCB (Australian Prostate Cancer BioResource), Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H; PRACTICAL consortium, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021; 11(1):9264. (M21)
4. Mancini F, Giorgini L, Teveroni E, Pontecorvi A, Moretti F. Role of Sex in the Therapeutic Targeting of p53 Circuitry. Front Oncol. 2021;11:698946. (M21)
5. Rad: *Cerović S, Ignjatović M, Brajušković G, Knežević Ušaj S, Dimitrijević J, Ćuk V. The value of intraoperative diagnosis in thyroid surgery. Archive of Oncology 2004; 12(1):47.*

citiraju 4x:

1. Farah Klibi F, Blel A, Neji O, Ferjaoui M, Ben Jilani S, Zermani R, The value of intraoperative frozen section in surgical management of thyroid nodules. Report of 409 cases. Annales de pathologie 2009; 29:80-5.(M23)
2. Mekni A, Limaiem F, Cherif K, Chelly I, Sahtout S, Bellil K, Bellil S, Kchir N, Zitouna M, Haouet S. Value of intraoperative frozen-section analysis in thyroid surgery. A retrospective study of 1534 consecutive biopsies. Presse Medicale 2008; 37(6/1):949-955.(M23)
3. Ben Abdelkrim S., Rammeh S., Ben Yacoub Abid L., Abdelkefi M., Ben Ali M., Mokni M. Frozen section analysis in thyroid surgery: Accuracy and limits (Review). Journal Africain du Cancer 2012; 4(3):171-5. (M23)
4. Makes B. Accuracy of frozen-section combined with imprint and fine needle aspitation biopsy in thyroid nodules. Med J Indones 2007; 16(2):89-93. (M23)
5. *Rad:* ***Dobrijević Z,*** *Matijašević S, Savić-Pavićević D, Brajušković G. Association between genetic variants in genes encoding Argonaute proteins and cancer risk: a meta-analysis. Pathology - Research and Practice 2020; 216(5):152906.*

citiraju 4x:

1. da Silva MNS, da Veiga Borges Leal DF, Sena C, Pinto P, Gobbo AR, da Silva MB, Salgado CG, Dos Santos NPC, Dos Santos SEB. Association between SNPs in microRNAs and microRNAs-Machinery Genes with Susceptibility of Leprosy in the Amazon Population. Int J Mol Sci. 2022;23(18):10628. (M21)
2. Pantazopoulou VI, Georgiou S, Kakoulidis P, Giannakopoulou SN, Tseleni S, Stravopodis DJ, Anastasiadou E. From the Argonauts Mythological Sailors to the Argonautes RNA-Silencing Navigators: Their Emerging Roles in Human-Cell Pathologies. Int J Mol Sci. 2020; 21(11):4007. (M21)
3. Nowak I, Sarshad AA. Argonaute Proteins Take Center Stage in Cancers. Cancers (Basel). 2021; 13(4):788. (M21)
4. de Souza TP, de Carvalho DC, Wanderley AV, Fernandes SM, Rodrigues JCG, Cohen-Paes A, Fernandes MR, Mello Junior FAR, Pastana LF, Vinagre LWMS, Silva ALDC, de Assumpção PP, Santos S, Khayat AS, Dos Santos NPC. Influence of variants of the *drosha*, *mir499a*, and *mir938* genes on susceptibility to acute lymphoblastic leukemia in an admixed population from the brazilian amazon. Am J Transl Res. 2020; 12(12):8216-8224. (M22)
5. *Rad: Nikolić Z, Branković A, Savić Pavićević D, Preković S, Vukotić V, Cerović S, Filipović N, Tomović S, Romac S, Brajušković G. Assessment of association between common variants at 17q12 and prostate cancer risk – evidence from Serbian population and meta-analysis. Clinical and Translational Science 2014; 7(4):307-13.*

citiraju 3x:

1. Galisa SLG, Jacob PL, Farias AA, Lemes RB, Alves LU, Nóbrega JCL, Zatz M, Santos S, Weller M. Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil. Genet Mol Biol. 2022; 45(1):e20210172. (M23)
2. Yang Y, Wang W, Zhang L, Zhang S, Liu G, Yu Y, Liao M. Association of single nucleotide polymorphism rs6983267 with the risk of prostate cancer. Oncotarget 2016; 7(18):25528-34. (M21a)
3. Jinga V, Csiki IE, Manolescu A, Iordache P, Mates IN, Radavoi D, Rascu S, Badescu D, Badea P, Mates D. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population. J Cell Mol Med. 2016. (M21)
4. *Rad: Dobrijević Z, Matijašević S, Išić Denčić T, Savić-Pavićević D, Nedić O, Brajušković G. Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis. Gene. 2021;766:145132.*

citiraju: 3x

1. Lee WS, Lee J, Choi JJ, Kang HG, Lee SC, Kim JH. Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients. Sci Rep. 2021;11(1):18594. (M21)
2. Wang J, Zhang Y, Ge F. MiR-186 Suppressed Growth, Migration, and Invasion of Lung Adenocarcinoma Cells via Targeting Dicer1. Journal of Oncology. 2021;2021.(M22)
3. Thunders M, Delahunt B. Gene of the month: *DICER1:* ruler and controller. J Clin Pathol. 2021; 74(2):69-72. (M22)
4. Rad: *Karanović J, Ivković M, Jovanović VM, Pantović M, Pavlović-Janković N, Damjanović A, Brajušković G, Romac S, Savić-Pavićević D. Tryptophan Hydroxylase 1 Variant rs1800532 is Associated with Suicide Attempt in Serbian Psychiatric Patients but does not Moderate the Effect of Recent Stressful Life Events. Suicide Life Threat Behav. 2016. 46 (6): 664-8.*

citiraju 3x:

1. Katherin S, John MJ. Biomarkers of Suicide Attempt Behavior: Towards a Biological Model of Risk. Current Psychiatry Reports. 2017;19(6). (M21)
2. Alam N, Ali S, Akbar N, Ilyas M, Ahmed H, Mustafa A, Khurram S, Sajid Z, Ullah N, Qayyum S, Rahim T, Usman MS, Ali N, Khan I, Pervez K, Sumaira B, Ali N, Sultana N, Tanoli AY, Islam M. Association study of six candidate genes with major depressive disorder in the North-Western population of Pakistan. PLoS One. 2021; 16(8):e0248454. (M22)
3. Sudol K, Mann JJ. Biomarkers of Suicide Attempt Behavior: Towards a Biological Model of Risk. Curr Psychiatry Rep. 2017;19(6):31. (M21)
4. *Rad: Brajušković G****.*** *Apoptosis in malignant diseases. Archive of Oncology 2005; 13(1):19-22.*

citiraju 3x:

1. da Silva BA, Aydos RD, Silva IS, Pereira DM, Carcalho Pde T, Dourado DM, Reis FA, Nacer RS. Lung apoptosis after intra-pulmonary instillation of Benzo(a)pyrine in Wistar rats. Acta Cir Bras. 2010; 25(1):117-20. (M23)
2. El-Awady S, Morshed M, El-Shobaky M, Abo-Hashem M, Ghazy H. Potential role of Bcl-2 expression and apoptotic body index in colorectal cancer. Hepato-Gastroenterology 2008; 55(81):76-81.(M23)
3. Gao L, Sun Y, Chen C, Xi Y, Wang J, Wang Z. Primary mechanism of apoptosis induction in a leukemia cell line by fraction FA-2-b-ß prepared from the mushroom *Agaricus blazei* Murill. Brazilian Journal of Medical and Biological Research 2007; 40:1545-55. (M23)
4. *Rad: Ušaj S, Tarabar D, Ćuk V, Cerović S, Brajušković G, Panišić M, Klem I, Eri Ž. The histological diagnosis of dysplastic and neoplastic lesions in inflammatory bowel disease: a pathological perspective. Acta Chrirurgica Iugoslavica 2004; LI(2):109-16.*

citiraju 3x:

1. Flores BM, O'Connor A, Moss AC. Impact of mucosal inflammation on risk ofcolorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. Gastrointest Endosc. 2017;86(6):1006-1011.e8. (M21)
2. Xu CM, Qiao CH. Loss of fragile histidine triad protein expression in inflammatory bowel disease. World Journal of Gastroenterology 2006: 12 (45): 7355-60. (M22)
3. No author name available. Detection and prevention of ulcerative colitis – associated dysplasia and colon cancer. [**Gastroenterology and Hepatology**](http://www.scopus.com/scopus/source/sourceInfo.url?sourceId=5100152302)2007; 3 (10):5-13**. (M23)**
4. *Rad: Balint B, Vučetić D, Vojvodić D, Petakov M, Brajušković G, Ivanović Z, Trkuljić M, Stojanović N. Cell recovery, cryothermal micro – damages and surface antigen expression as predictors for cold – induced GPIbβ/CD42b – cluster mediated platelet clearance after controlled – rate vs. uncontrolled – rate cryopreservation. Blood Blank Transfus Med 2004; 2(1):22-6.*

citiraju 2x:

1. Balint B, PaunovicD, Vucetic D, Vojvodic D, Petakov M, Trkuljic M, StojanovicN. Controlled-rate versus uncontrolled-rate freezing as predictors for platelet cryopreservation efficacy. Transfusion 2006; 46 (2): 230-5. (M22)
2. Balint B. Apheresis in donor and therapeutic settings: Recruitments vs. possibilities - a mticenter study Transfusion and apheresis science 2005; 33 (2): 181-9.(M23)
3. *Rad: Mihajlović Božić V, Brajušković G, Berger S, Spasić P. Malignant peritoneal mesothelioma. Archive of Oncology 2000; 8(1):25-6.*

citiraju 2x:

1. Andreadis C, Anthimidis G, Loukidis K, Ekonomou S, Kiziridou A, Valeri R, Mouratidou D. malignant peritoneal mesothelioma: an orphan disease. three casereports and an extensive review of the literature.Forum of Clinical Oncology 2006; 5 (4):325-34. (M23)
2. Goncalves C, Silva F, Cotrim I, Rosa A, Cipriano A, Abecassis N. Mesotelioma maligno do peritoneu – a proposito de um caso clinico. J Port Gastrenterol 2005; 12: 87-90. (M23)
3. Rad: *Strnad M, Brajušković G, Strelić N, Todorić-Živanović B, Stamatović D, Tatomirović Ž, Magić Z. Expression of programmed cell death proteins in patients with chronic myeloid leukemia. J BUON 2008; 13(3):403-8.*

citiraju 2x:

1. Stankov K, Mihajlovic D, Stanimirov B, Stankov S, Bajin-Katic K, Mikov I,Popovic S. Quantitative real time-polymerase chain reaction method in Bcr-Abltranslocation diagnostics. J BUON. 2010;15(2):318-22.(M23)
2. Magić Z, Supic G, Brankovic-Magic M. Towards targeted epigenetic therapy of cancer. J BUON 2009; 14 (Supll 1): S79-88. (M23)
3. Rad: [*Balint B, Vučetić D, Drašković B, Vojvodić D, Brajušković G, Čolić M, Trkuljić M.*](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16605192&query_hl=1&itool=pubmed_docsum) *Microprocessor-controlled vs. "dump-freezing" platelet and lymphocyte cryopreservation: a quantitative and qualitative comparative study. Vojnosanitetski pregled 2006; 63(3):261-8.*

citiraju 2x:

1. Nugraha Y, Sari P, Purwoko RY, Luviah E, Pawitan JA. Effect of Lysed Platelet Count in Platelet Concentrates on Various Growth Factor Levels after Freeze Thaw Cycles. International Journal of PharmTech Research 2014; 6(7): 2036-42. (M23).
2. Golab K, Leveson-Gower D, Wang XJ, Grzanka J, Marek-Trzonkowska N, Krzystyniak A, Millis JM, Trzonkowski P, Witkowski P. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int Immunopharmacol. 2013;16(3):371-5.(M22)
3. Rad: *Strnad M, Brajušković G****,*** *Strelić N, Todorić Živanović B, Tukić Lj, Stanković D. [Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia] [Article in Serbian]. Vojnosanitetski pregled 2006; 63(4):364-9.*

citiraju 2x:

1. Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E, Polydoros F, Clark RE. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia. 2015;29(7):1514-23. (M21a)
2. Lucas CM, Harris RJ, Giannoudis A, Clark RE. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica. 2015;100(5):e179-82. (M21a)
3. Rad: *Dimitrijević J, Brajušković G, Cerović S, Popović Z, Bogdanović R, Jovanović D, Hrvačević R, Aleksić A, Kovačević Z, Milosavljević I. Morphology of autoimmune diseases. Archive of Oncology 2004; 12(1):27-9.*

citiraju 2x:

1. Ma X, Zou J, He L, Zhang Y. Dry eye management in a Sjögren's syndrome mouse model by inhibition of p38-MAPK pathway. Diagn Pathol. 2014;9:5. doi:10.1186/1746-1596-9-5. (M22)
2. Andrade CKZ, Silva WA, Maia ER. Computational Approach for the Design of AP1867 Analogs: Aiming at New Synthetic Routes for Potential Immunosuppressant Agents. Journal of Biomolecular Structure & Dynamics 2007; 25(1): 35-48.(M23)
3. *Rad: Zolotarevski L, Jović M, Popov Aleksandrov A, Milosavljević P, Brajušković G, Demensku J, Mirkov I, Ninkov M, Kataranovski D, Kataranovski M. Skin response to epicutaneous application of anticoagulant rodenticide warfarin is characterized by differential time- and dose-dependent changes in cell activity. Cutaneous and Ocular Toxicology 2015; 1-18.*

citiraju 2x:

1. Popov Aleksandrov A, Mirkov I, Ninkov M, Mileusnic D, Demenesku J, Subota V,Kataranovski D, Kataranovski M. Effects of warfarin on biological processes otherthan haemostasis: A review. Food Chem Toxicol. 2018;113:19-32. (M21a)
2. Subota V, Mirkov I, Demenesku J, Popov Aleksandrov A, Ninkov M, Mileusnic D, Kataranovski D, Kataranovski M. Transdermal toxicity of topically applied anticoagulant rodenticide warfarin in rats. Environ Toxicol Pharmacol. 2016; 41:232-40. (M22)
3. *Rad: Petrović N, Jovanović-Ćupić S, Brajušković G, Lukić S, Roganović J, Krajnović M, Mandušić V. Micro RNA-21 expression levels in invasive breast carcinoma with a non-invasive component. Arch Biol. Sci. Belgrade 2015; 67(4):1285-95.*

citiraju 2x:

1. Petrovic N, Sami A, Martinovic J, Zaric M, Nakashidze I, Lukic S, Jovanovic-Cupic S. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathol Res Pract. 2017; 213(10):1264-1270. (M23)
2. Petrović N. miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in iniIitial Events of Breast Cancer Development. Mol Diagn Ther. 2016; 20(2):97-110. (M22)
3. Rad: *Brajušković G, Vukosavić S, Dimitrijević J, Cerović S, Kežević Ušaj S, Marjanović S, Romac S, Škaro Milić A. [Expression of the Bcl-2 family of proteins in peripheral blood B-lymphocytes in patients with chronic lymphocytic leukemia] [Article in Serbian]. Vojnosaitetski pregled 2004; 61(1):41-46.*

citira:

1. Badr G, Waly H, Eldien HM, Abdel-Tawab H, Hassan K, Alhazza IM, Ebaid H, Alwasel SH. Blocking type I interferon (IFN) signaling impairs antigen responsiveness of circulating lymphocytes and alters their homing to lymphoid organs: protective role of type I IFN. Cell Physiol Biochem. 2010; 26(6):1029-40. (M21)
2. Rad: *Brajušković G, Vukosavić S, Romac S, Cerović S, Knežević Ušaj S, Popović L, Marjanović S, Dimitrijević J, Škaro Milić A. [Apoptosis in chronic lymphocytic leukemia] [Article in Serbian]. Vojnosanitetski pregled 2002; 59(6):47-53.*

citira:

1. Al-Tonbary Y, Al-Hasan SA, Zaki M, Hammad A, Kandil S, Fouda A. Impact of anti-oxidant status and apoptosis on the induction phase of chemotherapy in childhood acute lymphoblastic leukemia. Hematology 2011;16(1):14-9.(M23)
2. Rad: *Brajušković G****.*** *[Genomics] [Article in Serbian]. Vojnosanitetski pregled 2006; 63(6):604-10.*

citira:

1. Gvozdanovic K, Culjak V, Margeta P. Development of new sequencing technologies and their application in genome analysis of domestic animals. Poljoprivreda 2015; 21(2): 66-72. (M23)
2. Rad: *Brajušković G, Škaro Milić A, Cerović S, Marjanović S, Knežević Ušaj S, Čizmić M, Dimitrijević J. [The Bcl-2 protein family in malignant diseases] [Article in Serbian]. Vojnosanitetski pregled 2004; 61(3):305-10.*

*citira:*

1. Vučević D, Radosavljević T, Đorđević-Denić G. The role of eosinophilic leukocytes in pathogenesis of bronchial asthma. Jugoslovenska Medicinska biohemija 2004; 23(4):333-41. (M23)
2. Rad: *Vučetić D, Balint B, Trajković Lakić Z, Mandić Radić S, Brajušković G, Miković D, Trkuljić M. Cryopreserved vs. liquid – state stored platelets – quantitative and qualitative comparative study. Blood Blank Transfus Med 2003; 1(2):81-8.*

citira:

1. Balint B, PaunovicD, Vucetic D, Vojvodic D, Petakov M, Trkuljic M, StojanovicN. Controlled-rate versus uncontrolled-rate freezing as predictors for platelet cryopreservation efficacy. Transfusion 2006; 46 (2): 230-5. (M22)
2. Rad: *Mirčić A, Vilimanović U, Brajušković G, Bumbaširević V. Apoptosis and appearance of multinuclear C6 glioma cells after tratment by microtubule poisons. Acta Veterinaria (Beograg) 2012; 62(1):17-26.*

citira:

1. Scott R, Karki M, Reisenauer MR, Rodrigues R, Dasari R, Smith WR, Pelly SC, van Otterlo WA, Shuster CB, Rogelj S, Magedov IV, Frolova LV, Kornienko A. Synthetic and biological studies of tubulin targeting c2-substituted 7-deazahypoxanthines derived from marine alkaloid rigidins. ChemMedChem. 2014;9(7):1428-35. (M21a)
2. Rad: *Cerović S, Tatić V, Dimitrijević J, Ilić S, Milović N, Aleksić P, Brajušković G.[Advanced prostatic carcinoma with low levels of serum prostate-specific antigen] [Article in Serbian]. Vojnosanitetski pregled 2002; 59(2):137-140.*

citira:

1. Seven B, Varolgu E, Cayir K, Sahin A, Kantarchi M. Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen. Hellenic Journal of Nuclear Medicine 2008; 11(1):53-54.(M23)
2. Rad: *Cerović S, Ignjatović M, Brajušković G, Knežević-Ušaj S, Ćuk V, Hrvačević R, Ajdinović B. [Papillary microcarcinoma of the thyroid and secondary hyperparathyroidism in a patient on hemodialysis] [Article in Serbian].*Acta Chir Iugosl 2004; L:93-5.

citira:

1. Katebi M, Maddah G, Tarhini M, Fawzi A. Papillary thyroid microcarcinoma with large and cystic neck metastasis: report of a case and review of articles. Journal of Research in Medical Sciences 2006; 11(5):334-8.(M23)
2. Rad: *Dimitrijević J, Brajušković G, Spasić P, Đuričić S, Bogdanović R, Radosavljević R. Pathologic characteristics of the kidney in hereditary nephropathy. Materia Medica 2006; 22 (2, suppl 1): 37-9.*

citira:

1. Dimitrijević J, Kovacević Z, Jovanović D, Ignjatović L, Rabrenović V, Djukanović L. Asymptomatic urinary abnormalities: histopathological analysis. Pathol Res Pract 2009;205(5):295-302.(M23)
2. Rad: *Jeremić N, Cerović S, Brajušković G****,*** *Tomović S, Maletić Vuković V. [Incidence of pelvic lymph node metastasis in radical prostatectomy] [Article in Serbian]. Vojnosaintetski pregled 2006; 63(12):1011-4.*

citira:

1. Wirth PM, Froehner M. Lymph node disease after radical prostatectomy. [**Minerva Urologica e Nefrologica**](http://www.scopus.com/scopus/source/sourceInfo.url?sourceId=19996) 2007; 59(1):53-7.(M23)
2. Rad: *Dimitrijević J, Todorović V, Aleksić A, Jovanović D, Pilčević D, Vignjević S, Mićić S, Jovanović P, Pilčević D, Kovačević Z, Hrvačević R, Maksić D, Brajušković G, Savić V, Bogdanović R. [Alport's syndrome and benign familial haematuria: light and electron microscopic studies of the kidney] [Article in Serbian]. Srpski arhiv za celokupno lekarstvo 2008; 136(Suppl 4):275-81.*

citira:

1. Jahanzad I, Mehrazma M, Makhmalbaf AO. The role of electron microscopy for the diagnosis of childhood glomerular diseases. Iranian Journal of Pediatrics 2011; 21(3):357-61. (M23)
2. Rad: *Cerović S, Brajušković G. [Forty years' use of Gleason grading in the diagnostics and treatment of prostate cancer] [Article in Serbian]. Vojnosaintetski pregled 2006; 63(12):1049-54.*

citira:

1. Walter BA, Valera VA , Pinto PA , Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. *Journal of Cancer* 2013; 4: 350-7. (M23)
2. Rad: *Cerović S, Čizmić M, Milović N, Ajdinović B, Brajušković G.[Pheochromocytomas as adrenal gland incidentalomas] [Article in Serbian]. Srpski arhiv za celokupno lekarstvo 2002; 130(2):47-51.*

citira:

1. Hyatt E, Rochelle A. Society of Radiologists in Ultrasound 2013 Toshiba Residents Program. Ultrasound Quarterly 2014; 30(3):205-7.(M23)
2. Rad: *Cerović S, Jeremić N, Brajušković G, Milović N. Maletić Vukotić V. [Incidence of locally invasive prostate cancer in patients with intermediate values of prostata – specific antigen] [Article in Serbian]. Vojnosanitetski pregled 2007; 64(8):531-7.*

citira:

1. Spasić A, Cerović S, Simić, D, Jovanović M, Nikolić I, Kovačević B, Soldatović I, Stojadinović M, Aleksić P. Significance of the correlation between the serum prostate-specific antigen and the percentage of prostate cancer volume in postoperative biochemical progression. Srpski Arhiv za Celokupno Lekarstvo 2017; 145 (11-12): 599-604. (M23)
2. Rad: Vučić N, Dobrijević Z, Kotarac N, **Matijašević S**, Vuković I, Budimirović B, Djordjević M, Savić-Pavićević D, Brajušković G**.** Association study between single-nucleotide variants rs12097821, rs2477686, and rs10842262 and idiopathic male infertility risk in Serbian population with meta-analysis. Journal of Assisted Reproduction and Genetics 2020. 37(11):2839-52.

citira:

1. Sutovskaya M, Burkova V, Vasilyev V, Sukhodolskaya E, Yurgenson D, Shibalev D, Karelin D, Dronova D, Mabulla A, Lazebny O. Fertility and infant survival in men and women from rural regions of Northern Tanzania: gene candidates and sex-specific genetic associations. J Anthropol Sci. 2020;98. (M21)

**Citiranost u knjigama i monografijama međunarodnog značaja**

Rad: *Pavlica Lj, Nikolić D, Magić Z, Brajušković G, Strelić N, Miličić B, Jovelić A. Successful Treatment of Postveneral Reactive Arthritis With Synovectomy and 3' Months' Azitthromycin. J Clin Rheumatol 2005; 11(5):257-63.*

citiraju:

1. Carlin EM, Ziza JM, Keat A. 2013 European (IUSTI/WHO) Guideline on the Management of Sexually Acquired Reactive Arthritis.
2. Carlin EM, Ziza JM, Keat A, Janier M. 2014 European Guideline on the Management of Sexually Acquired Reactive Arthritis.
3. United Kingdom National Guideline on the Management of Sexually Acquired Reactive Arthritis Clinical Effectiveness Group (CEG) - British Association of Sexual Health and HIV (BASHH) 2008;p.1-38.

Rad: *Savić Pavićević D, Miladinović J, Brkušanin S, Šviković S, Brajušković G, Romac S, Djurica S. Molecular genetics and genetic testing in myotonic dystrophy type 1 (DM1). BioMed Research International (Journal of Biomedicine and Biotechnology) 2013.*

citiraju:

1. Chuah M, Chai YC, Dastidar S, Driessche TV. Gene Therapy and Gene Editing for Myotonic Dystrophy. In: Duan D, Mendell JR, editors. Muscle Gene Therapy. Springer International Publishing / Springer Nature Switzerland AG 2019. pp. 525-48. ISBN:978-3-030-03094-0
2. Tohru M. Genetics of Myotonic Dystrophy. In: Takahashi MP and Matsumura T, eds. Myotonic Dystrophy -Disease Mechanism, Current Management and Therapeutic Development. Singapore: Springer Nature Singapore Pte Ltd. 2018. pp. 1-18. Print ISBN978-981-13-0507-8

Rad: [*Balint B, Vučetić D, Trajković-Lakić Z, Petakov M, Bugarski D, Brajušković G, Taseski J.*](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12803111&dopt=Abstract) *Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap). 2002; 32(4):363-75.*

citiraju:

1. Neumüller J, Ellinger A, Wagner T. Transmission Electron Microscopy of Platelets FROM Apheresis and Buffy-Coat-Derived Platelet Concentrates. In: Maaz K, ed. The Transmission Electron Microscope - Theory and Applications. In Tech 2015.p.255-84.
2. Pavlović M, Balint B. [Peritransplant Blood Component Therapy](http://link.springer.com/chapter/10.1007/978-1-4614-5505-9_11). Stem Cells and Tissue Engineering 2013, pp 61-67.

Rad*:Brajušković G, Vukosavić S, Dimitrijević J, Cerović S, Kežević Ušaj S, Marjanović S, Romac S, Škaro Milić A. [Expression of the Bcl-2 family of proteins in peripheral blood B-lymphocytes in patients with chronic lymphocytic leukemia] [Article in Serbian]. Vojnosaitetski pregled 2004; 61(1):41-46.*

citira:

1. Saxena A, Moshynka O. What Is the Clinical and Biological Signifikance of the Bcl-2 Family in Apoptosis Regulation in B-Cell Chronic Lymphocytic Leukemia (CLL)?. In: Nabhan C ed. Chronic Lymphocytic Leukemia Research Focus. Nova Science Publishers, Inc. 2007.p.77-111.

Rad: *Brajušković G, Vukosavić Orolicki S, Cerović S, Knežević Ušaj S, Perić P, Marjanović S, Dimitrijević S, Romac S, Škaro Milić A. The expression of caspase 3 in chronic lymphocytic leukemia. Archive of Oncology 2004; 12(1):65.*

citira:

1. Wojtowicz M, Wolowies D. Dysregulation of Apoptosis and Proliferation in CLL cells. In: Oppezzo P, editor. Chronyc Lymphocytic leukemia. In Tech; 2012. p. 37-62. ISBN 978-953-307-881-6.

Rad:*Trbojević J, Nešić D, Laušević Ž, Obradović M, Brajušković G, Stojimirović B. Histological characteristics of healthy animal peritoneum. Acta Veterinaria 2006; 56 (5-6): 405-12.*

citira:

1. Paulo NM, Moraes ÂM. The use of chitosan in surgery: Prevention of adhesions. In: Mackay RG, Tait JM, Handbook of chitosan research and applications 2011. pp. 259-270.

Rad:*Brajušković G****,*** *Mirčetić J, Savić Pavićević D, Cerović S, Tomović S, Jeremić N, Vuković I, Vukotić V, Romac S. Analysis of five single nucleotide polymor­phisms at locus 8q24 associated with pros­tate cancer in Serbian population. Virchows Arch 2011; 459 (Suppl 1):S319.*

citira:

1. Little J, Wilson B, Carter R, et al. Multigene Panels in Prostate Cancer Risk Assessment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. (Evidence Reports/Technology Assessments, No. 209. Available from: http://www.ncbi.nlm.nih.gov /books/NBK99070/.

Rad: *Branković A, Brajušković G, Nikolić Z. Vukotić V, Cerović S, Savić Pavićević D, Romac S. Endothelial nitric oxide synthase gene polymorphism and prostate cancer risk in Serbian population. Int. J. Exp. Path. 2013; 94(6):355-61.*

citira:

1. Yu Q, Li T, Li J, Zhong L, Mao X. Nitric Oxide Synthase in Male Urological and Andrologic Functions. In: Nitric Oxide Synthase - Simple Enzyme-Complex Roles. In Tech 2017. ISBN 978-953-51-3164-9.

Rad: *Nikolić Z, Savić-Pavićević D, Romac S, Brajušković G. Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta-Analysis. Clinical and Translational Science 2015; 8(1):23-31.*

citira:

1. Yu Q, Li T, Li J, Zhong L, Mao X. Nitric Oxide Synthase in Male Urological and Andrologic Functions. In: Nitric Oxide Synthase - Simple Enzyme-Complex Roles. In Tech 2017. ISBN 978-953-51-3164-9.

Rad: *Karanović J, Šviković S, Pantović M, Đurica S, Brajušković G, Damjanović A, Jovanović V, Ivković M, Romac S, Savić Pavićević D. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. World Journal of Biological Psychiatry 2015; 1-11.*

citira:

1. Wang Y, Zheng Y, Beal PA. Adenosine Deaminases That Act on RNA (ADARs). In: Chanfreau G and Tamanoi (editors). RNA Modification (The Enzymes, vol. 41) (1st ed). Academic Press; 2017. ISBN:

Rad: *Karanović J, Ivković M, Jovanović VM, Pantović M, Pavlović-Janković N, Damjanović A, Brajušković G, Romac S, Savić-Pavićević D. Tryptophan Hydroxylase 1 Variant rs1800532 is Associated with Suicide Attempt in Serbian Psychiatric Patients but does not Moderate the Effect of Recent Stressful Life Events. Suicide Life Threat Behav. 2016. 46 (6): 664-8.*

citira:

1. Wang Q., Dwivedi Y. (2017) Genetics of Suicidal Behaviour. In: Kumar U. (eds) Handbook of Suicidal Behaviour. Springer, Singapore. Online ISBN 978-981-10-4816-6

Rad: *Karanović J, Ivković M, Jovanović V, Šviković S, Pantović-Stefanović M, Brkušanin M, Damjanović A, Brajušković G, Savić-Pavićević D. Effect of childhood general traumas on suicide attempt depends on TPH2 and ADARB1 variants in psychiatric patients. J Neural Transm 2017; 124(5):621-9.*

citira:

1. Fries GR, Walss-Bass C. Gene-environment interactions in high-risk populations. In: Soares JC, Walss-Bass C and Brambilla P, eds. Bipolar Disorder Vulnerability Perspectives from Pediatric and High-Risk Populations. Academic Press 2018. pp. 49-68. ISBN: 978-0-12-812347-8.

Rad: *Brajušković G****.*** *Apoptosis in malignant diseases. Archive of Oncology 2005; 13(1):19-22.*

citira:

1. Bonchev D. Cellular Automata Modeling of Biomolecular Networks. In: Salcido A, ed. Cellular Automata - Innovative Modelling for Science and Engineering. InTech 2011; p. 275-300.

Rad: *Karanović J, Ivković M, Jovanović VM, Pantović M, Pavlović-Janković N, Damjanović A, Brajušković G, Romac S, Savić-Pavićević D. Tryptophan Hydroxylase 1 Variant rs1800532 is Associated with Suicide Attempt in Serbian Psychiatric Patients but does not Moderate the Effect of Recent Stressful Life Events. Suicide Life Threat Behav. 2016. 46 (6): 664-8.*

citira:

1. Wang Q., Dwivedi Y. (2017) Genetics of Suicidal Behaviour. In: Kumar U. (eds) Handbook of Suicidal Behaviour. Springer, Singapore. Online ISBN 978-981-10-4816-6

*Rad: Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. Front. Genet. 2018.*

citira:

1. Milunsky A, Milunsky JM. Genetic counseling: preconception, prenatal, and perinatal. Genetic disorders and the fetus. 2021:1-01. doi: 10.1002/9781119676980.ch1

Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Neurogenetics 2017; 18(4):207-18.*

citiraju:

1. Tomé S, Gourdon G. Fast assays to detect interruptions in CTG. CAG repeat expansions. In: Trinucleotide Repeats 2020; Humana, New York, NY. pp. 11-23.
2. Moxley RT, Hilbert JE; Meola Giovanni. The myotonic dystrophies. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. 6th Edition. 2020; vol 2. pp. 491-510.

Rad: *Filipović L, Spasojević M, Prodanović R, Korać A, Matijaševic S,* ***Brajušković G****, de Marco A, Popović M. Affinity-based isolation of extracellular vesicles by means of single-domain antibodies bound to macroporous methacrylate-based copolymer. N Biotechnol. 2022;69:36-48.*

citira:

1. Ferry G, Chabrol E, Boutin JA. Nanobodies in the pharmaceutical industry: Possible trends. Advances in Nanotechnology 2022; vol. 27. pp. 61 – 829.

Rad: *Dobrijević Z,* ***Matijašević S****, Išić Denčić T, Savić-Pavićević D, Nedić O, Brajušković G. Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis. Gene. 2021;766:145132.*

citira:

1. Шишкин СС- Полиморфизм некоторых ферментов и регуляторных белков человека (Биомедицинские аспекты). монографија 2021. ISBN: 978-5-00147-295-7.

**Citiranost u međunarodnim časopisima van SCI liste**

Rad: *Savić-Pavićević D, Miladinović J, Brkušanin S, Šviković S, Brajušković G, Romac S, Djurica S. Molecular genetics and genetic testing in myotonic dystrophy type 1 (DM1). BioMed Research International (Journal of Biomedicine and Biotechnology) 2013.*

citiraju:

1. ИВАНОВА ЕКАТЕРИНА ОЛЕГОВНА, МОСКАЛЕНКО АННА НИКОЛАЕВНА, ФЕДОТОВА ЕКАТЕРИНА ЮРЬЕВНА, КУРБАТОВ СЕРГЕЙ АЛЕКСАНДРОВИЧ, ИЛЛАРИОШКИН СЕРГЕЙ НИКОЛАЕВИЧ. МИОТОНИЧЕСКАЯ ДИСТРОФИЯ: ГЕНЕТИКА И ПОЛИМОРФИЗМ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ. АННАЛЫ КЛИНИЧЕСКОЙ И ЭКСПЕРИМЕНТАЛЬНОЙ НЕВРОЛОГИИ 2019; 1(13):15-25.
2. Bozovic I, Peric S, Pesovic J, Bjelica B, Brkusanin M, Basta I, Bozic M, Sencanic I, Marjanovic A, Brankovic M, Savic-Pavicevic D, Rakocevic-Stojanovic V. Myotonic Dystrophy Type 2 - Data from the Serbian Registry. J Neuromuscul Dis. 2018; 5(4):461-469.
3. Konstantinidou P, Moumou G, Zisopoulos K, Leontari R, Raikos N, Pavlidis P, Anestakis D. Cases of muscular dystrophy: Two incident reporting studies. Med Press. 2017; 1(1): 20-24.
4. Moreno-Zabaleta R, Gutierrez-Gutierrez G, Ramirez-Prieto MT, Montoro J, Casanova C. Respiratory and Sleep Disorders in 44 Spanish Patients with Myotonic Dystrophy Type I. J Sleep Med Disord 2016; 3(7):1069.
5. Sanchez FM. Fisioterapia en la Distrofia miotónica congénita. Reduca (Enfermería, Fisioterapia y Podología). Serie Trabajos de Fin de Grado 2016; 8 (1):132-180.
6. Castro RD, Ramirez CJ, Saldarriaga W, Isaza C. Distrofia miotónica Tipo 1: reporte de un caso de un pacientecolombiano. Revista Biosalud 2016; 15(2): 119-25.
7. Kalra S, Montanaro F, Denning C. Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies?. Journal of Neuromuscular Diseases 2016: 3(3):309-32.
8. Moreno-Zabaleta R, Gutierrez-Gutierrez G, Ramirez-Prieto MT , Montoro J , Casanova C. Respiratory and Sleep Disorders in 44 Spanish Patients with Myotonic Dystrophy Type I. Journal of Sleep Medicine & Disorders 2016; 3(7).
9. No list authors. Clinical and muscle biopsy pathological features and genetic testing in patients with myotonic dystrophy type 1. Journal of Apoplexy and Nervous Diseases 2013; 30(12).

Rad: *Nikolić Z, Savić Pavićević D, Vučić N, Cidilko S, Filipović N, Cerović S, Vukotić V, Romac S, Brajušković G****.*** *Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Experimental and Molecular Pathology 2015; 99:145-50.*

citiraju:

1. Dezfuli NK, Adcock IM, Alipoor SD, Salimi B, Seifi S, Chehrazi M, Varahram M, Mortaz E. The miR-196a SNP Rs11614913 but not the miR-499 rs37464444 SNP is a Risk Factor for Non-small Cell Lung Cancer in an Iranian Population. Tanaffos. 2022; 21(1):15-23.
2. Akhani A, Motaghi A, Sharif MO, Hemati S. Association of the mir-499 polymorphisms with oral cavity and oropharyngeal squamous cell carcinoma in an Iranian population. Dent Res J (Isfahan). 2020;17(3):174-178.
3. Azizi F, Soleimani M, Hosseini SY, Nik SA, Hosseini J. Gene Polymormisms and Prostate Cancer: A Systematic Review. Men's Health Journal - An international and peer-reviewed journal 2018; 2(1):e6
4. Banerjee HN, Kahan W, Kumar V, Verma M. Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer. Methods Mol Biol. 2018;1856:255-267.
5. Jie L, ZhiQiang L, Xiao L, BaiLu Y.Correlation analysis of genetic site and disease information based on neural networks and particle swarm optimization. Journal of Beijing University of Chemical Technology (Natural Science) 2018; 45(1):97-102.
6. Poltronieri-Oliveira AB, Madeira FF, Nunes DBSM, Rodrigues GH, Lopes BC, Manoel-Caetano FS, Biselli JM, Silva AE. Polymorphisms of miR-196a2 (rs11614913) and miR-605 (rs2043556) confer susceptibility to gastric cancer. Gene Reports 2017; 7:154-63.
7. Park JL, Kim M, Song KS, Kim SY, Kim YS. Cell-Free miR-27a, a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer. Genomics Inform. 2015;13(3):70-5.
8. Kim SK, Chu IS. A Database of Gene Expression Profiles of Korean Cancer Genome. Genomics Inform. 2015;13(3):86-9.

Rad: *Brajušković G, Vukosavić Orolicki S, Cerović S, Knežević Ušaj S, Marjanović S, Romac S. [Bcl-2 and Bax protein interaction in B-lymphocytes of peripheral blood in patients with chronic lymphocytic leukemia] [Article in Serbian]. Vojnosanitetski pregled 2005; 62(5):357-63.*

citiraju:

1. Huang C, Zhang D, Zhang Q, Wen J. Anti-apoptotic and uterotrophic effects of Heyan Kuntai capsules in uterus of ovariectomized rats. Tianjin Journal of traditional Chinese Medicine 2016; 33(11): 675-81.
2. Wang Y, He PC, Qi J, Liu YF, Zhang M. Tetra-arsenic tetra-sulfide induces cell cycle arrest and apoptosis in retinoic acid-resistant acute promyelocytic leukemia cells. Biomedical Reports 2015. 1-5. On line.
3. Qingfeng T, Xuan L,  Yan G, Ning Z, Lihong Z, Jian S, Qing J, Hong G, Qi L. Experimental study on inhibiting proliferation and inducing apoptosis of Zuojinwan alcohol extracts on human gastric cancer cells infected by Helicobacter pylori**.** [Chongqing medicine](http://c.wanfangdata.com.cn/Periodical-cqyx.aspx)[2012, 41(15)](http://c.wanfangdata.com.cn/periodical/cqyx/2012-15.aspx).
4. Zhao L, Li Q, LI W. Protective effect and mechanism of apoptosis inhibition of phosphocreatine injection to adriamycin – induced myocardium injury in rats. China Medical Engineering 2011; 19(8):5-28.
5. Meng A, liu C. Apoptosis induced by pseudolaric acid B in human melanoma cells. Basic and Clinical Medicine 2010; 30(11).
6. Wang H, Lei ZY, Chen H, Leng L, Ke Y, Cao B. Antitumor activity of PB-LY and its mechanism in vitro. [**Chinese Pharmacological Bulletin**](http://www.scopus.com.scopeesprx.elsevier.com/scopus/source/sourceInfo.url?sourceId=22908) 2008; 24(9):1204-8.
7. Wang Yuan, Zhang Mei HE, Peng-Cheng Liu, Yan-Feng QI, Jun Cjeng, Xiao-Yan Zhu Hua-Chao. Apoptosis of Retinoic Acid-Resistant APL NB4-R1 Cells Induced by As4S4 and Its Molecular Mechanism. Journal of Experimental Hematology 2015; 23(1).

Rad: *Branković A, Brajušković G, Nikolić Z. Vukotić V, Cerović S, Savić Pavićević D, Romac S. Endothelial nitric oxide synthase gene polymorphism and prostate cancer risk in Serbian population. Int. J. Exp. Path. 2013;94(6):355-61.*

citiraju:

1. Azizi F, Soleimani M, Hosseini SY, Nik SA, Hosseini J. Gene Polymormisms and Prostate Cancer: A Systematic Review. Men's Health Journal - An international and peer-reviewed journal 2018; 2(1):e6
2. Vijayakumar S, Prabhu S, Rajalakhsmi S, Manogar P. Review on potential phytocompounds in drug development for Parkinson disease: A pharmacoinformatic approach. Informatics in Medicine Unlocked 2016; 5:15-25.
3. Sun T, Chi Q, Wang G. [Research Progress of NOS3 Participation in Regulatory Mechanisms of Cardiovascular Diseases]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2016; 33(1):188-92. Review. Chinese.
4. Ma Y, Wang A, Zhong S, Jin L. A meta-analysis of ESR rs2234693 polymorphism associated with prostate cancer risk. Chinese Journal of Pathophysiology 2015; 31(1):104-8.

Rad: *Vučić N, Nikolić Z, Vukotić V, Tomović S, Vuković I, Kanazir S, Savić-Pavićević D, Brajušković G. NOS3 gene variants and male infertility: association of 4a/4b with oligoasthenozoospermia. Andrologia 2018; 50(1).*

citiraju:

1. Mahbouli S, Dupont C, Lameignère É, Levy R. Polymorphismes et nutrigénétique dans l’infertilité masculine idiopathique. Médecine de la Reproduction. 2020; 22(1):40-50.
2. Nadhim MH. Genetic Polymorphism in NOS Gene and Correlated with Peroxynitrite Levela in T2DM of Iraqi Patients. Plant Archives. 2020;20(2):1537-43.
3. Chavoshi R, Kaleybar SB. Association of nitric oxide synthase 3 gene rs1799983 G/T polymorphism with idiopathic asthenozoospermia in Iranian Azeri males: a case-control study. Hormone Molecular Biology and Clinical Investigation. 2020; 41(4).
4. Banihani SA, Khasawneh FH. Effect of lansoprazole on human sperm motility, sperm viability, seminal nitric oxide production, and seminal calcium chelation. Research in Pharmaceutical Sciences. 2018; 13(5):460.

Rad: *Pavlica Lj, Nikolić D, Magić Z, Brajušković G, Strelić N, Miličić B, Jovelić A. Successful Treatment of Postveneral Reactive Arthritis With Synovectomy and 3' Months' Azitthromycin. J Clin Rheumatol 2005; 11(5):257-63.*

*citiraju:*

1. Carlin E, Marzo-Ortega H, Flew S. British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021. Int J STD AIDS. 2021
2. Espinoza LR. Bases infecciosas de la artritis reactiva. Revista Argentina de Reumatología 2007; 18(2):19-25.
3. Carter JD, Espinoza LR. Interplay of environmental triggers and host response in reactive arthritis: can we intervene?. Future Rheumatology 2006; 1(6):717-27.
4. Toivanen A, Yli-Kerttula T, Mottonen T. Antibiotics in the treatment of reactive arthritis. [**Current Rheumatology Reviews**](http://www.scopus.com/scopus/source/sourceInfo.url?sourceId=4700152450) 2006; 2(3): 303-8.

Rad: *Nikolić Z, Savić-Pavićević D, Romac S, Brajušković G. Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta-Analysis. Clinical and Translational Science 2015; 8(1):27-31.*

*citiraju:*

1. Cerqueira AR, Fratelli CF, Duarte LC, Pereira AS, Morais RM, Sobrinho AB, Silva CM, Silva IC, Oliveira JR. The impact of NOS3 gene polymorphism on papillary thyroid cancer susceptibility in patients undergoing radioiodine therapy. The International Journal of Biological Markers. 2020; 35(4):87-91.
2. Зинчук В.В., Жадько Д.Д. ПОЛИМОРФИЗМ ГЕНА ЭНДОТЕЛИАЛЬНОЙ СИНТАЗЫ МОНООКСИДА АЗОТА. ЧАСТЬ 2. ПОЛИМОРФНЫЕ ВАРИАНТЫ T786C, 4A/B. Журнал Гродненского государственного медицинского университета 2017; 15(3): 267-74.
3. Vahora H, Khan MA, Alalami U, Hussain A. The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention. J Cancer Prev. 2016; 21(1):1-12.

*Rad: Dobrijević Z, Matijašević S, Išić Denčić T, Savić-Pavićević D, Nedić O, Brajušković G. Association between genetic variants in DICER1 and cancer risk: An updated meta-analysis. Gene. 2021;766:145132*

*citiraju:*

1. Meiklejohn KM, Darbinyan A, Barbieri AL. A review of DICER1: structure, function and contribution to disease. Diagnostic Histopathology. 2022.

Rad: [*Balint B, Vučetić D, Trajković-Lakić Z, Petakov M, Bugarski D, Brajušković G, Taseski J.*](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12803111&dopt=Abstract) *Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap). 2002; 32(4):363-75.*

*citiraju:*

1. Bienias J, Mazur A, Błaszczyńska K, Król D, Dyląg S. Ocena krwinek płytkowych po procesie kriokonserwacji. Postępy Nauk Medycznych 2013;7:501-5.
2. Balint B. **Coexistent cryopreservation strategies: microprocessor-restricted vs. Uncontrolled – rate freezing of the “blood-derived” progenitors/cells. Blood Bank Transfus Med 2004; 2(2):62-71.**

Rad: *Cerović S, Brajušković G, Vukotić Maletić V, Mićic S: Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl. 2004; 61: 513-8.*

*citiraju:*

1. Jaskulski J, Gołabek T, Kopczyński J, Orłowsk P, Bukowczan J, Dudek P, Chłosta P. [Does neuroendocrine differentiation have prognostic value in prostate core needle biopsies?]. Przegl Lek. 2013;70(11):933-5. Polish.
2. Ma Y, Yang H. Prognostic factors in prostate cancer. Chinese Journal of diagnostic pathology 2007; 14(5).

Rad: *Cerović S, Ignjatović M, Brajušković G, Knežević Ušaj S, Dimitrijević J, Ćuk V. The value of intraoperative diagnosis in thyroid surgery. Archive of Oncology 2004; 12(1):47.*

*citiraju:*

1. Stanciu-Pop C , Pop FC, Thiry A, Scagnol I, Maweja S, Hamoir E, Beckers A, Meurisse M, Grosu F, Delvenne P. INTÉRÊTS ET LIMITES DE L’EXAMEN EXTEMPORANÉ EN PATHOLOGIE THYROÏDIENNE Revue systématique de la littérature et évaluation fondée sur les preuves .Rev Med Liège 2015; 70(12): 638-43.
2. Abdessayed N, Koubba-Mahjoub W, ben Brahim E, Debbiche AC. The Value of Intra-Operative Frozen Section in Thyroid Neoplasm Management: Experience of One Center. Thyroid Disorders Ther 2017, 6:4.

Rad:*Trbojević J, Nešić D, Laušević Ž, Obradović M, Brajušković G, Stojimirović B. Histological characteristics of healthy animal peritoneum. Acta Veterinaria 2006; 56 (5-6): 405-12.*

*citiraju:*

1. Capella-Monsonís H, Tilbury MA, Wall JG, Zeugolis DI. Porcine mesothelium matrix as a biomaterial for wound healing applications. Mater Today Bio. 2020 May 17;7:100057.
2. Hey-Cunningham Aj, Berbic M, Ng CHM, Markham R, Fraser IS. Lymphatic vessels in peritoneal endometriotic lesions. Journal of Endometriosis 2011; 3(2):59-66.

Rad: *Nikolić Z, Savić-Pavićević D, Vukotić V, Tomović S, Cerović S, Filipović N, Romac S,Brajušković G. Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population. Cancer Causes Control. 2014; 25(11):1571-5.*

*citiraju:*

1. Zhang M, Wang Y, Wang C, You Z, Chen S, Kong Q, Xu B, Liu C, Chen M. Association of Hsa-miR-23a rs3745453 variation with prostate cancer risk among Chinese Han population: A case-control study. Medicine (Baltimore). 2019; 98(52):e18523.
2. Azizi F, Soleimani M, Hosseini SY, Nik SA, Hosseini J. Gene Polymormisms and Prostate Cancer: A Systematic Review. Men's Health Journal - An international and peer-reviewed journal 2018; 2(1):e6

Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. Front. Genet. 2018.*

citiraju:

1. Monckton DG. The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington's Disease: A Historical Perspective. J Huntingtons Dis. 2021;10(1):7-33.
2. Fontana L, Santoro M, D'Apice MR, Peluso F, Gori G, Morrone A, Novelli G, Dosa L, Botta A. Identification, molecular characterization and segregation analysis of a variant DMPK pre-mutation allele in a three-generation Italian family. Acta Myol. 2020;39(1):13-18.

Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Neurogenetics 2017; 18(4):207-18.*

citiraju:

1. Hamel JI. Myotonic Dystrophy. Continuum : lifelong learning in neurology 2022; 28(6):1715-34.
2. Tomé S, Gourdon G. Fast Assays to Detect Interruptions in CTG.CAG Repeat Expansions. Methods Mol Biol. 2020; 2056:11-23.

Rad: *Karanović J, Šviković S, Pantović M, Đurica S, Brajušković G, Damjanović A, Jovanović V, Ivković M, Romac S, Savić Pavićević D. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. World Journal of Biological Psychiatry 2015; 1-11.*

citiraju:

1. Uliaszek AA, Hamdullahpur K, Amestoy ME, Carnovale M. Longitudinal pathways between suicidal ideation and life stress. Anxiety Stress Coping. 2023:1-13.
2. Козлов ВА, Голенков АВ, Сапожников СП. The role of the genome in suicidal behavior (literature review). Суицидология. 2021;12(1):3-22.
3. Wang Y, Zheng Y, Beal PA. Adenosine Deaminases That Act on RNA (ADARs). Enzymes 2017; 41:215-68.

Rad: *Karanović J, Ivković M, Jovanović VM, Pantović M, Pavlović-Janković N, Damjanović A, Brajušković G, Romac S, Savić-Pavićević D. Tryptophan Hydroxylase 1 Variant rs1800532 is Associated with Suicide Attempt in Serbian Psychiatric Patients but does not Moderate the Effect of Recent Stressful Life Events. Suicide Life Threat Behav. 2016. 46 (6): 664-8.*

citiraju:

1. Kislov M, Chauhan M, Velenko P, Krupin K, Korolkova I, Zhigovanova M. Recent advancements in the genetics of suicidal behavior amongst population, worldwide. Journal of Forensic Medicine and Toxicology 2022; 39(1):116-24.
2. Song ZJ, Lai SK, Zhong SM, Jia YB. [Advances in Imaging Genetics of Suicidal Behavior]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021; 43(5):801-807.

Rad: *Dimitrijević J, Đukanović Lj, Kovačević Z, Bogdanović R, Maksić Đ, Hrvačević R, Aleksić A, Naumović R, Jovanović D, Brajušković G, Milosavljević I. Lupus nephritis: pathological features, classification and histologic scorning in renal biopsy. Vojnosanitetski pregled 2002; 59(6):21-33.*

citiraju:

1. Mosaad GM, Soliman AF, Ameen SG, Amer AS. Implication of plasma gelsolin in systemic lupus erythematosus patients. Egyptian Rheumatology and Rehabilitation. 2022; 49(1):1-7.
2. АРЗИМАНОВА Н. А., МАРАСАЕВ В. В., АБИССОВА Т. О. Immuno-morphological features of glomerular and tubulointerstitial kidney damage in patients with Systemic Lupzs Erythematousus. НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ 2009; 2.

Rad: *Nikolić Z, Brajušković G, Savić Pavićević D, Kojić A, Vukotić V, Tomović S, Cerović S, Filipović F, Mišljenović Đ, Romac S. Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population. Int J Clin Exp Med 2013; 6(1):57-66.*

citira:

1. Ghavami S, Taheri M, Hashemi M. Association between long non-coding rna polr2e rs3787016 polymorphism and cancer susceptibility: A meta-analysis of 8725 cancer cases and 10710 controls. Shiraz E-Medical Journal 2021; 22(4).

Rad: *Brkušanin M, Kosać A, Jovanović V, Pešović J, Brajušković G, Dimitrijević N, Todorović S, Romac S, Milić Rašić V, Savić-Pavićević D. Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients. J Hum Genet. 2015; 60(11):723-8.*

citira:

1. Zhuri D, Gurkan H, Eker D, Karal Y, Yalcintepe S, Atli E, Demir S, Atli EI. Investigation on the Effects of Modifying Genes on the Spinal Muscular Atrophy Phenotype. Glob Med Genet. 2022;9(3):226-236.
2. Barišić N, Vukić V, Lehman I, Novak M, Đapić T, Sertić J, Bošnjak Nađ K, Kern I, Najdanović B, Omerza L, Braovac D. Treatment of patients with spinal muscular atrophy in Croatia-positive results from the national registry and new challenges. Paediatria Croatica 2020; 64(4):236-51.

Rad: *Vučetić D, Balint B, Trajković Lakić Z, Mandić Radić S, Brajušković G, Miković D, Trkuljić M. Cryopreserved vs. liquid – state stored platelets – quantitative and qualitative comparative study. Blood Blank Transfus Med 2003; 1(2):81-8.*

citira:

1. Balint B. **Coexistent cryopreservation strategies: microprocessor-restricted vs. Uncontrolled – rate freezing of the “blood-derived” progenitors/cells. Blood Bank Transfus Med 2004; 2(2):62-71.**

Rad: *Balint B, Vučetić D, Vojvodić D, Petakov M, Brajušković G, Ivanović Z, Trkuljić M, Stojanović N. Cell recovery, cryothermal micro – damages and surface antigen expression as predictors for cold – induced GPIbβ/CD42b – cluster mediated platelet clearance after controlled – rate vs. uncontrolled – rate cryopreservation. Blood Blank Transfus Med 2004; 2(1):22-6.*

citira:

1. Balint B. **Coexistent cryopreservation strategies: microprocessor-restricted vs. Uncontrolled – ratefreezing of the “blood-derived” progenitors/cells. BloodBankTransfusMed 2004; 2(2):62-71.**

Rad: *Škaro Milić A, Brajušković G****,*** *Hristić M. Apoptosis and Malignity. Jugoslav Physiol Pharmacol Acta 1997; 33(1):1-31.*

citira:

1. Vovk IB, Zadorozhna TD, Andriiets OA, Pustovalova OI. Cytologic, Immuno-cytochemical and morphometric peculiarities of the vaginal epithelium in vulvovaginites in girls of pubertal age. Buk. Med. Herald. 2005; 9(1):50-3.

Rad: *Strnad M, Brajušković G****,*** *Strelić N, Todorić Živanović B, Tukić Lj, Stanković D. [Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia] [Article in Serbian]. Vojnosanitetski pregled 2006; 63(4):364-9.*

citira:

1. Cho WCS. **Recent progress and integrated therapy for leukemia. Journalof Modern Oncology**2007; 15(8):1051-4.

Rad: *Ušaj S, Tarabar D, Ćuk V, Cerović S, Brajušković G, Panišić M, Klem I, Eri Ž. The histological diagnosis of dysplastic and neoplastic lesions in inflammatory bowel disease: a pathological perspective. Acta Chrirurgica Iugoslavica 2004; LI(2):109-16.*

citira:

1. Xiang P, Shung Y, Danian JI, XU Fuxing XU, Pingan OU. Endoscopic and clinical features of Crohn disease. Chin J Dig Endosc 2006; 23(6):426-9.

Rad: *Brajušković G****.*** *Apoptosis in malignant diseases. Archive of Oncology 2005; 13(1):19-22.*

citira:

1. Authors. Expression of death receptor (Fas) , and it's specific ligand (FasL)in transitional cell carcinoma of the urinary bladder. Iraqi Academic Scientific Journals 2013; 1:98-105.

Rad: *Karanović J, Ivković M, Jovanović V, Šviković S, Pantović-Stefanović M, Brkušanin M, Damjanović A, Brajušković G, Savić-Pavićević D. Effect of childhood general traumas on suicide attempt depends on TPH2 and ADARB1 variants in psychiatric patients. J Neural Transm 2017; 124(5):621-9.*

citira:

1. Kislov M, Chauhan M, Velenko P, Krupin K, Korolkova I, Zhigovanova M. Recent advancements in the genetics of suicidal behavior amongst population, worldwide. Journal of Forensic Medicine and Toxicology 2022; 39(1):116-24.

Rad: *Kotarac N, Dobrijević Z, Matijašević S, Savić-Pavićević D, Brajušković G. Association of KLK3, VAMP8 and MDM4 genetic variants within microRNA binding sites with prostate cancer: evidence from Serbian population. Pathology and Oncology Research 2020; 26(4):2409-23.*

citira:

1. Melnik C, John SV, WeiskirchenR,Schmitz G. The endocrine and epigenetic impact of persistent cow milk consumption on prostate carcinogenesis. J Transl Genet Genom 2022; 6:1-45.

Rad: Vučić N, Dobrijević Z, Kotarac N, **Matijašević S**, Vuković I, Budimirović B, Djordjević M, Savić-Pavićević D, Brajušković G**.** Association study between single-nucleotide variants rs12097821, rs2477686, and rs10842262 and idiopathic male infertility risk in Serbian population with meta-analysis. Journal of Assisted Reproduction and Genetics 2020. 37(11):2839-52.

citira:

1. Duong Thi Thu Ha, Dinh Huong Thao, Nguyen Thuy Duong. Association of SOX5 rs10842262 with male infertility in 325 Vietnames individuals. TNU Journal of Science and Technology 2022; 227(5): 52-7.

**Citiranost u časopisima kategorije M24**

Rad: *Brajušković G, Savić-Pavićević D, Romac S. 60th Anniversary of the DNA Secondary Structure Discovery. Vojnosanitetski pregled 2013; 70(12):1165-70.*

*citira:*

1. Stajić M. Is there a gene for the human spirit? An analysis of the basic motifs and symbolism in the movie Gattaca. Entroantropološki problemi - Issues in Ethnology Anthropology 2017; 12(2):505-34.

Rad: *Brajušković G****.*** *[Genomics] [Article in Serbian]. Vojnosanitetski pregled 2006; 63(6):604-10.*

*citira:*

1. Stajić M. Is there a gene for the human spirit? An analysis of the basic motifs and symbolism in the movie Gattaca. Entroantropološki problemi - Issues in Ethnology Anthropology 2017; 12(2):505-34.

Rad: *Brajušković G. [DNA: 50 years’ of the double helix] [Article in Serbian].Vojnosanitetski pregled 2003; 60(6):763-6.*

*citira:*

1. Stajić M. Is there a gene for the human spirit? An analysis of the basic motifs and symbolism in the movie Gattaca. Entroantropološki problemi - Issues in Ethnology Anthropology 2017; 12(2):505-34.

Rad:*Brajušković G. [140 years of genetics] [Article in Serbian]. Vojnosaniteski pregled 2006; 63(5):509-12.*

*citira:*

1. Stajić M. Is there a gene for the human spirit? An analysis of the basic motifs and symbolism in the movie Gattaca. Entroantropološki problemi - Issues in Ethnology Anthropology 2017; 12(2):505-34.

**Citiranost u časopisima nacionalnog značaja (M50)**

Rad: [*Balint B, Vučetić D, Trajković-Lakić Z, Petakov M, Bugarski D, Brajušković G, Taseski J.*](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12803111&dopt=Abstract) *Quantitative, functional, morphological and ultrastructural recovery of platelets as predictor for cryopreservation. Haematologia (Budap). 2002;32(4):363-75.*

*citiraju:*

1. Balint B, Pavlović M, Todorović M. Recent strategies vs. challenges instem cell–based grafting:from innovative research to clinical practice. Bilt Transfuziol 2011;57(1-2):9-25.
2. Urošević I, Balint B, Popović S. Peripheral blood hematopoietic stem cells – biology, apheresis collection and cryopreservation. Med Pregl 2007; LX(1-2):42-7.
3. Balint B. Competitive operating freezing systems in the stem and progenitor cell cryopractice: An overview. Bilten za transfuziologiju 2004; 50(1-2):45-50.
4. Balint B, Cavor Lj, Paunović D. Uticaj leukoredukcije na koncentraciju proinflamacijskih citokina u koncentrovanim trombocitima. Bilten za transfuziologiju 2003; 49(1-2):5-12.

Rad: *Balint B, Vučetić D, Vojvodić D, Petakov M, Brajušković G, Ivanović Z, Trkuljić M, Stojanović N. Cell recovery, cryothermal micro – damages and surface antigen expression as predictors for cold – induced GPIbβ/CD42b – cluster mediated platelet clearance after controlled – rate vs. uncontrolled – rate cryopreservation. Blood Blank Transfus Med 2004; 2(1):22-6.*

*citiraju:*

1. Balint B, Pavlović M, Todorović M. Recent strategies vs. challenges instem cell–based grafting:from innovative research to clinical practice. Bilt Transfuziol 2011;57(1-2):9-25.
2. Vučetić D, Balint B, Vojvodić D, Ilić V, Subota V. [Evaluation of concentrated platelets activation level during storage based on the expression of membrane glycoproteins](http://scindeks.ceon.rs/article.aspx?artid=0354-44941102026V). Bilt Transfuziol 2011; 57(1-2):26-34.
3. Urošević I, Balint B, Popović S. Peripheral blood hematopoietic stem cells – biology, apheresis collection and cryopreservation. Med Pregl 2007; LX(1-2):42-7.
4. Balint B. Competitive operating freezing systems in the stem and progenitor cell cryopractice: An overview. Bilten za transfuziologiju 2004; 50(1-2):45-50.

Rad: *Dimitrijević J, Đukanović Lj, Kovačević Z, Bogdanović R, Maksić Đ, Hrvačević R, Aleksić A, Naumović R, Jovanović D, Brajušković G, Milosavljević I. Lupus nephritis: pathological features, classification and histologic scorning in renal biopsy. Vojnosanitetski pregled 2002; 59(6):21-33.*

*citiraju:*

1. Zdravković N, Zdravković N, Stojanović M. Systemic Lupus Erythematosus: from etiopatogenesis to up to date tretment’s methods. Timok Medical Gazzete 2019; 44(1): 26-30.
2. Pavlović T, Jordanova E, Pavlović D. Lečenje akutnog pogoršanja hronične obstruktivne bolesti pluća. Naučni časopis urgentne medicine 2018; 24(1): 63-73.

Rad: *Dimitrijević J, Hrvačević R, Brajušković G, Marić M, Kovačević Z, Spasić P, Štrbac M, Kronja G, Elaković D, Jovanović D, Savin M, Pavlović S, Blagojević R, Đukanović Lj. Renal Graft Histology: Relationship Between Transplant Rejection and Changes Not Considered to Be Due to rejection. Medicinska Istraživanja 1999; 33(1):89-93.*

*citira:*

1. Tatomirović Z, Bokun R, Dimitrijević J, Ignjatović L, Aleksić A, Hrvacević R.[Value of urinary cytology findings in the diagnosis of acute renal graft rejection]. Vojnosanit Pregl. 2003; 60(1):35-41.

Rad: *Knežević Ušaj S, Panišić M, Tarabar D, Ćuk V, Brajušković G, Petrović M. [Premalignant and malignant changes in idiopathic inflammatory bowel disease]. [Article in Serbian]. Acta Chirurgica Iugoslavica 2000; XLVII(1/2):43-50.*

*citira:*

1. Radovanović B, Nagorni A, Katić V, Stamenković I, Mihajlović D. [Precancerous lesions and colorectal cancer in ulcerative colitis](http://scindeks.ceon.rs/article.aspx?artid=0351-60830004215R). Acta Facultatis Medicae Naissensis 2000; 17 (3-4):215-223.

Rad: *Vučetić D, Balint B, Trajković Lakić Z, Mandić Radić S, Brajušković G, Miković D, Trkuljić M. Cryopreserved vs. liquid – state stored platelets – quantitative and qualitative comparative study. Blood Blank Transfus Med 2003; 1(2):81-8.*

*citira:*

1. Balint B. Competitive operating freezing systems in the stem and progenitor cell cryopractice: An overview. Bilten za transfuziologiju 2004; 50(1-2):45-50.

Rad: *Šijačić Nikolić M, Milovanović J, Bobinac M, Savić Pavićević D, Brajušković G, Diklić M. Variability of the Choloroplast DNA of Seddile Oak (Quercus Petraea Agg, Enrendorfer, 1967) in Serbia. Arch Biol. Sci. Belgrade 2009; 61(3):459-65.*

*citira:*

1. Trudić B, Orlović S, Galović L, Pekeč S, Stojanović D, Stojnić S. Molecular Technologies in Serbian Lowland Forestry under Climate Changes - Possibilities and Perspectives. SEEFOR (South-east European forestry) 2014; 5(2):103-15.

**Citiranost u inostranim doktorskim disertacijama:**

Rad: *Savić-Pavićević D, Miladinović J, Brkušanin S, Šviković S, Brajušković G, Romac S, Djurica S. Molecular genetics and genetic testing in myotonic dystrophy type 1 (DM1). BioMed Research International (Journal of Biomedicine and Biotechnology) 2013.*

*citiraju:*

1. Raphaela Victoria Mensel. Nicht-radioaktiver Nachweis von CTG-Repeats in Muskelgewebe von Patienten mit myotoner Dystrophie Typ 1. Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München. 2022.
2. Gro Solbakken. Trunk Muscle Impairment and Pain in Myotonic Dystrophy type 1: Association to CTG size and Function. Faculty of Medicine, University of Oslo. 2021. ISBN 978-82-8377-902-8.
3. Antoine Merien. Étude de la fonction des protéines MBNL au cours du développement à l’aide de cellules souches humaines induites à la pluripotence. Physiologie [q-bio.TO]. Université Paris-Saclay, 2021. Français.
4. PAR HILDA BIGDELI-AZARI, B. SC. MESURE DE L’INTELLIGENCE SANS IMPLICATION MOTRICE POUR DES INDIVIDUS ATTEINTS DE DYSTROPHIE MYOTONIQUE DE TYPE 1. UNIVERSITÉ DU QUÉBEC. 2020.
5. Ardui S. Determination of the Variability and Associated Epigenetic Signature of Tandem Repeats by Single Molecule Sequencing. 2018. PhD Thesis,KU Leuven Biomedical Sciences Group Faculty of Medicine Department of Human Genetics, Leuven, The Netherlands.
6. Brockhoff M. Identification of deregulated AMPK and mTORC1 signalling in myotonic dystrophy type I and their potential as therapeutic targets. Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel. Basel, Schweiz, 2017. Brockhoff, Marielle. Identification of deregulated AMPK and mTORC1 signalling in myotonic dystrophy type I and their potential as therapeutic targets. 2016, PhD Thesis, University of Basel, Faculty of Science.

Rad: *Brajušković G.Apoptosis in malignant diseases. Archive of Oncology 2005; 13(1):19-22.*

*citiraju:*

1. Baldomero Antonio Kato da Silva. Análise da frequência de apoptose pós injeção intrapulmonar de benzo[a]pireno em ratos wistar. Tese. Universidade Federal de Mato Grosso do Sul, Campo Grande, Brasil 2011.
2. Pereira AO. Prevalence of iron deficiency anaemia in indigenous children Teréna. Teses e dissertações defendidas na UFMS, Universidade Federal de Mato Grosso do Sul, Campo Grande, Brasil 2011.
3. Taburee P. Effect of cytokines on apoptosis of leukemic cell lines. A thesis. Mahidol University, Thailand, 2008.

Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Repeat Interruptions Modify Age at Onset in Myotonic Dystrophy Type 1 by Stabilizing DMPK Expansions in Somatic Cells. Front. Genet. 2018.*

citira:

1. Khristich, Alexandra. Investigating Mechanisms of Large-Scale GAA Repeat Contraction. N.Tufts University, ProQuest Dissertations Publishing, 2020. 27832877.
2. Marie De Antonio. Statistiques et modèles de survie pour améliorer la connaissance d’une maladie rare, la dystrophie myotonique. Médecine humaine et pathologie. Sorbonne Université, 2020. Français
3. McAllister WB. Identification and characterisation of genetic variation that modifies age at onset in Huntington’s disease (Doctoral dissertation, Cardiff University, 2019).

Rad: *Brkušanin M, Kosać A, Jovanović V, Pešović J, Brajušković G, Dimitrijević N, Todorović S, Romac S, Milić Rašić V, Savić-Pavićević D. Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients. J Hum Genet. 2015; 60(11):723-8.*

*citira:*

1. Pras A. The Molecular Role of SERF in Amyloid Formation (Doctoral dissertation, University of Groningen, 2021)
2. Vorster Elena. Determining the molecular basis of Spinal Muscular Atrophy in the Black South African population. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. 2017.

Rad: *Dimitrijević J, Đukanović Lj, Kovačević Z, Bogdanović R, Maksić Đ, Hrvačević R, Aleksić A, Naumović R, Jovanović D,* Brajušković G, *Milosavljević I. Lupus nephritis: pathological features, classification and histologic scorning in renal biopsy. Vojnosanitetski pregled 2002; 59(6):21-33.*

*citiraju:*

1. Melike B. The impact of the ISN/RPS classification of glomerulonephritis in systemic lupus erythematosus on the histological diagnosis of focal and diffuse lupus nephritis. University of Calgary, Medical Science. 2013.
2. 王贞, 唐政, 章海涛, 胡伟新, 刘志红, 黎磊石. *家族性系统性红斑狼疮临床及肾脏病理特征分析* (Doctoral dissertation). 2009.

Rad: *Nikolić Z, Savić Pavićević D, Vukotić V, Tomović S, Cerović S, Filipović N, Romac S, Brajušković G. Association between genetic variant in hsa-miR-146a gene and prostate cancer progression: evidence from Serbian population. Cancer Causes Control. 2014; 25(11):1571-5.*

*citira:*

1. Gam Rihab. Identification and assessment of molecular biomarkers in haematopoietic stem cell transplantation. Newcastle University. 2016. PhD

Rad: *Nikolić Z, Savić Pavićević D, Vučić N, Romac S, Brajušković G. Association between genetic variant in hsa-miR-146a gene and cancer risk: an updated meta-analysis. Public Health Genomics 2015; 18(5):283-98.*

*citira:*

1. Kim CH. Environmental Tobacco Smoke, Genetic Susceptibility, and Lung Cancer among Never Smokers. Univesity of California. Los Angeles. USA. PhD in Epidemiology. 2016.

Rad: *Nikolić Z, Branković A, Savić Pavićević D, Preković S, Vukotić V, Cerović S, Filipović N, Tomović S, Romac S, Brajušković G. Assessment of association between common variants at 17q12 and prostate cancer risk – evidence from Serbian population and meta-analysis. Clinical and Translational Science 2014; 7(4):307-13.*

*citira:*

1. Nayára Izabel Viana Moura. Correlação entre polimorfismos genéticos relacionados á hereditariedade, fatores hormonais e o câncer de próstata. Correlation between genetic polymorphisms related to heredity, hormonal factors and prostate cancer. Faculdade de Medicina. São Paulo, 2017. Doctoral Thesis.

Rad: *Karanović J, Šviković S, Pantović M, Đurica S, Brajušković G, Damjanović A, Jovanović V, Ivković M, Romac S, Savić Pavićević D. Joint effect of ADARB1 gene, HTR2C gene and stressful life events on suicide attempt risk in patients with major psychiatric disorders. World Journal of Biological Psychiatry 2015; 1-11.*

*citira:*

1. Dolanbay O. Kendine zarar verme veya özkıyım girişimi nedeniyle acil servise başvuran hastalarda reelin gen polimorfizminin ve reelin enzim düzeylerinin araştırılması/Investigating reelin gene polymorphism and reelin enzyme level at patients who referenced emergency cervice because of suicide or self HARM attempt. T.C. FIRAT ÜNİVERSİTESİ TIP FAKÜLTESİ ACİL TIP ANABİLİM DALI. 2016.

Rad: *Pešović J, Perić S, Brkušanin M, Brajušković G, Rakočević-Stojanović V, Savić-Pavićević D. Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions. Neurogenetics 2017; 18(4):207-18.*

*citira:*

1. Zhang J. Binding of MBNL1 to CUG Repeats Slows 5'-to-3'RNA Decay by XRN2 in a Cell Culture Model of Type I Myotonic Dystrophy (Doctoral dissertation, Colorado State University, 2017).

Rad: *Škaro Milić A, Brajušković G, Hristić M. Apoptosis and Malignity. Jugoslav Physiol Pharmacol Acta 1997; 33(1):1-31.*

*citira:*

1. Правдина, Ольга Валерьевна. Клинико-морфологическая оценка эффективности препарата Глутоксим в комплексной терапии больных псориазом : диссертация ГОУВПО "Новосибирская государственная медицинская академия"] Новосибирск, 2004.

Rad: *Popović L, Tatić V, Ilić S, Jaćević V, Cerović S, Ušaj Knežević S, Brajušković G. Correlation between mast cells and different biological potential of fibrohistiocytic tumors. Archive of Oncology 2002; 10(1):126.*

*citira:*

1. Elizabeth K. Malament. Rol de los mastocitos en la tumorigenicidadde ulínea de adenocarcinoma de pulmón murino. Editor Lilia Lauria de Cidre. Facultad de Ciencias Exactas y NaturalesLicenciatura en Ciencias Biológicas. Las tesinas de Belgrano. Universidad de Belgrano. Buenos Aries. Argentina 2007.

Rad: *Cerović S, Čizmić M, Milović N, Ajdinović B, Brajušković G.[Pheochromocytomas as adrenal gland incidentalomas] [Article in Serbian]. Srpski arhiv za celokupno lekarstvo 2002; 130(2):47-51.*

*citira:*

1. Alice Bertron Épouse Besnier. Les tumeurs composites surrénaliennes phéochromocytome : ganglioneurome : caractéristiques cliniques et biologiques d'une série de patients suivis aux CHU de Lille et de Rouen. Thèse d'exercice de Médecine. Universite de Rouen, Rouen, France 2012.

Rad: *Cerović S****,*** *Brajušković G, Vukotić Maletić V, Mićic S: Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl. 2004; 61:513-8.*

*citira:*

1. Strittmatter F. Freisetzungsmuster onkologischer Biomarker beim Prostatakarzinom. Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultat derLudwig-Maximilians-Universitat zu Munchen 2009.

Rad:*Trbojević J, Nešić D, Laušević Ž,Obradović M, Brajušković G, Stojimirović B. Histological characteristics of healthy animal peritoneum. Acta Veterinaria 2006; 56(5-6): 405-12.*

*citira:*

1. Straaten FV. Circulatie en drainage van het peritoneale vocht bij de hond en kat. Door. Faculteit diergeneeskunde. Universiteit Gent. Academiejaar 2011-2012.

Rad: *Strnad M, Brajušković G, Strelić N, Todorić-Živanović B, Stamatović D, Tatomirović Ž, Magić Z. Expression of programmed cell death proteins in patients with chronic myeloid leukemia. J BUON 2008; 13(3):403-8*.

*citira:*

1. Skorta I. Hemmung von Bcr/Abl durch Imatinib führt zu einer Cisplatin-Sensitivierung und zu einer modulierten p53-Funktion bei Bcr/Abl-positiven Zellen. Von der Fakultät für Energie-, Verfahrens- und Biotechnik der Universität Stuttgart zur Erlangung der Würde eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigte Abhandlung. Institut für Zellbiologie und Immunologie der Universität Stuttgart und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie Stuttgart und Universität Tübingen 2009.

Rad: *Brajušković G, Škaro Milić A, Marjanović S, Cerović S, Knežević Ušaj S. The ultrastructural investigation of mitochondria in B – CLL cells during process apoptosis. Archive of Oncology 2004; 12(3):139-41.*

*citira:*

1. Жукова, Мария Владимировна. Симбиотическая ассоциация Wolbachia-Drosophila melanogaster: ультраструктурная организация и взаимодействие в условиях стресса. Новосибирский государственный университет, 2011.